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The following abbreviations have been used throughout this thesis and are described in foil
in brackets after their first use in the text.
AA: Afferent arteriole
ACE : Angiotensin converting enzyme
AMP : Adenine monophosphate
ANF : Atrial natriuretic factor
Ang : Angiotensin
AOGEN : Angiotensinogen
AT : Angiotensin II receptor
ATCC : American Tissue culture
Collection
ATP : Adenosine triphosphate
BAC : Bacterial artificial chromosome
BP : Blood pressure
BSA : Bovine serum albumin
COD1 : X-linked cone-rod dystrophy
CTP : Cytidine triphosphate
CVD : Cardiovascular disease
DAB : Diaminobenzidine
DEPC : Diethyl pyrocarbonate
DMEM : Dulbecco's modified Eagle's
medium
DNA : Deoxyribonucleic acid
DOCA : Deoxycorticosterone acetate
dpc : Days post-coitum
DTT : Dithioerythritol
EA: Efferent arteriole
ECM : Extracellular matrix
EDTA : Ethylenediaminetetraacetic acid
eNOS : endothelial nitric oxide synthase
ERK : Extracellular signal-regulated
kinase
ET-1 : Endothelin-1
ETa : Endothelin receptor A
GFP : Green fluorescent protein
GMEM : Glasgow's modified Eagle's
medium
GTP : Guanosine triphosphate
hAOGEN : Human angiotensinogen
HPLC : High performance liquid
chromatography
hRen: Human renin
HRP : Horseradish peroxidase
I3C : Indole-3-carbinol
iNOS : Inducible nitric oxide synthase
IPTG : Isopropyl P-D-thiogalactoside
JG: Juxtaglomerular
JGA: Juxtaglomerular apparatus
JGC : Juxtaglomerular cell
LVH : Left ventricle hypertrophy
M6Pr: Mannose-6-phosphate receptor
MAP : Mean arterial pressure
MAP kinase : Mitogen-activated protein
kinase
MD : Macula densa
MH : Malignant hypertension
mRNA : Messenger RNA
NO : Nitric oxide
NTP : Nucleic acid triphosphate
PBS : Phosphate-buffered saline
PCR : Polymerase chain reaction
PP : Pulse pressure
PRC : Plasma renin concentration
QTL : Quantitative trait loci
RAAS : Renin-angiotensin-aldosterone
system
RAS : Renin-angiotensin system
RNA : Ribonucleic acid
RT-PCR: Reverse transcriptase
polymerase chain reaction
SBP : Systolic blood pressure
s.d. : Standard deviation
SDS : Sodium dodecyl sulphate
SHR : Spontaneous hypertensive rat
SMC : Smooth muscle cell
SMG : Submandibular/submaxilliary
gland
SPSHR : Stroke-prone SHR
SSC : Sodium- chloride/citrate buffer
TBS : Tris-buffered saline
TEM : Transmission electron microscope
TGF : Transforming growth factor
TGR: Transgenic rat
tRNA : Transfer ribonucleic acid
TTP : Thymidine triphosphate
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Abstract
The renin-angiotensin system (RAS) is a key biochemical pathway controlling homeostasis and
blood pressure. The initial step of the RAS is carried out by renin to produce angiotensin (Ang)
I which is converted to Angll by the angiotensin-converting enzyme (ACE). Renin is
synthesized as a pro-enzyme which can be activated in dense core granules of the renal
juxtaglomerular cells or released as prorenin. There is evidence that prorenin can, in addition, be
activated in a reversible manner, via a prorenin receptor. Recently, a specific (pro)renin receptor
was identified in human tissues. Binding of this receptor to (pro)renin caused increased cleavage
of angiotensinogen and stimulation of an intracellular signalling pathway. The aim of this thesis
is to investigate the biology of prorenin, its maturation and the (pro)renin receptor.
Expression of the mouse putative (pro)renin receptor (RR) was detected by RT-PCR in all
tissues and cell lines examined including human mesangial cells previously reported to be
negative for RR. Mouse RR was also present during development from E9.5. The mouse and rat
RR cDNA were found to be highly homologous (92% and 91%, respectively) to the human
cDNA. Surprisingly, the translated human, mouse and rat cDNAs exhibited sequence identity
with a small protein co-purifying with a bovine vacuolar-ATPase called M8-9 which had not
been reported previously. V-ATPases are critical for cell survival. Phylogenic studies revealed
RR is highly conserved between species and likely to be important physiologically. The role of
RR was investigated in a high circulating prorenin rat model \TGR(Cyplal-Ren2)], in which
(pro)renin triggers malignant hypertension (MH).
Uptake of prorenin by the heart previously demonstrated in this transgenic model may be
mediated by RR. In the present study, the animals, from a new colony, had a gradual
hypertensive response. Cardiovascular stiffening was measured using echo(cardio)graphy.
Despite an obvious hypertrophic remodeling and longer exposure to the inducer, no signs of
microinfarctions or inflammatory infiltration cells were observed in the heart. Fibrinoid necrosis
of small intra-renal vessels with glomerulosclerosis and mesenteric artery remodeling were also
observed. The phenotype differs from the original work. Surprisingly, RR was not up-regulated.
The reasons for the phenotypic differences between TGR(Cyplal-Ren2) colonies were
examined. Two main observations were made: dietary sodium levels appear to correlate with the
severity of MH and TGR(Cyplal -Ren2) animals reported in this thesis had a lower pathogen
load.
To investigate the possible role of RR, a prorenin decoy peptide was used to attempt to
ameliorate the MH phenotype in TGR(Cyplal-Ren2) animals. This peptide which competes
with prorenin for binding to RR, has been showed to improve vascular injuries in diabetic
nephropathy. In TGR(Cyplal-Ren2), however, no changes in the MH phenotype could be
observed, except in the mesentery in which less severe fibrinoid necrosis developed.
To complement work on RR, prorenin maturation and renin storage were studied during
development. The data showed the complete absence of renin granules in mouse kidneys before
birth. This indicates that renin could not be stored and may not be processed through the
regulated pathway as observed in the adult. Low sodium diet and ACE inhibition triggered
(pro)renin granules to be produced in the foetal kidney. Two ACE inhibitors differing in their
ability to cross the placenta were used. The data suggest that foetal renin granule formation is
under dual control from both foetal and maternal RAS.
Although the (pro)renin receptor may be important physiologically, the data presented in this
thesis suggest a more fundamental role in cell biology than had previously been recognised. The
lack of evidence for regulation of RR in a model of high prorenin and malignant hypertension
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The World Health Organisation (WHO) reported that, in 2001, 33.5 million people were
affected by so-called "non-communicable diseases", namely cancer, stroke and
cardiovascular diseases (CVD), worldwide. Half of these individuals were diagnosed as
having CVD making these conditions the most important cause of death after smoking. The
healthcare and social costs in the United States of America alone for the treatment of CVD
and lost man hours were estimated to $368.4 billion by the American Heart Association
(2004). Stroke and CVD have become the two leading causes of deaths in Western society.
Although CVD were originally thought to be "Western world conditions", there has been a
marked increase in the number of affected people in "developing" countries (World Health
Organisation 2003). This prompted the WHO to make prevention and research in CVD a
new priority. Many cardiovascular conditions, namely cardiac hypertrophy, arrhythmias,
coronary heart disease and myocardial infarction have been linked to high blood pressure.
The increase in CVD risk can be attributed to physiological and structural changes to target
organs, in particular to the heart and the kidneys.
1.1 Hypertension
Hypertension (or increased blood pressure) is the chronic physiological state in which
arterial blood pressure is elevated and may potentially cause harm to patients if untreated.
The European Society of Hypertension and the European Society of Cardiology guidelines
on the management of hypertension 2003 recommended that blood pressure-lowering
treatment be prescribed to patients with systolic pressure above 140mmHg and diastolic
pressure above 90mmHg, although additional factors such as diabetes must be taken into
account in the evaluation of the blood pressure level threshold (European Society Cardiology
2003). Hypertension is well known to be a complex multi-factorial disease making
assessment, screening and choice of treatment difficult. Physiological mechanisms regulating
blood pressure are themselves numerous and interlinked (Figure 1.1).
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Figure 1.1: Mechanisms and pathways involved in the regulation of normal blood pressure. The two
main physiological influences on blood pressure are cardiac output and peripheral resistance which are
themselves under the control of several systems such as sympathetic nervous system or/and the renin-
angiotensin system. ADH = vasopressin, ADR = adrenaline, Angll = angiotensin II, ET = endothelin, NA
= noradrenaline. NO = nitric oxide. Blue boxes represent physiological responses while red boxes indicate
organs or anatomical structures. Adapted from Mayet and Hughes (2003).
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Treatments available for hypertension are of five classes (Genest 2001; Ramsay et al. 1999):
diuretics (the most commonly used), P-blockers, calcium-channel blockers, angiotensin-
converting enzyme (ACE; see below) inhibitors and antagonists of angiotensin receptors (see
below). The choice of therapy is dependent on age, level of blood pressure,
progression/complications such as renal diseases and environmental factors. In more than
90% of hypertensive cases, the cause is unknown. This is termed essential (or primary)
hypertension. Remaining cases called secondary hypertension are the results of an
underlying condition such as: chronic kidney disease, chronic alcohol abuse, hormonal
disturbances and endocrine tumours (Wales 1997). The prevalence of hypertension is
increased by several factors such as poor diet, high sodium intake, obesity, smoking,
diabetes, family tendency to high blood pressure and certain medicines such as
corticosteroids (Kannel 1990; Kannel 2000; Kannel et al. 2002; Kannel et al. 1970; Sowers
and Haffner 2002).
Hypertension is a polygenic trait in which the effects may be, in addition, modulated by
gene-environment (as described above) interactions. Monogenic disorders of hypertension
although uncommon, also exist (Lifton et al. 2001). For example, individuals with apparent
mineralocorticoid excess syndrome display high blood pressure due to a deficiency in 11 -(3-
hydroxysteroid dehydrogenase type II. This allows an erroneous activation of the
mineralocorticoid receptor by glucocorticoid which leads to increased renal sodium and
water reabsorption. (Stewart 1999). In Liddle's syndrome, a mutation in the epithelial
sodium channel was found to be responsible for a similar phenotype to the mineralocorticoid
excess syndrome (O'Shaughnessy 2001). These single-gene forms of hypertension
contributed to the advances in the understanding of the systems involved in blood pressure
regulation. Both syndromes are characterised by low or suppressed plasma renin and
aldosterone levels. This suggested that the renin-angiotensin-aldosterone system (RAAS)
and sodium homeostasis are important systems in maintenance of volume homeostasis,
electrolyte balance and therefore, the regulation of blood pressure.
Malignant hypertension (MH) is a severe complication of hypertension resulting in a
characteristic lesion. Fibrinoid arterial or arteriolar necrosis affects the small arteries of the
kidney. Small arteries of the brain, gut, heart, adrenal and retina are also susceptible to this
lesion (Robertson 1997).
The most severe outcomes of MH are myocardial infarction, heart and kidney failure and
strokes. Left ventricular hypertrophy (LVH) and microalbuminuria precede the development
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of the cardiac and renal injuries, respectively. These can be used as markers of hypertensive
complications in humans and also in animal models (Abdi and Johns 1996; Griffin and
Bidani 2004; Mayet and Hughes 2003). The physiological changes involved in LVH have
been shown to be linked to both haemodynamic factors such as shear stress (Hudlicka 1994)
and non-haemodynamic events such as the renin-angiotensin (Sadoshima et al. 1993;
Yamazaki et al. 1995) or the adrenergic system. The precise mechanisms causing LVH are
unclear and it may be that LVH is responsible for the increased blood pressure. However,
increased blood pressure leading to increased mechanical stretch is initially involved in the
development of this phenotype (Morgan et al. 1998). The involvement of the RAS in the
hypertensive pathophysiology of cardiac and vascular damage is discussed in more detail in
Chapter 1.4.4.
1.2 Animal models ofhypertension
Animal models of hypertension are widely available. They allow the study of a variety of
mechanisms and markers involved in the pathogenesis of hypertension which may be
applicable to human disease. The importance of genetic background of the strains used in
hypertension research is now well known. As well as being a major determinant in animal
studies, this aspect has also been utilised to identify quantitative trait loci (QTL) associated
with hypertension (and cardiovascular associated phenotypes) in both genetic and transgenic
models and more recently to generate congenic lines. To date, evidence is available showing
that at least one blood pressure QTL has been identified on each rat chromosome, except for
chromosomes 6, 11 and 15 (Rapp 2000).
1.2.1 Genetic models
Genetic models such as the spontaneous hypertensive rat (SHR), the spontaneous
hypertensive stroke-prone rat (SPSHR) or the Dahl salt-sensitive rat are useful tools to study
the effects of blood pressure and of genetic predisposition to hypertension. The following
paragraphs highlight the main characteristics and regulatory systems and factors involved in
the pathogenesis of hypertension in these models.
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1.2.1.1 Spontaneous hypertensive rat
The spontaneous hypertensive rats (SHR) were obtained by inbreeding Wistar-Kyoto rats
with the highest blood pressure. They develop hypertension (systolic blood pressure up to
180-200mmHg) from the age of 4-6 weeks, largely independently of dietary salt content and
display cardiac hypertrophy and renal dysfunction. All animals have impaired endothelium-
dependent relaxation (Pinto et al. 1998) without gross apparent vascular complications and
many SHR will develop heart failure if untreated (Pinto et al. 1998). End-organ damage was
shown to be dissociated from high blood pressure since diuretics and vasodilators reduce
blood pressure but do not reduce cardiac hypertrophy compared with ACE inhibitors (Fukui
et al. 1989; Limas et al. 1984). However, both ACE inhibition (captopril treatment) and
vasodilation (hydralazine treatment) improved aortic remodelling, namely increased
intimal/medial thickness and intimal collagen deposition, demonstrating that these processes
are linked to hypertension rather than being dissociated from it (Limas et al. 1984).
The atrial natruretic factor (released by cardiac tissue in response to increased mechanical
stress) is significantly reduced by ACE inhibition whereas a lesser effect was obtained using
the vasodilator hydralazine (Fukui et al. 1989). Although, the RAS is associated with
hypertension in cardiovascular remodelling events, a direct involvement of the RAS in the
cardiac end-organ damage observed in the SHR has been demonstrated independently of
blood pressure.
The RAS is, however, not the sole system involved in the pathophysiology of SHR. Strong
evidence is available suggesting that oxidative stress in the vasculature is an important
determinant in the pathophysiology of SHR. Development of arterial stiffness has been
reported in SHR and it appears that in the early phase of hypertension in this model, changes
in arterial structure and endothelial response to increased pressure are involved whereas in
older SHR loss of elastic properties is observed (Safar et al. 2001).
It is known that oxidative stress occurs prior to blood pressure rising (Nabha et al. 2005;
Vaziri et al. 1998). While nitric oxide (NO) production by endothelial NO synthase (eNOS)
is well known for its vasorelaxing properties, excessive NO production through the inducible
NO synthase (iNOS) may have cytotoxic effects and contribute to the endothelial
dysfunction seen in models of hypertension (Hong et al. 2000). Vascular eNOS is increased
in SHR before and after the onset of hypertension, possibly as a protective mechanism but
appears to be offset by increased expression of detrimental iNOS in the renal vasculature and
this may be a potential mechanism for renal end-organ damage. Inhibition of iNOS (by
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aminoguanadine treatment) decreases blood pressure and improves vascular function (Hong
et al. 2000). Inhibition of the transcription factor NF-kB can, in addition, reduces the extent
of cardiac hypertrophy in SHR independently of blood pressure reduction (Gupta et al.
2005). Treatment with Tempol, a superoxide dismutase mimetic, abolished the rise in
systolic blood pressure normally observed in SHR (Nabha et al. 2005). This was further
confirmed by a significant over-expression of iNOS in the proximal tubule of the SHR's
kidney and a reduction in the antioxidant enzyme glutathione dismutase (Kumar et al. 2005).
Although endothelium dysfunction may play an important role in the pathogenesis of SHR,
endothelin-1 (a potent vasoconstrictor released by endothelial cells) is not increased in SHR
(Schifffin et al. 1995). While the mechanisms of the development of hypertension and of
end-organ damage are still being investigated, the SHR has been one of the most widely used
genetic models that has contributed to the elucidation of the aetiology of essential
hypertension (Pinto et al. 1998). This model is currently being used for the identification of
quantitative trait loci (QTL) associated with blood pressure regulation (Dominiczak et al.
2000). SHR is also used for the generation of congenic lines. Congenic lines are a subset of
animals in which a chromosomal region has been substituted by the homologous region of
another strain (McBride et al. 2004). Linkage with large chromosomal regions is the first
step to identify candidate genes and congenic lines allow the identification of more refined
chromosomal areas associated with the phenotypic trait of interest (Dominiczak et al. 2000).
Further investigation of the blood pressure status of these lines reveals information
concerning more precise chromosomal region of interest and the identification of QTLs
(Dominiczak et al. 2000; McBride et al. 2004).
A subgroup of SHR is characterised by higher levels of hypertension and their tendency to
die of stroke and is termed the stroke-prone SHR (SPSHR) (Sun and Zhang 2005). The
phenotype can be accelerated by administration of a high-fat/high-salt diet (Abrahamsen et
al. 2002). The SPSHR is characterised by hypertension and weight loss. In the kidney,
increased levels of the pro-inflammatory cytokine TGF-pl which up-regulates fibronectin,
collagen and plasminogen-activator inhibitor-1, and causes fibrosis in the kidney
(Abrahamsen et al. 2002) were detected. All these detrimental factors were improved or
abolished by concomitant ACE inhibitor or ATi antagonist treatment suggesting that the
RAS is promoting pro-inflammatory, pro-thrombotic and fibrotic events in the SPSHR. In
their studies using the SHR and the SPSHR (crossed with their respective control strains),
Dzau et al. (1995) used congenic lines and reported a locus for the angiotensin-converting
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enzyme linked to salt-sensitive hypertension. Additional loci that co-segregate with
hypertension using different crosses of genetically hypertensive strains have been reported
[reviewed in (Dzau et al. 1995)]. Using the SPSHR and normotensive controls, glutathione-
S-transferase ( involved in oxidative stress) was identified as phenotypic candidate after
congenic lines were produced for linkage analysis followed by genome-wide mRNA
expression studies (McBride et al. 2004)
1.2.1.2 Lyon Hypertensive rats andMilan Hypertensive rats
Other inbred genetically hypertensive rats have been produced on different strain
backgrounds such as the Lyon hypertensive rats (Sassard et al. 2003) from Sprague -Dawley
stocks and the Milan hypertensive rats (Bianchi et al. 1975) strains from Wistar stocks.
These two rat models display similar features such as hypertension, cardiac hypertrophy and
increased renal vascular resistance. Each strain has a low, normal or high blood pressure sub¬
group allowing phenotypic comparison.
Lyon rats display salt-sensitive hypertension, decreased lifespan, increased body weight and
heart weight, dyslipidemia and increased insulin/glucose ratio (Bilusic et al. 2004) which are
features common to the metabolic syndrome in humans. Although renal and plasma renin
and prorenin levels are reduced in this model compared to normotensive controls,
angiotensin-converting enzyme (ACE) inhibition abolishes established hypertension, cardiac
hypertrophy and restores the heart to normal physiology (Sassard et al. 2003). Early ACE
inhibition prevented hypertension and cardiac hypertrophy suggesting that an activated RAS
is needed in the developing hypertension phase (Lantelme et al. 1997). It has, indeed, been
hypothesised that a short-term rise in plasma renin may be involved in early stages of
hypertension in the Lyon rats (Sassard et al. 2003). Concomitant angiotensin (Ang) II
infusion with an ACE inhibitor causes a rise in blood pressure suggesting an increased
sensitivity to Angll (Lantelme et al. 1997).
Other mechanisms controlling blood pressure in the Lyon and Milan models may be due to
activation of local RAS notably in the brain as demonstrated for the deoxycorticosterone
acetate -salt model (Itaya et al. 1986) or the "Goldblatt" model (Kagiyama et al. 2001).
Comparison between two strains, the Japanese SHR (and normotensive controls WKY) and
the Lyon strains showed that they possess intrinsic differences independent of blood
pressure. The SHR/WKY were found to have higher carotid wall stiffness, increased aortic
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hypertrophy and levels of collagen and an exaggerated affinity of aortic smooth muscle a-
receptors than the Lyon strain (Safar et al. 2001). This suggested that genetic factors also
play a role in the phenotypes observed.
Post-weaning Milan hypertensive rats (MHR) displayed blood pressure levels 40 to 50 mm
Hg higher than in their normotensive controls. Plasma renin activity was lower in MHR. The
most striking feature in this model was the renal phenotype. Urine output in MHR was 50%
to 100% greater possibly due to sodium retention which was greatly increased compared to
control animals during the period when the blood pressure difference developed (Bianchi et
al. 1975). The authors suggested that the kidney may play a crucial role in the pathogenesis
of hypertension in MHR. Further studies revealed that an intrinsic inability of the proximal
tubule cells to reabsorb fluid was present as well as a reduced of calcium ATPase activity in
the kidney ofMHR and may be the cause of the abnormal fluid and sodium handling (Salvati
et al. 1987). This cellular anomaly was also found in red blood cells which were
characterised by smaller volume and lower sodium contents. This impaired mechanism is
genetically modified at the stem cell level and, in humans, correlated with a renal phenotype
similar to that of MHR (Bianchi et al. 1986). The same research group later identified
modifications in a cytoskeleton protein, adducin, consisting of three sub-units encoded by
three separate genes.
A polymorphism in the a-sub-unit was identified in MHR which correlated with increased
blood pressure and a linkage analysis revealed an association between the adducin a-sub-unit
polymorphism and hypertension in Caucasian populations (Barlassina et al. 1997; Bianchi et
al. 1994). This polymorphism is thought to influence kidney function through the regulation
of ion handling by epithelial tubular cells. More recently, plasma levels of ouabain, a
hypothalamic hormone which modulates Na(+)/K(+)-ATPase activity in renal tubular cells,
were found to correlate with the number of copies of the mutated adducin a-sub-unit allele in
cultured renal cells (Staessen and Bianchi 2005). A competitive inhibitor of ouabain was
shown to lower blood pressure in MHR and humans and is being considered in clinical trials.
1.2.1.3 Dahl salt-sensitive rat
Another genetic model of hypertension is the Dahl salt-sensitive rat which was inbred from
Sprague-Dawley stocks on the basis of their developing high blood pressure with salt diet
(Pinto et al. 1998). The rats develop hypertension on normal sodium diet and displayed
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increased mortality on high sodium diet. As for the SHR, cardiac hypertrophy (and cardiac
failure) and endothelial impairment were present but with more severe renal damage. A close
relationship between polymorphism in the atrial natruretic factor (ANF) and angiotensin-
converting enzyme (ACE) genes and hypertension in these rats was reported (Deng and
Rapp 1992) and links in part the RAS to the pathophysiology of this model. Congenic strains
produced with the Dahl salt-sensitive rat have shown that the QTL marked by the inducible
form (but not the constitutive form) of nitric oxide synthase (iNOS) is segregating with
alleles relating to blood pressure (Deng and Rapp 1995), thus identifying iNOS as a potential
candidate influencing blood pressure in the Dahl salt-sensitive rat.
1.2.2 DOCA-salt model
The "pharmacological model" of deoxycorticosterone acetate (DOCA)-salt (known as a salt-
retaining hormone and to cause renal tubular enlargement) treatment is another model of
hypertension. It was first performed in chicks which were treated with DOCA-salt for 20
days and develop high blood pressure and end-organ damage after chronic administration of
DOCA (Selye 1942). The model was characterised by increased water intake, generalised
oedema, cardiac hypertrophy, aortic/large vessel thickening due to collagen deposition and
increased renal weight. It was demonstrated that, in the DOCA-salt treated rat, plasma renin
activity is low (lower than controls), hence constituting a low-renin model of hypertension
(Wilson et al. 1987). Altered regulation of central sympathetic and pressor systems as well
as the brain RAS are involved in the development of hypertension (Gomez-Sanchez et al.
1996). In phases of development of hypertension and maintenance of hypertension,
intracerebroventricular administration of the ACE inhibitor, captopril, causes suppression of
drinking response to hypertension as well as inhibition of vasopressin release and restoration
of impaired baroreceptors reflexes (Itaya et al. 1986). Central RAS inhibition appears
therefore to be involved in the amelioration of blood pressure via action on sodium
metabolism and the baroreceptors (Itaya et al. 1986). Another hypertensive mechanism in
this model and the genetic models described above is endothelial dysfunction. It was shown
that in DOCA-salt treated rats, the levels of circulating endothelin-1 are normal but
endothelial cells of aortic and mesenteric vessels overexpress endothelin 1 and when SHR




The Goldblatt model (Goldblatt et al. 1934) is perhaps the oldest model of hypertension. The
original model was applied to dogs in which the renal artery was constricted ("clipped") on
one side, hence reducing renal blood flow while the other kidney is either left intact (2-
kidney/l-clip) or removed surgically (1-kidney/1-clip). The initial "clipping" causes the
kidney to respond to the reduced blood flow by producing excessive amounts of renin
causing systemic increase in renin levels (Goldblatt et al. 1934). This, in turn, leads to an
increase in blood pressure mediated by Angll vasoconstriction and fluid retention (Goldblatt
et al. 1934). The intact kidney is then involved in regulating salt and fluid balance as a result
of the unilateral renal artery stenosis. This surgical model has since been applied to various
species such as the rat (Abdi and Johns 1996; Morgan et al. 2001), the monkey (Panek et al.
1991) and the mouse (Wiesel et al. 1997). The increased blood pressure and dysregulation of
homeostasis is even more marked in the 1-kidney/l-clip model since the intact kidney is not
present to compensate for the "clipped" kidney. Berg et al. reported that the blood pressure,
renin-angiotensin system (RAS) activation and fluid homeostasis is returned to normal when
the constricted renal artery is "undipped" (in the 2-kidney/l-clip) in rats (Berg et al. 1979).
It therefore provides a reversible (although surgical) model of high renin and renovascular
hypertension which mimics the equivalent human condition of renal artery stenosis.
The 2-kidney/l-clip animals are characterised by increased renin release in the circulation
and increased plasma renin activity leading to increased Angll production. This causes
vasoconstriction, cardiac hypertrophy and, in the kidney, increased natriuresis, hence this
model constitutes, not only a high renin model but also a volume depleted state (Pinto et al.
1998). Administration of a renin inhibitor returns mean arterial pressure and plasma renin
activity to normal (Panek et al. 1991). Moreover, the effects of Angll were shown to be
attenuated by injection of the RNA anti-sense to the angiotensin I receptor type 1 (Galli and
Phillips 2001), confirming the involvement of the RAS in the pathology of the 2-kidney/l-
clip animals. It is worth noting that, after the initial phase of RAS activation and
hypertension in the dog, the blood pressure can decrease due to collateral vessel
development (Watkins et al. 1976). In the 2-kidney/l-clip monkeys, the blood pressure
remains elevated after 24 weeks (Panek et al. 1991) and in the 2-kidney/l-clip rat, it has
been shown that, although the peripheral (circulating) RAS returns to normal, the blood
pressure remains elevated for several months (Kagiyama et al. 2001). This is dependent on
activation of a central RAS which was inhibited by intracerebroventricular injection of anti-
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sense RNA for angiotensin I receptor type 1 (Kagiyama et al. 2001). The 2-kidney/l-clip
model is known to be sensitive to sodium diet modulation, i.e. blood pressure decreases on
low sodium diet (Leenen and de Jong 1975) which may be the result of renal or central
control over sodium balance.
1.2.4 Transgenic models
Transgenic models have become widely used in the field of cardiovascular science and
several rat lines have been generated in order to study the involvement of renin-angiotensin
system (RAS) genes and pathways in the pathophysiology of hypertension.
1.2.4.1 Human AOGENx human renin transgenic rats
Two normotensive transgenic rat lines were produced, one carrying the human
angiotensinogen gene (hAOGEN) and the other harbouring the human renin gene (hRen)
(Ganten et al. 1992). Plasma human AOGEN was increased in line TGR(hAOGEN) with
expression of hAOGEN in liver, kidney, brain, lung, heart, and the gastrointestinal tract. The
TGR{hRen) line had increased human renin in the kidney after sodium depletion. In addition,
human renin infusion in TGR(hAOGEN) also triggered an increased in blood pressure which
was inhibited by a human renin inhibitor. When the same renin inhibitor was added to
plasma samples of sodium depleted double transgenic animals, the human renin activity was
inhibited but not the rat renin activity and rat renin infusion in TGR(hAOGEN) triggered an
increased in blood pressure which was not inhibited by the hRen inhibitor. This study
demonstrated the species specificity of renin for its substrate angiotensinogen. However, the
double transgenic animals did not develop hypertension. A second double transgenic line
was produced using the original hAOGEN animals and a new hRen line (Bohlender et al.
1997) but no information has been published regarding this new line. The new double
transgenic line has also been shown to succumb to end-organ damage affecting mainly the
heart and the kidney (Luft et al. 1999). Infiltration of inflammatory cells in the vascular wall
precedes fibrinoid injury. The authors demonstrated that blood pressure reduction was
achieved with both ACE inhibitors and angiotensin receptor inhibitors but only partly with a
renin inhibitor. The latter, however, prevented the development of vascular injury as did
endothelin receptor blockers.
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Using blood pressure lowering drugs that do not interfere with the RAS (such as the
vasodilator hydralazine), it was later demonstrated that the role of the RAS in the
inflammatory pathways responsible for end-organ damage in this model is independent of
hypertension (Mervaala et al. 2000). This double transgenic model was also used to study
the effects of endothelin-1 (ETi) and Angll in the phenotype of this model (Gerbaulet et al.
2005). Sub-pressor doses of angiotensin receptor type I (AT]) inhibitor and endothelin
receptor A (ETA) blocker did not affect the hypertension in these rats but a combination of
both agents did. Similarly, coronary artery remodelling, cell proliferation and inflammation
were reduced by both treatments and in combination showing that Angll is involved in all
these processes and there is a synergistic action of both Angll and ETi in the pathogenesis of
malignant hypertension. This model has also been proposed as a model of gestational
hypertension as pregnant TGR(/l4GJ) developed hypertension in late gestation when mated
with TGR(hRen) males (Bohlender et al. 2000). Blood pressure returned to normal after
delivery but the offspring developed the phenotype described above. The data suggested that
placental tissue of foetal origin was capable of expressing human renin and of converting
human AOGEN ofmaternal or foetal origin.
1.2.4.2 TGR(mRen2)27
TGR(mRen2)27 are transgenic rats carrying a transgene containing the mouse Ren2 gene
(Mullins et al. 1990). They display fulminant hypertension from 5 weeks of age (230mmHg)
and the animals suffer from malignant hypertension (MH) injuries leading to heart failure
unless treated with ACE inhibitors.
The TGK(mRen2)27 animals displayed suppressed concentrations of active plasma and renal
renin, low or unchanged levels of plasma Angll but increased levels of circulating prorenin
compared to controls (Lee et al. 1995). The highest expression of the transgene was found in
the adrenal gland as demonstrated by adrenalectomy which reduces plasma prorenin by 80%
and returns blood pressure to normal (Tokita et al. 1994). These findings underline the
importance of the RAS and local RAS and, in particular, of prorenin in the development of
hypertension and hypertensive injuries in these animals. As discussed in the double
transgenic rat model (Luft et al. 1999), some treatments such as hydralazine (a vasodilator)
have been shown to reduce the blood pressure without preventing/attenuating the vascular
and organ injuries present in these models suggesting other mechanisms such as activation of
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the RAS plays an important role in the pathology observed (Pinto et al. 1998). In
TGR(mRen2)27, ACE inhibitors (e.g. quinapril) and angiotensin receptor antagonists (e.g.
losartan) have hypotensive effects accompanied by a decrease in the severity of end-organ
damage (Teisman et al. 1998). Furthermore, there is an indication that these hypertensive
agents can prevent end-organ damage when administered in sub-pressor doses, again
showing dissociation of hypertension from end-organ damage (Linz et al. 1989). In addition,
Jacinto et al demonstrated that impaired peripheral and intrarenal responses to endothelium-
dependent vasodilators may be responsible for an exaggerated peripheral and renal response
to the vasoconstriction effects of Angll (Jacinto et al. 1999). Increased sensitivity to Angll
was also demonstrated in the genetic low-renin Lyon hypertensive rat model (Lantelme et al.
1997).
Crosses of TGR(mRen2)27 to other rat strains have showed that malignant hypertension is
linked to the strain genetic background, TGR(mRen2)27 rats on a Fischer (F344) background
displaying the most extensive injuries whereas TGR(mRen2)27 rats on a Lewis background
had the least damaging lesions (Mullins and Mullins 2003). Linkage analysis has shown that
factors on chromosome 10 and 17 close to the ACE and ATj loci are linked with the
malignant hypertension phenotype in the TGR(mRen2)27 animals (Kantachuvesiri et al.
1999).
1.2.4.3 Other "prorenin " rat transgenic models
Another transgenic rat model was generated to study the effects of exaggerated circulating
rat prorenin by directing expression of a rat prorenin-containing transgene to the liver
(Veniant et al. 1996). Plasma prorenin levels were similar to the previous model but plasma
renin levels were normal. The animals, however, did not display elevated blood pressure
until after the renal and cardiac lesions were well established, indicating that prorenin may
be involved in the MH lesions independently of blood pressure. An inducible rat model of
hypertension TGR(Cyplal-Ren2) was recently developed in this laboratory based on Ren-2
transgene used in TGR(mRen2)27 animals. In this instance, the transgene was under the
control of cytochrome P450 Cyplal promoter (Kantachuvesiri et al. 2001). The promoter is
induced when the animals are fed a diet containing the natural xenobiotic indole-3-carbinol
(I3C) which allows discreet and precise control over the onset of hypertension. The
expression of the transgene is detected 24h after induction (0.3% I3C in food) in the liver.
Upon chronic induction, TGR(Cyplal-Ren2) animals displayed a rapid increase in BP
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accompanied by weight loss and polyuria, together with an activated circulating RAS (in
particular prorenin) and malignant hypertension lesions. This model has been further
characterised haemodynamically and is described with all the other "prorenin" transgenic
animals in Chapter 4. Using the advantages of this inducible model, congenic lines carrying
the Ren2 transgene and the region of chromosome 10 associated with blood pressure derived
either from the Lewis and the Fischer (F344) are currently being developed (Mullins and
Mullins 2003).
The renin-angiotensin-aldosterone system plays an important role in regulating blood
volume, arterial pressure, and cardiac and vascular function. The RAS is a pivotal circulating
component of homeostatic regulation and in addition pathways for the RAS have been found
in a number of tissues. In addition, Angll has been shown to be a reproductive and growth
hormone. Hence, the RAS plays a crucial role in normal physiology and is involved in the
pathogenesis of hypertensive disease which explains why a large body of work, including
this thesis has focussed on the study of its regulation in a variety of biological systems.
1.3 The Renin-Angiotensin-Aldosterone System
Angll, the resulting peptide and effector molecule of the RAS cascade, possesses a variety of
actions such as resistance vessels constriction thereby increasing systemic vascular
resistance and arterial pressure, adrenal cortex stimulation to release aldosterone, which in
turn acts upon the kidneys to increase sodium and fluid retention, triggering the release of
anti-diuretic hormone from the posterior pituitary which acts upon the kidneys to increase
fluid retention, stimulation of thirst response within the brain, facilitation of norepinephrine
release from sympathetic nerve endings and inhibits norepinephrine re-uptake by nerve
endings, thereby enhancing sympathetic adrenergic function and causing cardiac and
vascular hypertrophy.
Angll, a potent vasoconstrictor peptide, is produced from the initial cleavage of
angiotensinogen following its release from the liver by renin in the circulation. Renin and its
secretion are therefore major determinants (and limiting factors in humans) of the RAS. The
product, angiotensin (Ang) I is, in turn, cleaved by the angiotensin-converting enzyme (ACE
- located on the luminal surface of the vascular endothelium in the lungs) forming Angll
(Figure 1.2). AngI can also be converted to Angll by ACE-independent mechanisms such as
tissue plasminogen activator, cathepsin G or chymase (Johnston and Risvanis 1997). Angll,
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itself, plays an important role in the regulation of blood pressure, volume homeostasis, salt
balance and also tissue remodelling. The effects ofAngll occur via binding to its receptors,
named angiotensin receptor-type 1 (ATi) and angiotensin receptor-type 2 (AT2) to cause
increased sodium and water retention in the proximal renal tubule, increased aldosterone
release from the zona glomerulosa of the adrenal gland, itself causing increased sodium and
water retention in the distal renal tubule and vasoconstriction (Campbell 1987). Embryonic
development, notably in the vasculature and the kidney, is known to be dependent, in part,
on the renin-angiotensin system (RAS). During development all components of the RAS are
present, although appearing at different stages of development. Angiotensin (Ang) II is a
well-recognised reproductive (Speth et al. 1999) and development hormone (Tebbs et al.
1999). The respective contribution of the maternal RAS and the foetal RAS to embryonic
development is not fully understood.
Knock-out models of components of the RAS, namely angiotensinogen (AOGEN), renin,
angiotensin-converting enzyme (ACE) and angiotensin receptors have provided useful
information regarding the importance of the RAS in development. The kidney appears to be
a primary target for abnormalities. These could be caused by a variety of mechanisms
relating to maternal and/or foetal blood pressure regulation, the absence of renin-expressing
cells in the foetus or the decreased availability of Angll in the mother, the foetus and/or the
uteroplacental complex. Although the deformities in the RAS knock-out animals are very
severe, the results from these animals have revealed hidden roles for the RAS in
embryogenesis. It raises the possibility that, during gestation, modulations in the RAS by
water and electrolyte imbalances (Ross et al. 2005), dietary modifications such as maternal
undernutrition (Kwong et al. 2000; Langley-Evans and Jackson 1996), salt intake (Lawlor
and Smith 2005) and increased maternal blood pressure may have lasting effects on the
















Figure 1.2: The renin-angiotensin-aldosterone system. The diagram depicts the classical roles of the
circulating RAS in blood pressure regulation (adapted from Campbell et al., 1987)
1.3.1 Renin and prorenin
1.3.1.1 Synthesis
Renin is an aspartyl protease that functions to convert its only known substrate, angiotensinogen
(AOGEN) producing the decapeptide AngI by proteolytic cleavage at the N-terminus (Poulsen
and Jacobsen 1993). It was first reported, in 1971, that plasma and amniotic fluid contained more
renin after dialysis to pH 3.3-3.6 (Lumbers 1971) and after treatment with proteolytic enzymes
(Morris and Lumbers 1972), respectively. The authors postulated that renin may therefore first
exist as an inactive pre-pro-enzyme activable by low pH and proteolysis. Poulsen et al. reported
that renin is synthesized as a pre-pro-enzyme of 50kDa (Poulsen et al. 1979) using a cell-free
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translation system whereas renin of 40kDa size was purified from the submandibular gland
(SMG) (Nielsen et al. 1979). This confirmed the idea that renin was first produced in a precursor
form. In addition, Nielsen et al. reported that renin from the submandibular gland is not stored
nor secreted in an inactive or high molecular weight and that the only form of renin in this organ
is the fully active 40kDa enzyme. High molecular weight "renins" have also been reported in the
plasma and may represent renin bound to plasma lipoproteins or serine protease inhibitors such
as pepstatin (Nielsen et al. 1979). The reasons for the discrepancy in molecular size compared to
Poulsen et al. and Nielsen et al. are unclear and may be due to the methodological differences.
Further work on the biosynthesis of the mouse renin was performed by Catanzaro and colleagues
who reported that mouse renin translated from mRNA (selected using a renin cDNA) was a
45kDa protein (Catanzaro et al. 1983). Similarly, the presence of a translation product from
SMG of 45kDa in size, in mice characterised by high renin levels was reported (Piccini et al.
1982). The authors showed that renin from the SMG was produced in amounts between 50- to
100-fold higher than in the kidney in "high renin" animals, that it was under testosterone-control
and that it is produced from a second renin gene (Piccini et al. 1982). Preprorenin was converted
to the 43kDa prorenin which, in turn, was converted rapidly to a 38kDa single chain renin
(Catanzaro et al. 1983).
This renin form could be hydrolysed to 33kDa and 5kDa chains linked by disulphide bonds
(Figure 1.3). This is in accordance with the estimation ofMisono et al. based on the amino-acid
sequence (Misono et al. 1982). In addition, the light chain (5kDa) was found to provide
enzymatic stability (Pratt et al. 1983). A similar pathway is present in humans but the heavy and
light chains have molecular weights of 22kDa and 18kDa, respectively (Do et al. 1987). It was
also reported that only the one- and the two-chain renin (but not prorenin) have enzymatic
activity (as quantified by binding to pepstatin) (Pratt et al. 1983). This is in contradiction with
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Figure 13: Processing of mouse pre-prorenin. As described in text, the "pre" signal is removed to give
rise to prorenin which in turn can be proteolytically resulting in removal of the prosegment. The resulting
renin is 38kDa in molecular weight and can be slowly hydrolysed to 2-chain renin in which the 2 sub-units
are linked by a disulphide bridge.
1.3.1.2 Maturation ofprorenin andprocessing ofrenin
Using anti-sera corresponding each to the N-terminus, the C-terminus and the middle portion of
the prosegment, Taugner et al. (1987) determined the fate of human prorenin during granule
secretion. The prosegment was demonstrated to be cleaved off step by step: the N-terminus is
removed in the Golgi whereas the middle portion and C-terminus are cleaved off in the
endoplasmic reticulum (Taugner et al. 1987). Both in humans and mice, the resulting prorenin
can then either be: a) secreted constitutively, b) packaged into low density granules ("juvenile")
or, c) converted intracellularly to active renin (40kDa) and stored in dense core/mature granules
before secretion when required (Friis et al. 2000). Compared with mature granules, juvenile
granules were found to have a lower fusion ability and therefore be less likely to undergo
exocytosis (Taugner and Metz 1986).
After prorenin secretion, the mechanisms of downstream prorenin activation/conversion are, to
date, unclear. In the plasma, in the presence of protease inhibitors, the conversion of prorenin is
much slower than in the kidney (Leckie and McGhee 1980) but candidate enzymes for prorenin
activation include cathepsin D and G, acid protease and kallikrein. Cathepsin B, which co-
localises with renin into storage granules may be responsible for the conversion of prorenin
(Taugner et al. 1985) but the mechanisms are still unclear.
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Evidence is accumulating in favour of an additional pathway of non-proteolytic activation of
prorenin. Prorenin is now known to be activated without changes in molecular weight and
with the ability to return to an inactive conformation by trypsin or acid treatment (Derkx et
al. 1987). Non-proteolytic activation of prorenin (Figure 1.4) may play an important role in
the normal physiology, notably during gestation since high levels of prorenin are detected in
the amniotic fluid, the role of which is unknown. It may be a crucial element in the
pathophysiology of high prorenin states such diabetes and in animal models characterised
with high circulating and local prorenin such as TGR(mRen2)27 transgenic animals and the
diabetic streptozotocin-treated rats.
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Figure 1.-1: Schematic representation of prorenin activation pathway. The predominant pathway
of prorenin activation is by the removal of the prosegment as found in immature and juvenile
secretory granules of the juxtaglomerular cells leading to the formation of renin. Other pathways may
be responsible for proteolytic activation of prorenin in the plasma but these are, to date, unclear. A
new non-proteolytic activation of prorenin has been identified and may involve binding to a receptor.
Although not depicted in this cartoon, non-proteolytically activated prorenin may be able to convert
AOGEN into Angl. Aog = angiotensinogen. Reproduced from (Danser and Deinum 2005).
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The physiological mechanisms of prorenin non-proteolytic activation, however, remain
unclear but it has been shown that an antibody corresponding to the N-terminal of prorenin
induces activation (Suzuki et al. 1999) and the rate of prorenin activation is determined by
this sequence (Suzuki et al. 2000). In addition, Suzuki et al. identified two key regions in the
prosegment for non-proteolytic conversion using two antibodies: the first one blocked the re-
inactivation of acid-activated prorenin and the other non-proteotycally activated prorenin
(Suzuki et al. 2003).
1.3.1.3 Juxtaglomerular cells
Renin is mainly released by a discreet renin-secreting population of cells of the
juxtaglomerular apparatus (Figure 1.5). The smooth muscle cells of the afferent arterioles are
capable, under stimulation (e.g. sodium concentration decrease sensed by the macula densa)
to undergo reversible differentiation (Taugner et al. 1984). The renin-secreting population
extends to the pre-glomerular portion of the afferent arteriole (Hackenthal et al. 1990). These
cells, called epitheloid cells, situated in the media of the afferent arterioles extend in varying
length depending on renin production/secretion stimulation.
In addition, there is heterogeneity between arterioles, not all of them containing granulated
renin-producing cells. Furthermore, Hackenthal et al. (1990) reviewed the mechanisms of
renin secretion and reported that, along the afferent arterioles, smooth muscle cells at varying
stages of metaplastic differentiation can be observed. Therefore, close to the macula densa
the cells are "plump" in shape with many dense core granules and have lost their contractility
and downstream from the macula densa, the cells become gradually more spindle-shaped,
have less or no dense core granules (and only "immature renin granules") and are more
contractile (Hackenthal et al. 1990).
The formation of renin granules in JG cells is described in Chapter 7. Renin release from
granules in JG cells can be stimulated or inhibited by a number of stimuli. Although, an
increase in intracellular calcium has been shown to inhibit renin secretion from JG cells, it is
generally a triggering factor for the release of other enzymes contained in secretory vesicles.
Lysosomal enzymes such as cathepsins are present in secretory granules and co-localise with
renin (Taugner et al. 1985). Although renin granules are acidic, they may however lack the
necessary machinery for calcium-associated exocytosis. This is why renin granules are often
referred to as "modified lysosomes".
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Figure 1.5: Juxtaglomerular apparatus. The juxtaglomerular apparatus is made up of the afferent
arteriole (AA), efferent arteriole (EA) and macula densa (MD). JG cells are located in the media of the
afferent arteriole (arrows) and contain dense core renin granules. Reproduced and adapted from
(Hackenthal et al. 1990).
The developmental occurrence of renin-expressing cells has been shown to start at E13
in the mouse (Kon 1999). During embryogenesis, some renin-expressing cells are
present prior to vessel formation in the loose renal mesenchyme (Gomez et al. 1990b).
Renal granulated cells, possibly containing renin have been found in species of fish
which do not possess a macula densa such as chondrichtyes (Wilson 1984). This is also
observed in the zebrafish where mesonephric cells are present before macula densa cells
appear (Liang et al. 2004). These findings suggest that renin has a physiological role in
development separate from blood pressure regulation. Renin expression in the developing
mouse kidney, however, essentially follows the formation of the arcuate and interlobar arteries
[(Mullins et al. 2000), Figure 1.6] suggesting a physiological role of renin in renal development
notably in vascular branching before blood pressure regulation. At embryonic day 17.5 (El7.5),
renin expressing cells are found within the afferent arteriole wall and then become a discreet
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population localised to the JG location in the adult as described and illustrated above. A similar
pattern is observed in the rat (Gomez and Norwood 1995) and in both rats and mice, renin
mRNA is developmentally regulated, its expression being higher in the foetus and the newborn




Figure 1.6: Development pattern of renin expression using a transgenic LacZ-expressing mouse line.
Renin is first expressed in the large arcuate arteries and interlobar arteries and is gradually shifted
outwards during the peri-natal period to reach a discreet localisation in the juxtaglomerular apparatus.
Reproduced and adapted from (Mullins et al. 2000).
JG cells are considered to be terminally differentiated from SMC since they possess SMC
characteristics and produce the hormone renin. It has been shown that when homeostasis is
threatened (as it may happened during haemorrhage or hypotension), smooth muscle cells of the
renal arterioles can be recruited and they undergo reversible metaplastic differentiation (Gomez
et al. 1990b; Pentz et al. 2001). Reversible metaplastic transformation allows production of renin
in response to those physiological changes (Figure 1.7). Hence, the number of renin-positive
cells along the afferent arterioles varies. This allows "extra" renin-producing cells to be present
as to trigger the RAS cascade leading to the production ofAngll and restoration ofnormal blood
pressure. Whether these cells return to their original smooth muscle cell-only characteristic is
unclear. Using a GYV-Renl reporter system, Sequeira-Lopez et al. (2004) followed the fate of
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renin-expressing cells from their embryonic location to their recruitment under salt depletion
conditions. The authors demonstrated that it was the same renin-producing cells which line the
afferent and efferent arterioles during nephrogenesis which become SMC but retain the
"memory" of becoming renin producing when needed (Figure 1.7). Specific ablation of renin-
expressing cells by placing the diphteria toxin A chain under the control of the Renld promoter
in two renin-gene mice (Pentz et al. 2004) showed that renin cells per se are involved in renal
development. Although renin-expression was normal in the submandibular gland (due to Ren2
expression), renin expressing cells were not seen in the kidney. Homozygous animals displayed
phenotypic renal abnormalities mainly associated with tubular (dilation and atrophy) and
glomerular (hyperplasia or atrophy) morphology.
Figure 1.7: Fate of renin producing cells. Schematic representation of the fate of JGC and SMC during
development and during episodes ofRAS activation.
The presence of renin granules pre-natally is still a matter of debate. Post-natally, the presence of
renin granules is unequivocal (Bruhl et al. 1974; Egerer et al. 1984). However, few reports
demonstrate the presence of renin granules in JG cells during renal development. Considering
renin dense core granules only contain active renin, it may be of interest to clarify whether renin
granulation (and foetal active renin production) indeed occurs pre-natally in the mouse.
Could it be that renal prorenin has a direct role in early renal development? Would
pharmacological or dietary changes which modulate renin and prorenin expression/processing
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have an effect on embryonic development? The stimuli involved in the formation of granules
were studied using ACE inhibition and dietary sodium modifications during pregnancy in
Chapter 7. Is their a role for a (pro)renin receptor/non-proteolytic conversion of prorenin in
these events?
1.3.1.4 Renin Secretion
The release of active renin from JG cells is controlled by several distinct mechanisms:
a) intra-renal receptors, namely baroreceptors, which sense changes in arteriolar pressure and
cell volume and the macula densa which senses changes in sodium chloride delivered to the
distal nephron (Schnermann 1998). This process appears to be a new mechanism in evolutionary
terms. Species of fish (e.g. teleost fish) which have plasma and kidney renin activity do not
possess a macula densa suggesting a fairly recent acquirement of tubulo-glomerular feedback
regulation (Wilson 1984).
b) via sympathetic nervous system action. The (Tadrenoreceptor activation under decreased
blood pressure conditions, for example, triggers the stimulation of sympathetic nerves or the
release of catecholamines inducing JG renin release (Hackenthal et al. 1990),
c) humoral factors such as prostaglandins and catecholamines can stimulate the release of renin
whereas Angll, aldosterone and ANF (in part due to a negative feedback loop) inhibit it
(Hackenthal et al. 1990),
d) intracellular second messengers are released as a response to all the above stimuli and either
induce (e.g. cyclic AMP) or suppress (e.g. Ca2+) the release of renin (Kurtz and Wagner 1999).
Increased blood pressure and Angll can increase intracellular calcium secretion, an event known
to trigger the release ofmaterial stored in secretory granules. This, however, does not apply to
the release of renin from JG cells since it is prevented by increased levels of circulating Angll as
part of a negative feedback loop. This phenomenon has been referred to as the "calcium
paradox". Adrenocortical cells of TGR(mRen2)27 rats which express the mouse Ren2 gene in
the adrenal gland (and in tissues normally expressing Ren2 in mice) can be stimulated by the
calcium ionophore A23187 (Peters and Clausmeyer 2002). This demonstrates that adrenal renin
secretion is under differential regulation than that of the JG cells. The exact cellular events
governing the release of renin from JG cells are not fully understood but electrophysiological
studies have shown that exocytosis involved in this process (Friis et al. 2000).
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1.3.1.5 Expression and localisation in extra-renal tissues
As mentioned above, the main site of renin release is the kidney. In humans, the kidney is
the only known organ to release active renin and extra-renal sites of renin production secrete
prorenin exclusively (Sealey and Rubattu 1989). However, some non-renal renin producing
tumours have been described (Atlas et al. 1984). In addition, in the mouse, active renin has
been found to be released by the submandibular gland (Catanzaro et al. 1983) and by the
adrenal gland (Berka et al. 1996; Deschepper et al. 1986; Inagami et al. 1989). It is the
detection of high levels of renin in the mouse sub-maxilliary gland (SMG) which allowed the
purification of the aspartyl protease (Cohen et al. 1972). Deschepper et al. (1986) used a
combination of immunocytochemistry and in situ hybridisation (ISH) to determine renin
expression and protein location in several mouse tissues: in the kidney, both renin protein
and mRNA were present at the vascular pole of the glomerulus, in the adrenal the outer layer
of the cortex showed the strongest antibody and riboprobe signal suggesting that in these
tissues transcriptional events and protein processing occur at the same sites and in the testis,
renin mRNA and protein were localised to the cytoplasm of the Leydig cells. In the pituitary,
the ISH signal was identified in both the intermediate and anterior lobes while the protein
was exclusively found in the anterior lobe. Although controversial, this suggests that renin
may be taken up/trafficked to the anterior lobe from the intermediate lobe (Deschepper et al.
1986).
In addition to the kidney, sites of prorenin production include the adrenal, the pituitary, the
reproductive organs and the uteroplacental complex, namely myometrium, placenta, and
chorio-decidua (Berka et al. 1996; Carretero et al. 1972; Lumbers 1993; Nakayama et al.
1989; Poisner 1998; Skinner 1987). These tissues have been shown to contain renin and
prorenin but it is unclear whether prorenin produced at those sites is converted to renin and
released in the circulation or taken up as prorenin prior to conversion in tissues. The direct
actions of prorenin have been a recent area of research and there has been a controversy
about the existence of a (pro)renin receptor. This may help to elucidate the functional role of
prorenin and why prorenin is the only "renin species" present in several extrarenal tissues.
Another example of prorenin localisation is in the amniotic fluid which contains high
amounts of prorenin (Broughton-Pipkin 1993; Lumbers 1993). Several possibilities for the
origin of amniotic fluid prorenin have been put forward such as the chorion, the foetal
kidney/urine, maternal circulation or the maternal ovaries but the source of amniotic fluid
prorenin and its role in pregnancy/embryonic development is still unclear.
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1.3.1.6 Renin genes
Phylogenetic studies identified two groups of mice, the first group produced low levels of
"thermostable" renin {i.e. active renin) in the submandibular gland (SMG) and the second
group secreted high levels of "thermolabile" renin [{i.e. prorenin); (Wilson and Taylor
1982)]. This was originally thought to be arising from a single renin gene with different
regulatory elements. However, the identification and cloning of two distinct renin genes
were performed by Southern blotting using a renin cDNA from DBA/2 mouse
submandibular gland as a probe (Mullins et al. 1982). It was also discovered that SMG renin
levels were genetically controlled and that high and low SMG renin levels correlated with
the number of renin genes (Piccini et al. 1982; Wilson and Taylor 1982). Whereas humans,
rats and most strains of mice possess only one renin gene (denoted Renlc for mice), some
strains of mice carry two renin genes {Renld and Ren2). This was found to be unique to
mouse and due to a gene duplication on chromosome 1 and not due to chromosomal
rearrangement. It has been estimated that the Renl gene duplication event occurred 2.75-5.5
million years ago but it cannot be ruled out that Renlc mice were the result of an ancestral
duplication followed by gene deletion (Dickinson et al. 1984). It was also demonstrated that
there is a sexual dimorphism and that renin from SMG is synthesized in greater amounts in
male and testosterone-treated female mice carrying two renin genes (Catanzaro et al. 1983;
Piccini et al. 1982).
Although only renin activity derived from Ren2 has been detected in the SMG of two-renin
gene strains of mice, Renlc transcript and isozyme activity has been measured (although at
lower levels than Ren2 in two-renin gene strains) in the SMG of one-renin gene strains of
mice (Wilson and Taylor 1982). After mouse kidney cDNA library screening, Renl was first
found to be present at higher levels that Ren2 in the kidney (Field et al. 1984). However,
subsequent work showed that, in the kidney, both Ren2 and Renld transcripts were present in
equivalent amounts and when the transcript abundance was normalised to the number of
renin-producing cells, Ren2 mRNA expression was found to be equivalent in kidney JG cells
and in SMG granular convoluted tubule cells (Field and Gross 1985). The authors
hypothesized that elevated expression in the SMG of two-renin gene mice may not be due to
gene upregulation but to the inability to repress Ren2 gene expression. The mouse renin
genes span 13kB containing 9 exons and 8 introns and all three murine renins share 97%
homology at the protein levels (Figure 1.8).
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Mouse Renlc MDRRRMPLWALLLLWSPCTFSLPTRTATFERIPLKKMPSVREILEERGVDMTRLSAEWGV 60
Mouse_Renld MDRRRMPLWALLLLWSPCTFSLPTRTATFERIPLKKMPSVREILEERGVDMTRLSAEWGV 60
Mouse_Ren2 MDRRRMPLWALLLLWSPCTFSLPTG-TTFERIPLKKMPSVREILEERGVDMTRLSAEWDV 59
































Mouse Ren2 ALHAMDIPPPTGPVWVLGATFIRKFYTEFERHNNRIGFALAR 401
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Figure 1.8: CLUSTAL alignment of amino acid sequence for all three murine renin protein from renin
genes Renlc, Renld and Ren2. N-Iinked glycosylation sites are boxed and are only present in "/few/"
proteins. Note the high degree of homology between the three amino-acid sequences. = identity, =
conserved substitution, = semi-conserved substitution.
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Renin proteins show differences at 3 asparagine-linked glycosylation sites found exclusively
in proteins arising from the "Re«7" genes. The modifications at the gene level were found to
be lacking in a wild type strain of mice which carries two renin genes suggesting that the
duplication of the Ren locus occurred prior to glycosylation site insertions (Sigmund and
Gross 1991). Genotypic differences between "RenV genes and the Ren2 gene may be
involved in the sorting of prorenin into the regulated pathway. Renld and Renl are separated
by 21Kb and share the same transcription direction with Ren2 upstream of Renld (Sigmund
and Gross 1991). While null mutants for the Ren2 gene displayed no histopathological
injuries and reduced plasma prorenin (Sharp et al. 1996), deletion of the Renld gene in two-
renin gene mice revealed important but subtle phenotypic changes, namely absence of renin
granules in JG cells, macula densa hyperplasia and sexually dysmorphic hypotension (Clark
et al. 1997). In contrast, one-renin gene mice in which Renlc has been deleted, had severe
kidney defects associated with tubules and macula densa and required salt injection to
prevent neonatal death (Yanai et al. 2000). Increased fluid intake and urine output were
observed. These animals were completely devoid of renin granules in JG cells, displayed
hypotension and absence of plasma Angl.
1.3.2 Angiotensinogen
The precursor of angiotensin peptides, angiotensinogen (AOGEN), is a large protein
composed of 452 amino acids. It is released constitutively from the liver where it does not
appear to be stored (Menard et al. 1993). Unlike renin in the kidney, AOGEN expression in
the liver does not increase when homeostasis is threatened (Ingelfinger et al. 1986). AOGEN
expression does, however, increase in the kidney re-enforcing the idea of a locally regulated
RAS (Ingelfinger et al. 1986). The expression of AOGEN is up-regulated by several other
factors such as exogenous Angll administration. It has been shown that renin and
angiotensin do not compartmentalise into the same secretory granules suggesting that they
are produced by different cells in tissues (Menard et al. 1993). Because the association
constant of AOGEN with renin is high compared to the catalytic constant, it has been
suggested that AOGEN may be a renin inhibitor rather than a substrate for the formation of
Angl (Poulsen and Jacobsen 1986) but no experimental data have proved or disproved this
hypothesis.
Angiotensinogen (AOGEN) is first detected in the mouse foetus from E13dpc in the liver
and from E18dpc in the kidney (Niimura et al. 1997). Although, AOGEN expression is first
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detected in the rat foetus from E11.5dpc (in the yolk sac) (Lee et al. 1987), expression of
AOGEN is very low in the liver during gestation and increases dramatically post-natally
(Niimura et al. 1997), possibly as a result of stimuli associated with birth or preparation for
extra-uterine life. It is interesting that, in the kidney, renin expression precedes that of its
substrate, AOGEN,while it is unclear whether renin is secreted as an active enzyme during
development. In addition, AOGEN is detected in foetal fat suggesting a role in temperature
regulation and also in the brain and in the kidney where it may be involved in organ
development (Gomez and Norwood 1995). Angiotensinogen null mice (Tanimoto et al.
1994) display phenotypic changes in the vascular structure of the kidney, notably a striking
thickening of the renal arterioles. It is possibly associated with a negative feedback on renin
secretion and hence, deregulated renin-expressing cell recruitment. In contrast with
angiotensinogen null mice or the ACE null mice (Esther et al. 1996), the abnormalities
reported in the "renin cell ablation" model (Pentz et al. 2004) do not affect the vasculature
which is normal whereas dilated and atrophic tubules were observed. It appears therefore
that renin-expressing cells (which may not contain active renin granules during
development) are needed for the formation of the tubular network while the RAS cascade
appears to be required for vasculogenesis.
1.3.3 Angiotensin-converting enzyme
The angiotensin-converting enzyme (ACE) is a zinc metalloproteinase which metabolises
many polypeptides. There are two forms of ACE, a somatic (140-160kDa) and a germinal
(80kDa) form, both originating from the same gene but transcribed through the involvement
of two distinct promoters. The main role of somatic ACE is the conversion of AngI to Angll
(Figure 1.9). However, additional functions for this metalloproteinase include the
inactivation of bradykinin and the hydrolysis of substance P, both known as vasodilators
(Turner and Hooper 2002). The germinal form of ACE is found exclusively in the testes and
is thought to be important in fertility. A small proportion (10%) of ACE is found in the
plasma but the majority is located in tissues notably, lungs, vasculature, heart, kidney and the
adrenal gland. Somatic ACE is mainly made by the endothelium and contains two
extracellular catalytic sites and a transmembrane domain. ACE is also produced by smooth
muscle cells and by macrophages. Hence, in the vasculature, ACE appears to mediate many
different actions such as vasoconstriction, inflammation, vascular remodelling and also
regulation of thrombotic response through the formation of Angll and the degradation of
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bradykinin (Dzau et al. 2001). Very little ACE is detected in the heart under normal
physiological conditions and most of cardiac ACE is found in the endothelium of arteries
and arterioles (Yamada et al. 1991). Cardiomyocytes are known to express ACE in vitro and
possess the ability to produce Angll, only when stretch-induced (Sadoshima et al. 1993).
Hence, ACE has a pivotal role in normal physiology and in the patholophysiogy of
cardiovascular disease. In humans, an insertion/deletion (I/D) polymorphism at the ACE
locus has been found to be responsible for variations in blood pressure. Blood pressure and
serum and cardiac ACE levels are increased in individuals with the D allele and have been
found to be more susceptible to LV hypertrophy (van Berlo and Pinto 2003). Factors mapped
to chromosome 10 close to the ACE locus have also been linked to the malignant
hypertension phenotype in the TGR(mRen2)27 animals (Kantachuvesiri et al. 1999).
Tissue ACE activity and mRNA are highest in the lung during embryonic development but
are also prominent in the kidney, heart and aorta (Yosipiv and El-Dahr 1998). ACE is first
detected in the foetal rat from E18dpc in the lungs and E16dpc in the kidney (Gomez and
Norwood 1995), suggesting, once more, the importance of a potential renal RAS during
development. In addition, ACE expression has been located in the proximal tubule mediating
the formation of locally produced Angll which may influence growth and establishment of
tubular structures in late gestation (Jung et al. 1993). The presence ofACE in the developing
cardiovascular structures is also of importance since Angll is know to promote cellular
growth of neonatal rat cardiomyocyte (Schorb et al. 1993) and bradykinin was found to have
anti-proliferative effects in blood vessels, mechanism which may be inhibited by ACE
during development to promote vasculogenesis (Linz and Scholkens 1992). The severe
hypotension observed in ACE null mutants could be due to the absence of Angll but also to
the accumulation of bradykinin. In addition, in these animals, the development of the renal
arterial tree is blunted (Esther et al. 1996). Angll therefore appears to have a distinct role in
renal vasculogenesis. Similarly to AOGEN null mutants, papillary and tubular atrophy were
observed which suggests that it is the absence of Angll which is responsible for this
phenotype.
1.3.4 Angiotensin II and its receptors
Most of Angll cardiovascular effects are mediated by the binding to its highly specific
receptor located on the cell membrane primarily in the adrenal glands, vascular smooth
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muscle cells, the kidney, the brain and the heart (Unger 2002). Ang II receptors (AT) exist in
two distinct forms, type I and type II, which are expressed in different tissues (Timmermans
et al. 1993). They are both 7-transmembrane domain receptor coupled to a G-protein
associated with pathways involving phospholipases, calcium channels and kinases (Kim and
Iwao 2000; Timmermans et al. 1993; Unger 2002). The two receptors display only 34%
amino acid sequence homology overall (Timmermans et al. 1993).
In addition to its vasoconstrictor effects, Angll has growth factor properties which are
involved in cell growth and differentiation during development. These properties may also
play a role in the pathogenesis of cardiac hypertrophy, arterial stiffness and vascular injuries
seen in hypertension and diabetes. Ruiz-Ortega et al. have reviewed the mechanisms of
Angll action and they reported that the AT] receptor promotes inflammation, growth and
proliferation while the AT2 receptor counteracts these actions. Indeed, after myocardial
infarction in rats, the expression of AT] receptor (Tan et al. 2004) as well as levels of
angiotensinogen and renin proteins (Passier et al. 1996) was increased in cardiomyocytes
and renin has been detected in the heart at the site of infarct after a similar surgical
intervention in the rat (Sun et al. 2001). These findings suggest local Ang II formation and a
role in cardiac/vascular injury.
Other functions and actions of Angll are exemplified by the fact that AT] receptor in the
brain has been associated with central actions on homeostasis such as pressor and drinking
responses, vasopressin release and salt appetite (Ganong 1984; Phillips 1987). This receptor
is also known to be involved in cell growth and proliferation in a variety of cardiovascular
associated cells implicating it in pathologies such as left ventricular hypertrophy,
atherosclerosis and glomerulosclerosis (Lucius et al. 1999; Unger et al. 1996). Angll
infusion in rats can induce cardiac hypertrophy (Yamazaki et al. 1999) and
glomerulosclerosis (Miller et al. 1991) without elevation of blood pressure. Angll (via the
AT 1 receptor) also has similar hypertrophic effects on cultured vascular smooth muscle cells
(Unger et al. 1996). The mechanisms by which Angll triggers these injuries are not fully
understood but excessive cell growth and induction of extracellular matrix, as well as
intracellular pathways (e.g. MAP kinases) may play an important role (Kim and Iwao 2000).
Angll is well known to have angiogenic effects as well as promoting cell growth and
proliferation through its ATi receptor, mechanisms which may be important in embryonic
development. AT) inhibition and angiotensin receptor blockade are also known to cause
similar abnormalities, notably disrupting the vascular branching and glomerular development
in the kidney (Gomez and Norwood 1995).
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Recently, two isoforms of the AT] receptor, AT]a and ATib, have been identified in the
mouse (Sasamura et al. 1992). These receptors are the products of two distinct, highly
homologous genes. ATja is highly expressed in the kidney, liver, adrenal gland, brain, heart,
lung and the reproductive organs whereas the localisation of AT1B is less widespread and
high expression levels confined to the adrenal gland, the brain and testes (Burson et al.
1994). In double null mutants for AT]a and AT1B, ACE inhibition has the effect of increasing
mean arterial pressure suggesting that the AT2 receptor signalling may be diminished by the
treatment (Oliverio et al. 1998). This agrees with the hypothesis that AT2 may oppose
detrimental effects of Angll (via the ATi receptor). Mice lacking the ATiB receptor subtype
displayed normal growth (Oliverio et al. 1997) whereas mice lacking both isoforms had
decreased body weight and renal abnormalities resembling that of the ACE or AOGEN null
mutants, namely papillary and tubular atrophy and thickening of the vascular wall (Oliverio
et al. 1998). The authors showed that the severity of the abnormalities is greater in the
double knockout mice showing that both ATi receptor subtypes are needed for normal renal
development. Hence, each subtype can partly compensate for the absence of the other
(Oliverio et al. 1998).
AT2 receptors are expressed at high density throughout development in all tissues from El 1
until El 9, when its expression begins to decrease and in the adult, is only present in the
adrenal gland, the ovary, the uterus and some areas of the brain (Dzau 1995). The receptor
also occurs as a feature of certain conditions such as heart failure where it may be involved
in tissue repair (Lucius et al. 1999; Unger et al. 1996). It may be that cells that express AT2
in adult life revert to a foetal phenotype of angiotensin-receptor expression in these
conditions. Many reports suggest that AT2 is therefore involved in cell differentiation, tissue
growth, wound healing and apoptosis (Lucius et al. 1999; Nakajima et al. 1995; Unger et al.
1996). It has been demonstrated that Angll has direct growth promoting effects through AT2
during organogenesis in an in vitro cultured whole rat embryo model and that this effect
could be blocked via specific inhibition with an AT2 receptor inhibitor (Tebbs et al. 1999).
This differs from the work ofNorwood et al. who reported that AT2 being expressed in early
undifferentiated mesenchyme may have a role in early nephrogenesis rather than late foetal
development (Norwood et al. 1997). The earlier results could, however, be due to the culture
conditions. AT2 receptor null mice revealed a role for this receptor in arteriogenesis during
development since the expression of calponin (an actin binding protein responsible for actin-
myosin interactions) is lowered in the aorta compared to wild-type animals (Yamada et al.
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1999). It may, therefore, be that the AT] and AT2 receptor functions differ from one organ to
the other and between the adult and the embryo.
Although Angll may contribute to tubulogenesis, the data suggest that Aug II plays a lesser
role in tubular framework development. This is further confirmed by Nagata et al. who
reported that Angll added to a ureteric bud culture did not trigger any advance in tubular
growth (Nagata et al. 1996). The antagonising role of AT2 receptor to ATi functions has
been reported and it may inhibit cell proliferation and promote cell differentiation. This is
suggested by the presence of AT2 receptors in the ureteric bud during early differentiation of
the nephron in the developing kidney (Aguilera et al. 1994), although the level of AT2
expression in this localization has been reported to precede glomeruli proliferation (Gimonet
et al. 1998). The renal abnormalities displayed by AT2 null mutants were less severe than
that of the AT) null mutants (Miyazaki and Ichikawa 2001) in which vascular and tubular
components of the kidney were affected.
1.3.5 Angiotensin III and IV
Other Angll derived peptides have been found to have biological activities. Angll has a very
short half-life in the circulation and it can be converted to a 7-amino acid peptide termed
AngUI by removal of the N-terminal asparagine residue by aminopeptidase A. AngUI
appears to have central actions notably triggering vasopressin release after intra-
cerebroventricular injection (Zini et al. 1996). However, the mechanisms remain unknown
and it is not clear through which receptor it carries out its actions.
AngUI can also be metabolised to a hexapeptide termed Ang(3-8) or AnglV by
aminopeptidase B [(Wright et al. 1995); Figure 1.9]. AnglV, which can be found in the
plasma displays a lower affinity for AT) and AT2 than Angll (de Gasparo et al. 2000) and
recently, a receptor for AnglV (AT4) was purified (Albiston et al. 2001). AT4 is widely
distributed in tissues, namely kidney, heart, brain, lung, prostate and small intestine (Wright
et al. 1995). AnglV has also been shown to block the increase ofRNA and protein synthesis
caused by Angll in cardiomyocytes and therefore may be involved in counteracting
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Figure 1.9: Formation of angiotensin peptides. The first step of step is catalysed by renin resulting
in the conversion of the 452 amino-acid AOGEN (shown truncated in the above figure) to the 10
amino-acid Angl. AngI is then converted to Angll, the effector molecule of the RAS by ACE. Angll
is further metabolised to the heptapeptide AngUI and the hexapeptide AnglV by aminopeptidase A
and aminopeptidase B, respectively. Adapted from Robertson (1997).
In the brain, AT4 expression overlaps with expression ofAT] and AT2 but it is also uniquely
expressed in areas such as the cerebral cortex, the hippocampus and the cerebellum which
are associated with memory and cognitive processes as well as sensory /motor functions
(Wright et al. 1995). In addition, AnglV is involved in facilitating blood flow in the brain
after intra-cerebroventricular injection and in the kidney after injection in the renal artery
(Harding et al. 1994) suggesting that AnglV is also part of a local RAS. Interestingly, the
findings of Kakinuma et al, showed that infusion ofAngll and Ang IV inhibited the tubular
atrophy observed in the AOGEN null mice (Kakinuma et al. 1999).
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1.4 The Renin-Angiotensin System in Hypertensive Disease
1.4.1 Cardiac Hypertrophy
Hypertension is linked to cardiac hypertrophy which is characterised by an increase in
cardiac muscle mass (Figure 1.10). Tissue culture studies have shown that cardiomyocytes
and fibroblasts are activated by Angll via the ATi receptor (Sadoshima and Izumo 1993a).
In cardiomyocytes, Angll activates second messenger pathways via phospholipases C, D,
and A2 and protein kinase C which are linked to the transcription factor c-fos (Booz et al.
1999; Sadoshima and Izumo 1993b). Angll also increases the tyrosine phosphorylation of
cytosolic proteins and up-regulates MAP kinases (ERK1 and 2) which may cause
hypertrophic responses (Booz et al. 1999). The signalling pathways involved in the
cardiomyocyte hypertrophy are complex and it is now well known that cardiomyocyte
growth (and notably protein synthesis) stimuli such as MAP kinases and second messengers
are activated by stretch (Yamazaki et al. 1999). Stretching of cardiomyocyte cultures in vitro
triggers the release of Ang II which acts directly on the cells as a growth factor (Sadoshima
et al. 1993; Yamazaki et al. 1995). In vivo, this response to stretching may cause
hypertrophy but may be adaptative to improve cardiac contraction compensating for
increased wall tension.
Aikawa et al. showed that integrins were activated in response to mechanical stress in
cardiomyocytes again via a MAP kinase (p38) pathway (Aikawa et al. 2002). The cardiac
interstitium is made up of non-myocyte cells namely, fibroblasts and endothelial cells. It is
the fibroblast population which is responsible for the production of extracellular matrix
(ECM) proteins. Studies in humans and animal models have implicated Angll as a growth
promoter of both cardiomyocytes and fibroblasts during the remodelling events which occur
to trigger hypertension and myocardial infarction (De Mello and Danser 2000; Dostal et al.
1996; Kenchaiah and Pfeffer 2004; Kim and Iwao 2000; Mayet and Hughes 2003).
The abnormal accumulation of fibrillar collagen plays a role in such pathology (Baker et al.
1992). In addition, cardiac fibroblast culture medium was shown to induce protein synthesis
and signal transduction events rapidly in neonatal rat ventricular myocytes and to increase
angiotensinogen messenger RNA (mRNA) levels (Booz et al. 1999). Cardiac fibroblasts
have been shown, in turn, to respond to Angll with increased expression of integrins
(transmembrane receptors involved in cell attachment to the ECM) and a-actinin in SHR
(Kawano et al. 2000). The expression of these genes was inhibited by the ATi receptor
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Figure 1.10: Actions of Angll on cardiac cells. The effects of Angll via AT) on both
cardiomyocytes and cardiac fibroblast contribute towards the hypertrophic response of the heart
leading to cardiac dysfunction.
Angiotensin-receptor inhibition in rats with pressure-overload hypertrophy was also effective
in reducing left ventricular wall thickness and mass (Iwai et al. 1995). In addition, Kojima et
al. showed that it is not just a reduction of blood pressure which may resolve cardiac
hypertrophy in rats with malignant hypertension since angiotensin-receptor inhibition was
beneficial but a classic diuretic was not (Kojima et al. 1994). In addition, it was
demonstrated that sodium intake plays an important role in the cardiac hypertrophic response
to angiotensin II but not the BP response to Ang II (Morgan et al. 1998). Interactions
between sodium intake and Angll and left ventricular hypertrophy was also reported in
Goldblatt rat models (Morgan et al. 2001).
1.4.2 Renal and Vascular Fibrosis
In addition to cardiac hypertrophy, renal and vascular fibrosis are some of themost important
complications of hypertension (Abdi and Johns 1996; Griffin and Bidani 2004; Mayet and
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Hughes 2003). The mechanisms described above for cardiac hypertrophy, notably
mechanical stress (Hudlicka 1994), ECM proteins adhesion molecules (Ignotz and Massague
1986) and RAS activation (Navar et al. 2002; Ruiz-Ortega and Egido 1997) have also been
shown to cause vascular remodelling in large and peripheral vessels. Large arteries exhibit
two functions: 1) a conduit function which determines mean arterial blood pressure and
blood flow. It enables appropriate delivery of oxygen-rich blood to tissues and alterations in
the conduit properties of large arteries such as those caused by atherosclerosis result in
stenosis or ischaemia in brain, heart or kidney; 2) a buffering function which determines
pulsatile pressure and flow. It enables the pulsatile blood flow from the heart to be turned
into continuous flow at the peripheral level. It is dependent on the visco-elastic properties of
the aorta and large arteries and can be modulated by vascular remodelling. Pulse pressure
(PP) in determined by both properties and in ageing /hypertensive states, increased PP in a
result of increased in 1) and decrease in 2). It is therefore an important determinant on blood
pressure status and is sensitive to the mechanisms described below.
In addition, resistance arteries are also affected by remodelling in hypertensive disease.
These changes involve media thickening, reduced lumen diameter and consequent increased
media:lumen ratio. The mechanisms triggering these structural changes involve hypertrophy
and hyperplasia of vascular smooth muscle cell (VSMC) and increased extracellular matrix
abundance. Inflammation including macrophage infiltration, fibrosis and increased
expression of pro-inflammatory genes (such as interleukins) is also pivotal to vascular
remodelling (Touyz, 2006). Hence vascular remodelling of large and small arteries has many
implications during hypertensive states.
Mechanical stimuli can act on the blood vessels by increasing vascular tone (Hudlicka 1994)
and an increase in vascular resistance to blood flow is characteristic of hypertensive states. It
appears that very small changes in arterial diameter and thus in the blood flow have an
impact on the heart in humans (Hughes et al. 1993). As for cardiac hypertrophy,
hypertensive vascular/renal dysfunction may be the result of a similar involvement and of
pro-flbrotic and pro-inflammatory factors. In addition, renal damage has been used as a
phenotype in QTL analysis on the basis of the association between hypertension and renal
damage. Two QTLs for renal sclerosis and proteinuria have been found, the former co-
localising with blood pressure QTL on rat chromosome 1 (Rapp 2000). This section
underlines the complexity of the mechanisms involved in cardiac, vascular and renal disease
associated with hypertension (and diabetes or atherosclerosis) and highlights the pivotal role
of the RAS in the hypertensive pathogenesis. More recently, the adaptive role of kallikrein in
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vascular shear stress was highlighted in humans with a loss-of function polymorphism in the
human tissue kallikrein gene (resulting in a decrease in the enzyme activity) (Azizi et al.
2005).
Although many interlinked additional factors modulate vascular remodelling, Angll alone is
a powerful mediator of events regulating vascular structures:
1) Tyrosine kinases (e.g.: Src or JAK) cause phosphorylation of cytosolic proteins such as
MMP2 in endothelial cells or DP3K in VSMC following Angll binding to ATi. PI3K, in
turn, triggers signal transduction cascade which may cause increased cell survival and
proliferation augmenting muscle cell contraction.
2) MAP kinase activation results in a variety of responses in VSMC population such as
hyperplasia, hypertrophy, inflammation and collagen synthesis. Activation of AT]
receptors promotes tyrosine phosphorylation and stimulates mitogen-activated protein
kinases and proliferation. Following Angll binding to AT1; insulin-like growth factor 1
(IGF-1) receptor, epidermal-derived growth factor (EDGF) receptor and platelet-derived
growth factor (PDGF) receptors become "transactivated" resulting in further MAP kinases
activation. The process of receptor transactivation by Angll is poorly understood but is
thought to involve intermediate intracellular mediators such as increased intracellular
calcium (Laurette et al. 2005).
3) NADPH oxidase is involved in the formation reactive oxygen species (ROS) and has an
important role on oxidative stress. Oxidative stress results from an imbalance between the
formation of deleterious reactive oxygen species and the production of antioxidants (Touyz
and Schifffin 2004). NADPH oxidase activation leads to the formation of superoxide and
hydrogen peroxide which cause cellular damage and activation of NF-kB and AP-1
resulting in increased adhesion molecules, chemokines and cytokines but also in a decrease
of bio-availability of the vasodilator nitric oxide. Superoxide also inhibit the formation of
the vasodilating molecule endothelial-derived relaxing factor while hydrogen peroxide
stimulates the release of endothelial-derived contracting factor. ROS in turn activate MAP
kinases triggering the cascade of events leading to fibrotic and inflammatory responses.
iNOS expression together with NF-kB (by which the iNOS promoter is regulated) were
also increased in the renal cortex of SHR compared to control (Kumar et al. 2005). In
cultured rat aortic smooth muscle cells, interleukin-6 was able to induce an increase in
ROS, notably superoxide and this was accompanied by an up-regulation of AT] receptor
expression (Wassmann et al. 2004). In addition, the authors reported an impaired
endothelium-dependent vasodilation triggered by interleukin-6 in mouse cultured aortic
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rings although this was not observed in AT] receptor knock out mice. Similarly, ATi
antagonism and inhibition ofNF-kB in rats with unilateral ureteral obstruction (a model of
obstructive nephropathy) had beneficial effects on the renal formation of reactive oxygen
species (Nakatani et al. 2002).
4) Intracellular calcium. Angll binding to its G protein-coupled receptor results in
phosholipase C-mediated formation of inositol triphosphate which triggers release of
calcium from sarcoplasmic reticulum stores. Transactivation of calcium channel also
increases the influx of calcium ions from extracellular locations. These events, together
with inhibition of myosin light chain phosphatase mediate actin-myosin interaction and
cellular contraction in VSMC increasing vascular tone.
TGF-P receptors are single-pass transmembrane proteins. A role for TGF-P has been
reported (Ignotz and Massague 1986; Tharaux et al. 2000; Yamamoto et al. 1993) in
hypertensive renal disease and TGF-P is known to be up-regulated by Angll and also by
glucose (hence its major role in diabetic nephropathy). Using a transgenic mouse model
expressing the reporter gene luciferase under the control of the collagen I a2-chain, Fakhouri
et al., showed that administration of exogenous Angll, ET-1 and TGF-P activates the
collagen-1 gene in aortic and renal cortical tissues (Fakhouri et al. 2001). The mechanisms
underlying this response have been attributed to activation of MAP/ERK pathway and TGF-
P (Tharaux et al. 2000). Using specific ET receptor antagonist, it was shown that the Angll-
mediated up-regulation of collagen-1 expression also involves ET-1. Additional in vitro
studies have shown that both Angll and ET-1 may promote the synthesis of fibronectin and
collagen in a dose-dependent manner (Fakhouri et al. 2001). ET-1 is also up-regulated by
superoxide. Other factors involved in hypertensive fibrotic/inflammatory events are the
plasminogen activator inhibitor-1 (Dong et al. 2003), chymase (Miyazaki and Takai 2001);
or increased cell adhesion (Okamoto et al. 2004).
1.5 Local versus Circulating Renin-Angiotensin System
1.5.1 Local RAS - Tissue and intracellular RAS
It is now well established that the renin-angiotensin system is not just an endocrine {i.e.
circulating) system since Angll can be produced locally in a number of tissues such as the
vascular beds, the brain or the heart. The idea of the existence of a local RAS (paracrine or
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autocrine) arose from the following findings: anephric patients have a plasma level of renin
which does not reach zero, continue to have high levels of plasma prorenin and retain the
ability to produce Angll suggesting that Angll can be produced independently of renal renin
production (Sealey et al. 1977; Weinberger et al. 1977). Similar findings were obtained in
animals having undergone bilateral nephrectomy (Danser et al. 1994). Secondly, recent
reports have demonstrated that all the components of the renin-angiotensin system (RAS) are
present in several tissues suggesting the existence of a local paracrine or autocrine.
1.5.1.1 Cardiac RAS
Angll can be readily detected in the heart but it is still a matter of debate whether Angll is
made intracellularly by cardiomyocytes or taken up by cardiac tissue. In order to allow
cardiac synthesis, the presence of renin, AOGEN and ACE is required. It is unclear whether
cardiac renin comes from uptake or de novo synthesis. Renin protein was detected in rat
cardiomyocytes cultured in serum-free conditions [reviewed by (Schuijt and Danser 2002)].
This may be explained by sequestration prior to serum removal or due to the recently
identified "Renin 1A", an intracellular form of the enzyme arising form an alternatively
spliced transcript lacking exon 1 (hence the "PRE" segment of the precursor enzyme which
act as a signal for secretion) which has been replaced by exon1A (Clausmeyer et al. 2000).
Another reason for the presence of renin in the heart is uptake of prorenin following binding
to the mannose-6-phosphate receptor (M6Pr) (Saris et al. 2001a) to the more recently
identified human (pro)renin receptor ((Nguyen et al. 2002) and Chapter J) or to an as yet
unidentified receptor. In the case of non-glycosylated renin (e.g. from Ren2 gene) a role for
mannose-6-phosphate receptors in renin uptake can be excluded.
If recombinant prorenin and AOGEN are added to cultured rat neonatal cardiomyocytes,
total cellular protein content increases as well as leucine and thymidine incorporation and
this was inhibited by ATi antagonist, but not AT2 antagonist or mannose-6-phosphate (Saris
et al. 2002). The cell growth promoting effects were not observed if prorenin or AOGEN
alone were used separately. Furthermore, the absence of intracellular AngI in these cells is in
agreement with other reports (de Lannoy et al. 1997) showing that AOGEN is neither
present in cardiomyocytes or taken up by these cells. The conversion ofAOGEN by prorenin
must, however, be the result of non-proteolytic/reversible activation of prorenin following
binding to receptors other than M6Pr (Saris et al. 2002). van Kesteren et al. (1999) also
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showed that cardiomyocytes did not release either renin or angiotensinogen in a stretch-
induced hypertrophy experiment suggesting hypertrophy was Angll-independent.
Using the isolated perfused rat heart model, de Lannoy et al. collected coronary effluent and
interstitial transudate separately. They reported that infusion of renin or AOGEN in this
model did not result in the formation of AngI suggesting that in vivo, circulating AOGEN-
and circulating (pro)renin-independent Angll formation in cardiac tissues is unlikely to
occur. However, if AOGEN and renin were infused concomitantly, AngI could be detected
in the interstitial fluid which may be explained by enzymatic action of renin on its substrate
in the liquid phase. In addition, the authors showed that the AngI concentration in coronary
effluent was higher than in the interstitial fluid suggesting that there might be an additional
site of AngI production at the luminal vascular location where renin may be receptor-bound.
Transfection of rat hepatoma cells with a mutated AOGEN cDNA results in a non-secreted
protein which enhanced growth through upregulation of platelet-derived growth factor
expression. (Cook et al. 2001). This was inhibited by losartan but not candesartan The latter
is known to bind to surface ATi without further internalisation of the receptor and pre-
treatment with candesartan prevented cellular growth inhibition by losartan. This suggests
that there are two distinct types of ATi receptor on the cell surface and in a nuclear location
but this may depend on the cell type.
ACE mRNA was found in the heart, by autoradiography (Yamada et al. 1991). ACE was,
more precisely, found on the cell membrane where its active domain is extracellular and no
ACE could be detected in the cytosol (Beldent et al. 1995) while ACE inhibition had no
effect on release of intracellular Angll in stretched cardiomyocytes suggesting that
intracellular Angll in these cells is not dependent on membrane-bound ACE (Sadoshima et
al. 1993). All the evidence points towards a "partial cardiac RAS" and dismisses the
hypothesis that, under normal physiological circumstances, Angll may be produced
intracellularly by cardiomyocytes. Angll may, nonetheless, be produced in the interstitial
fluid or on the luminal surface of the cardiac vasculature and subsequently internalised
through a ATi-mediated endocytosis. The lack of intracellular Angll synthesis does not
mean that Angll does not have intracellular actions. Indeed, Angll has been shown to be
present in nuclear fractions and to be involved in the regulation transcription via binding to
chromatin (Re and Parab 1984), process which is dependent on binding to AT] since this is
inhibited by losartan treatment. IfAngll is present in the heart, what is its function in cardiac
physiology? Is Angll solely triggering processes during pathophysiological events such as
myocardial infarction? In cases of hypotension, Angll and activation of the RAS will
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contribute to the homeostatic response and its vasoconstricting actions will participate in the
re-establishment of normal blood pressure.
In normal physiological situations, Angll is involved in vasoconstriction of intra-cardiac
vessels and possibly in the regulation of cardiac inotropy. However, excess Angll in the
heart has detrimental effects. Mice over-expressing AT] specifically in the heart were
normotensive but displayed ventricular hypertrophy and fibrosis accompanied with increased
ANF expression leading to heart failure at 4-5 months of age (Paradis et al. 2000). Another
cardiac specific ATj over-expressor mouse model resulted in a more severe phenotype. The
animals died a few weeks after birth due to cardiomyocyte hyperplasia, bradychardia and
heart block (Hein et al. 1997). Differences between the two models may be due to the mouse
strain used but both models demonstrate that Angll promotes cell growth in vivo consistent
with previous in vitro studies showing mitogenic effects of Angll (Kojima et al. 1994;
Yamazaki et al. 1995). In addition, in ATI null mutants, the extent of the ventricular
remodelling was improved after experimental myocardial infarction (Harada et al. 1999).
1.5.1.2 Intrarenal RAS
The kidney is responsible for the majority of the production and release of plasma renin and
the presence of a renal RAS has been thoroughly evaluated since locally produced Angll
may exert vasoconstricting effects on the intra-renal vasculature, hence affecting vascular
tone, glomerular filtration pressure and reabsorption of sodium (Figure 1.11). Zou et al.
showed that, following infusion of Val5-AngII for two weeks in rats, two-third of the renal
Angll was of plasma origin, a process mediated by Angll via binding to AT] (Zou et al.
1998). However, total kidney AngI and Angll contents are consistently higher than plasma
levels indicating that AngI and Angll are produced in the kidney and are not solely a result
of uptake from the circulation (Navar et al. 2002). Celio and Inagami studied the presence of
the RAS components in the kidney by immunocytochemistry. Renin was found in the JG
cells at the vascular pole of the afferent arterioles, ACE was bound to the luminal surface of
the endothelial cells of the renal arteries and arterioles in addition to the capillary loops of
the glomueruli whereas Angll was exclusively located in the cytoplasm of the JG cells
(Celio and Inagami 1981). In addition, Angll is found in the interstitial fluid, and ATi is
detected in SMC or afferent and efferent arterioles and mesangial cells as well as in all the
nephron segments (Navar et al. 2002). AOGEN mRNA and protein, renin and all the other
components of the RAS have been detected in the proximal tubule (Moe et al. 1993). It is not
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known how much Angll is produced in the JG cells, the interstitial fluid and in the tubular
fluid. The arguments against JG cell internalisation of Angll through ATj are that Angll is
not present in SMC although ATi receptors are present on the surface of these cells and that
pre-treatment of kidney sections with Angll does not increase ATi immunodetection (Celio
and Inagami 1981). Angll located in the JG cells may constitute a link connecting distal
tubular fluid to resistance of glomerular arterioles, hence regulating tubulo-glomerular
feedback in addition to a macula dense-driven mechanism. Furthermore, locally produced
Angll by a proximal tubule RAS may provide a rapid response able to modulate fluid and
salt reabsorption preceding that of the circulating RAS in response to homeostatic changes.
Figure 1.11: The intra-renal RAS. Diagram depicting the actions of a local RAS in the kidney,
mainly renal blood flow by constriction of the efferent and afferent arteriole, glomerular filtration rate
by constriction of the afferent arteriole and on proximal reabsorption of sodium chloride and
bicarbonate. Note that the origin of renin and AOGEN is not detailed on the schematic representation.
However, they have been detected in the proximal tubule and renin and ACE have observed in the
afferent and efferent arterioles. Reproduced from (Zhuo and Mendelsohn 1993).
1.5.1.3 Adrenal RAS
All the genes of the RAS are indeed expressed in the adrenal and renin is localised to zona
glomerulosa cells which are the aldosterone-producing cells and in the inner adrenal cortex
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(Deschepper et al. 1986). This does not, however, mean that all adrenal Angll is locally
produced. 125I-Ang I intravenous infusion resulted in accumulation of 125I-AngII but not 125I-
Angl in the adrenal gland and this was reduced by 80% after administration of the AT]
antagonist, eprosartan showing that a major proportion of Angll in the adrenal gland is the
result of accumulation after uptake from the circulation (van Kats et al. 2005). In addition,
this report suggested that involvement of a recently identified truncated prorenin found in the
adrenal mitochondria (Clausmeyer et al. 1999) in the intracellular generation of Angll is
unlikely. The remaining angiotensin II found in the adrenal after eprosartan treatment may
be the result of incompletely blocked AT] receptors or due to (pro)renin uptake in by the
adrenal as part of a local RAS.
When nephrectomised rats {i.e. with low levels of circulating Angll and with levels of renin
near zero), aldosterone release is markedly increased as is the number of adrenal cells
expressing renin (Peters et al. 1999). Angll infusion to nephrectomised rats prevented the
increase in aldosterone release suggesting that an intra-adrenal RAS is present but inhibited
under normal conditions when Angll is present in the plasma. This action ofAngll may have
implications for the pathogenesis of the hypertensive rat model TGR(mRen2)27 in which a
mouse Ren2 transgene is highly expressed in the adrenal gland (Peters et al. 1993). Due to
increased level of plasma prorenin, plasma and renal renin levels are suppressed whereas
circulating Angll levels are unchanged or low. Uninhibited adrenal RAS may result and
contribute towards the hypertensive phenotype. This did not apply to TGR(mRen2)27 in
which adrenal renin and prorenin (of transgene origin) release can be triggered by Angll in
cell preparations (Peters et al. 1993). This effect was only observed for prorenin after
prolonged exposure to Angll whereas renin release was a rapid and sustained response.
Although these results suggest that stimulation of renin and prorenin release occurs through
different intracellular pathways as previously shown for the pituitary cell line AtT-20 and
CHO cells (Paul et al. 1992), the stimulation of renin release by Angll may represent
epigenetic effects on the phenotype of this transgenic model.
1.5.1.4 Other tissue RAS
Renin activity has long been reported in the brain (Ganten et al. 1971). AOGEN, ACE and
Angl/II are also found in the brain suggesting that Angll may be produced locally
(McKinley et al. 2003). ATi and AT2 receptors have also been detected in many parts of the
brain where Angll is thought to function as a neurotransmitter involved in sympathetic
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control of thirst, sodium excretion and renin release (McKinley et al. 2003). All RAS
components have also been found in reproductive tissues such as the ovary and the utero¬
placental unit where locally produced Angll may regulate smooth muscle cell contraction,
steroid synthesis and cell growth/differentiation (Nielsen et al. 1995). There may be a direct
role for renin and prorenin independently of Angll production via binding to the newly
identified human renin receptor (Nguyen et al. 2002) or to another unknown receptor to
trigger non-proteolytic activation of prorenin and/or downstream intracellular signalling.
1.5.2 Renin Uptake
von Lutterotti et al. (1994) concluded that, although controversial, renin synthesis does not
occur in the heart under normal physiological conditions (von Lutterotti et al. 1994). There
is, in addition, evidence of an uptake of prorenin by the heart. Miiller et al. (1998) showed
that isolated hearts from transgenic rats over-expressing the human angiotensinogen gene,
perfused with human renin, generated Angll (Muller et al. 1998). This continued after renin
infusion was stopped, suggesting that renin was taken up and sequestered in cardiac tissues
and this effect was abolished by the administration of the specific human renin inhibitor,
remikiren. In their review, De Mello and Danser (2000) concluded that Angll synthesis in
the heart depends on renin and angiotensinogen being taken up by cardiac tissues. Additional
reports of prorenin uptake come from transgenic rat studies (Kantachuvesiri et al. 2001;
Prescott et al. 2000). Firstly, a transgenic mouse model was obtained by crossing animals
expressing human renin in the liver with animals expressing human angiotensinogen in the
heart (Prescott et al. 2000). The double transgenic progeny display AngI presence in the
heart suggesting uptake of (pro)renin by cardiac tissues. Similarly, in the inducible rat model
TGR(Cyplal-Ren2), the uptake of prorenin by cardiac tissues is demonstrated by a high
level of circulating prorenin which precedes cardiac prorenin detection which, in turn,
precedes cardiac renin presence (Kantachuvesiri et al. 2001). The mechanisms of prorenin
uptake remain, however, unclear.
Several molecules have been identified as renin-binding molecules. The mannose-6-
phosphate receptors (M6Pr) are involved in the internalisation of prorenin in endothelial
cells (van den Eijnden et al. 2001) and cardiac cells (Saris et al. 2001a; Saris et al. 2001b;
van Kesteren et al. 1997) leading to rapid proteolytic conversion of prorenin to renin. This
only applies to glycosylated renin forms since a mannose-6-phosphate group is needed for
binding to this receptor. In addition, cardiomyocytes in vitro were shown to bind to prorenin
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from amniotic fluid and from plasma of anephric patients suggesting that these prorenin
species are unglycosylated (Saris et al. 2001b). Prorenin uptake and/or conversion to renin
could be of significance in the heart for the local formation of Angll and may play a role in
cardiac hypertrophy and tissue repair. The uptake process is, however, not unique to prorenin
since M6Pr also bind thyroglobulin. The pathway of prorenin uptake followed by proteolytic
processing to renin (Saris et al. 2001a; Saris et al. 2001b) is now accepted as a clearance
pathway for prorenin (Schuijt and Danser 2002). This is further supported by the fact that
myocyte proliferation in response to stretch is independent on intracellular Angll formation
although prorenin is taken up by cardiomyocytes in this study (Saris et al. 2002).
The renin-binding protein (RnBp) binds avidly and specifically to renin (as observed in
kidney homogenates) and masks its protease activity. It was, however, shown to be identical
to an epimerase (Maru et al. 1996) and it is thought to be involved in the modulation of the
release of active renin from renin-producing cells (Inoue et al. 1990). In addition, RnBp null
mouse mutants displayed no phenotypic changes in renin synthesis, secretion or activity (and
other RAS components) or in blood pressure (Schmitz et al. 2000) indicating that RnBp has
no effect on the RAS cascade.
It has been shown that prorenin through Angll formation can induce cardiomyocyte
proliferation but this process was independent of M6Pr and more likely to be due-non
proteolytic activation of prorenin (Saris et al. 2002). Studies with the inducible hypertensive
rat model have shown that uptake of prorenin also occurs in the heart preceding the
formation of renin (Kantachuvesiri et al. 2001). The source of prorenin in this model is the
transgene carrying the mouse Ren2 gene which gives rise to a non-glycosylated form of
prorenin suggesting once again that mechanisms independent of M6Pr are involved
(Kantachuvesiri et al. 2001).
Recently, Nguyen et al. (2002) described a novel renin receptor (in human kidney). It is a
45kDa transmembrane protein. Transfection of the cloned cDNA into non-expressing cells
resulted in expression of a protein which specifically binds to renin and prorenin but not to
other aspartyl proteases. Binding of this receptor to renin and also prorenin resulted in an
increased cleavage of angiotensinogen and the stimulation of an intracellular signalling
pathway involving MAP kinases. The discovery of a renin receptor, would not only
strengthen the argument that (pro)renin is taken up in tissues but it also implies a direct




It has been proposed that prorenin/renin may not solely be upstream components of the RAS
cascade with the endpoint of generating Angll for blood pressure regulation (Sealey and
Rubattu 1989). The arguments for a direct involvement of prorenin are:
1) prorenin possesses a 'renin-like' activity. Although this activity is lower compared to
renin, the levels of plasma prorenin are several-fold higher than renin conferring it a
substantial capacity for angiotensin production (Skinner 1987);
2) prorenin is present in very high levels in the feto-placental tissues where, unlike in the
kidney, it is not converted to renin before secretion and released as prorenin (Poisner 1998).
Renin activity can, however, be measured at high levels suggesting an activation of prorenin,
possibly via receptor binding or other non-proteolytic pathways (Poisner 1998);
3) the RAS is well known to be hyper-stimulated during development where it participates in
angiogenesis (Walther et al. 2003) and in cell growth/differentiation (Tebbs et al. 1999). In
addition, an intact RAS is essential for normal renal development (Guron and Friberg 2000);
4) there is a strong relationship between renal foetal renin concentration and gestational age
(Gomez and Norwood 1995). In addition, high levels of prorenin in the amniotic fluid again
suggest a role in feto-placental development (Lumbers 1993). High levels of circulating
prorenin have been also reported in humans and animal models displaying a variety of
pathologies such as diabetes with nephropathy and retinopathy, pre-eclampsia/pregnancy-
induced hypertension and hypertension-induced vascular injuries.
1.6.1 Prorenin and Diabetes
Despite renin plasma concentrations being normal of even low in human patients with
insulin dependent diabetes mellitus, prorenin values are significantly correlated to a
microvascular pathophysiology (Deinum et al. 1999). Franken et al. had previously reported
that increased plasma prorenin levels are a more important determinant in retinopathy than
nephropathy (Franken et al. 1990). The reasons for increased prorenin levels are unknown
and the mechanisms involved remain unclear. It was shown that deregulation of renal renin
secretion was not involved since the ratio of arterial to venous renal prorenin was not
elevated (Franken et al. 1990). This could be due to increased secretion of prorenin from
extra-renal sites or decreased degradation of renin in the circulation.
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The production of TGF-pi was demonstrated to be up-regulated in humans with diabetic
nephropathy (Yamamoto et al. 1993). Furthermore, transgenic mice over-expressing TGF-(3l
in JG cells were characterised by increased plasma prorenin concentration (Krag et al. 2000).
It is possible that prorenin (which has some "renin activity") contributes towards an elevated
Angll level since ACE inhibitors and AT] receptor antagonists decrease the incidence of
vascular complications associated with diabetes (Cooper 2004). Similarly, these treatments
have been known to reduce the development of type 2 diabetes in patients with hypertension
(Scheen 2004). More recently, Ichihara et. al. (2004) reported a marked improvement of end-
organ damage (notably nephropathy) in streptozotocin-induced diabetic animals after
administration of a peptide consisting of the handle region of prorenin. This was
accompanied by a decrease in renal Angll. The authors speculated that this "decoy peptide"
may competitively bind the putative prorenin/renin receptor and hence, block the non-
proteolytic conversion of prorenin with downstream Angll production. The results again
suggest a role for prorenin and the prorenin receptor (Nguyen et al. 2002) in the onset of
vascular diabetic injuries.
1.6.2 Prorenin in Pre-eclampsia and in Pregnancy-Induced Hypertension
Prorenin and renin levels are elevated during pregnancy in humans (de Leon et al. 2001) and
in the mouse (Xia et al. 2002). It was shown that in women with pregnancy-induced
hypertension plasma renin concentrations (PRC) are elevated whereas no changes in PRC in
women with pre-eclampsia. Conversely, a recent study in which prorenin was measured after
acid activation revealed that both renin and prorenin were elevated in pre-eclamptic amnion,
chorion and placenta (Singh et al. 2004). This is in disagreement with other studies which
measured it with different methods and this may be the reason for the discrepancy. Another
explanation could be the stage of gestation at wliicli the samples where taken. In the study,
the tissues were collected at term whereas in other studies the gestational stage is not
mentioned. Increased levels of renin and prorenin only in the chorion have been found in
pregnancy-induced patients (Kalenga et al. 1996). The fact that the patients displayed
pregnancy-induced hypertension rather than pre-eclampsia may explain this difference. It
would therefore appear that elevated piorenin in feto-placental tissues might be associated
with another form of vascular pathology.
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1.6.3 Prorenin and Hypertension
In human patients with hypertension, however, plasma prorenin levels vary widely and it
appears that only a sub-group of hypertensive patients display elevated plasma prorenin
levels (Atlas et al. 1977). In the TGR(mRen2)27 rat transgenic model of hypertension,
animals displayed suppressed concentrations of active plasma and renal renin, low or
unchanged levels of plasma Angll but increased levels of circulating prorenin compared to
controls (Lee et al. 1995). This and other studies (Bohm et al. 1995; Gardiner et al. 1993;
Jacinto et al. 1999) have demonstrated that the hypertension occurring in these rats is caused
by activation of ATi receptors by Angll in addition to a local RAS stimulation. It has been
shown that the expression of the Ren2 transgene was detected at extra-renal sites (see below)
whereas the kidney renin was decreased or unchanged. In the adrenal gland, increased levels
of Ren2 mRNA (i.e. from the transgene) correlated with increased steroid excretion
(Langheinrich et al. 1996). Despite these findings, mineralocorticoid excess did not appear to
play a role in the hypertensive pathology since the aldosterone antagonist, spironolactone,
did not have anti-hypertensive effects, confirming the involvement of a local adrenal RAS.
In addition, bilateral adrenalectomy resulted in a significant decrease in plasma prorenin
demonstrating that the adrenal gland is the major source of circulating prorenin in this model
(Bachmann et al. 1992). However, significant levels of active plasma renin remained after
nephrectomy with adrenalectomy (Tokita et al. 1994). These results suggest that extra-renal
sites of Angll generation and the high levels of circulating prorenin may be potential
candidates for the triggering of the injuries observed in the heart, kidney and vasculature of
these animals. This is further confirmed by the fact that transgene expression precedes the
onset of hypertension (Zhao et al. 1993).
Evidence for a local vascular RAS component was given in these transgenic rats in which
expression of Ren2 mRNA was observed in mesenteric/aortic tissues (Hilgers et al. 1992).
Peters et al. reported that plasma prorenin was elevated in those animals which have not yet
developed hypertension (Peters et al. 1996). Reduction in BP alone was not enough to
prevent the vascular and cardiac pathology in TGR(mRen2)27 rats and Angll was shown to
play a vital role in hypertrophic responses in the vasculature since ACE inhibitors and ATi
receptor blockers were more effective than diuretics and/or vasodilators in reducing the MH-
associated lesions (Brosnan et al. 1999). It was suggested by the authors that a local RAS
may be involved and that aortic expression of the Ren2 transgene may lead to increased
Angll levels in this tissue causing hypertrophic vascular growth. Similarly, the fact that ACE
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inhibitors and ATi receptor blockers can ameliorate hypertension without improving cardiac
function may be due to locally formed Angll from a local RAS independently of its
generation in the circulation. Left ventricular hypertrophy was also present in
TGR(mRen2)27 rats and they displayed increased wall (media) thickness in the heart and the
aorta with focal perivascular fibrosis due to increased myocyte and vascular myocyte size as
well as increased synthesis of extracellular matrix proteins (Lee et al. 1995). The kidneys of
these rats were also subject to pathological alterations, mainly increased thickness of the
arcuate and interlobular arteries (Langheinrich et al. 1996). Some glomerular damage was
also present (Bachmann et al. 1992) without affecting renal function in adult rats. The severe
increase in blood pressure may also cause endothelial damage and proliferation (also
potentially triggered by Angll) with endothelial swelling and fibrinoid necrosis as
demonstrated by Kincaid-Smith et al. in their model. Renal ischaemia due to vascular
alterations can also trigger RAS activation causing a further increase in blood pressure
(Kantachuvesiri et al. 1999). Due to the susceptibility of this model to MH, the animals had
to be kept under blood pressure-lowering treatment.
Another rat model carrying the Ren2 transgene was generated to study the effects of high
levels of circulating rat prorenin by directing the expression of the transgene exclusively in
the liver (Veniant et al. 1996). Endogenous renin expression in the kidney was similar to
wild type unlike in the previous model in which renal renin was decreased but the animals
displayed characteristic MH lesions in the heart and in the kidney suggesting a direct effect
of circulating prorenin in the pathophysiology of hypertension and that prorenin caused MH
lesions independently of blood pressure._The advantages of an on-off switch for the Ren2
transgene are evident in terms of control over the duration and intensity of the hypertension.
The inducible rat model of hypertension, TGR(Cyplal-Ren2) displayed a rapid increase in
BP accompanied by weight loss and polyuria, as a result of salt and water depletion
(Kantachuvesiri et al. 2001). The animals exhibited hypertensive injuries in several vascular
beds and organs. There was a distinct difference in the response to injury, the heart and the
mesentery exhibiting greater sensitivity whereas the kidneys appeared to be affected to a
lesser extent (Collidge et al. 2004). Prorenin was detected in cardiac tissues following
transgene induction which preceded the detection of renin suggesting an uptake of prorenin.
Prorenin produced in treated TGR(Cyplal-Ren2) is derived from the mouse Ren2 gene and
does not possess glycosylation sites preventing its binding to mannose-6 phosphate
receptors.
Taken together, these results indicate that (pro)renin uptake results from binding and
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internalisation through an additional receptor-mediated mechanism. The recent report of a
(pro)renin receptor in human tissues demonstrated an increase in Angll formation following
binding of prorenin (and renin) to this receptor. The existence of a (pro)renin receptor links
the malignant hypertension injuries of TGR(Cyplal-RenI) to a locally activated renin-
angiotensin-system in the heart (and perhaps also in the vasculature), in particular prorenin
and/or inflammation may play an important role in the mechanisms underlying vascular and
end-organ injury due to hypertension.
1.7 Aims ofthe thesis
Considering the potential importance of prorenin and renin in the development of vascular
and cardiac injuries in animal models of hypertension and diabetes and in patients exhibiting
hypertension, diabetes and pre-eclampsia, the general aim of this thesis is to examine the
pathophysiology of (pro)renin and its putative receptor in hypertension. For this purpose,
identification of potential mouse homologue(s) to human (pro)renin receptor and cloning the
full length cDNA was performed. Expression profile of the putative (pro)renin receptor at
different embryonic stages tissues and localisation of this receptor in adult tissues and cell
lines was undertaken. Conservation of the putative (pro)renin receptor between species was
assessed (Chapter 3). In order to establish the potential role of the putative (pro)renin
receptor in the pathophysiology of malignant hypertension, an inducible rat model of
hypertension characterised by high circulating prorenin, TGR(Cyplal-Ren2), was used.
Detailed cardiovascular phenotyping using echocardio- and echography methods and
histopathology of this model was undertaken as well as the regulation of the putative
(pro)renin receptor in this high circulating prorenin model (Chapter 4). The modulation of
the phenotype due to environmental and experimental factors and genetic background was
evaluated through survey questionnaires and extensive microsatellite marker screening
{Chapter 5). The direct involvement of this putative (pro)renin receptor in the cardiovascular
injuries of this transgenic model was studied through inhibition of the receptor by a decoy
peptide {Chapter 6). To complement my studies on the putative (pro)renin receptor, prorenin
maturation and renin storage during development was examined. The role of foetal
(pro)renin/RAS regulation in foetal renin granulation independently of blood pressure
regulation was also be investigated. A separate, parallel study investigated the absence or
presence of renin granules in the renal juxtaglomerular cells during the peri-natal period and
at identifying when these granules can first be detected in the kidney and provided insight in
the process of prorenin maturation and may help identify the pathways of renin secretion
during embryogenesis. Finally, the stimuli involved in the regulation of (pro)renin
granulation during peri-natal kidney development were studied and the differential roles of





All chemicals and solutions were purchased from Sigma, (UK) unless otherwise stated.
2.2 Common Laboratory Solutions





Distilled water to final volume of 1L
DNA gel loading buffer
0.025% (w/v) bromophenol Blue





Distilled water to final volume of 1L
Adjust to pFl 7.4
MOPS solution
MOPS: 20.6g
DEPC-treated 50mM sodium acetate to
final volume of 800ml
RNA gel running buffer
MOPS solution: 800ml
0.5M Sodium EDTA: 10ml
Adjust to pH 7
DEPC-treated water to final volume of 1L
RNA gel loading buffer
95% (v/v) deionised formamide
0.025% (w/v) bromophenol Blue
0.025% (w/v) xylene cyanol FF




Glacial acetic acid: 57.1 ml
0.5M sodium EDTA: 100ml.
Adjust to pH 8.5





Adjust to pH 7.05
Distilled water to final volume of 200ml
Tail Buffer
1M Tris HC1 (pH 8): 12.5ml
0.5M sodium EDTA (pH 8): 50ml
5M sodium chloride: 5ml
20% SDS: 12.5ml
Distilled water to final volume of 250ml
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2.3 Cell Lines
Cell lines, AS4.1 (ATCC no: CRL2193, a mouse kidney tumour cell line), E14TG2a (ATCC
no: CRL 1821, a mouse embryonic stem cell line) were kind gifts ofDr P. Lawlor and Dr M.
Sharp (University of Edinburgh, UK) and HMC (a human mesangial cell line) was a kind
gift from Dr B. Banas (University of Regensburg, Germany). AS4.1 and HMC were grown
in monolayers in DMEM/F12 medium (Invitrogen, UK) supplemented with 10% foetal calf
serum and 2mM L-glutamine and passaged every 3 days or when 70% confluent with
trypsin/EDTA. E14TG2a were cultured in monolayer on gelatin coated-cell culture flasks in
GMEM supplemented with 2mM L-Glutamine, 10% foetal calf serum, 1 OOpM sodium
pyruvate, 1% non-essential amino-acids, 100pM 2-mercapto-ethanol and 103 units of
leukaemia inhibitory factor. The cells were passaged every three days with
trypsin/EDTA/chicken serum.
2.4 Animals
All experimental procedures for this thesis were performed at the University of Edinburgh
with the exception of the echographic study on TGR(Cyplal-Ren2) inducible transgenic rat
model (Chapter 4) which was performed at the University of Maastricht (The Netherlands)
by myself.
2.4.1 Mice - General procedures
The mice were purchased from Charles River (Margate, UK) and Harlan (Oxon, UK). The
breeding, maintenance and study of animals were performed according to Home Office
regulations (in pairs in standard cages and 12h light-dark cycles). Prior to and during any
experimental procedures, mice were given free access to water. For control animals and prior
to any experimental procedures, mice were given free access to standard commercial rodent
chow containing 0.32% sodium and 0.395% chloride (CRM, Special Dietary Services,
Witham, UK). For foetal tissue collection, female mice were paired with males in the
afternoon before plug examination and were examined for vaginal plugs the following
morning. The time of the plug detection was termed embryonic day 0.5 (E0.5).
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2.4.2 Tissue collection from mice - Foetal and adult tissues
For studies described in Chapter 3, on the selected time point, the embryos were dissected
out of the uterus rapidly under a dissecting microscope. One placental cone was saved and
treated as described below for adult tissues. Using fine forceps, the heart and lungs, liver and
gut of the foetus were removed to expose the dorsal part of the embryos' abdomen. Gender
was determined visually for embryos older than E15.5. The kidneys were removed, placed in
KNAlater (Ambion, Texas, USA) and kept at 4°C until needed. In the case of newborn or
young pups, decapitation was performed prior to removing the kidneys.
Cervical dislocation or carbon dioxide asphyxiation was used to collect tissues from the
mother such as heart, lungs, submandibular gland, liver, kidneys, adrenal glands, ovary,
mesenteric fat, muscle and brain in that order. The adult tissues were also placed in
KNAlater and kept at 4°C until processed for RNA extraction. Tissues for in situ
hybridisation (whole embryos or adult tissues) were dissected out rapidly and placed on
crushed dry ice until frozen and kept at -80°C until required.
2.4.3 Mouse renin granulation studies - Set up and endpoints
Mice were purchased from Charles River (Margate, UK), except for the 1 -renin/2-renin gene
comparison study for which the FVB/N mice were bought in from Harlan (Oxon, UK). The
breeding, maintenance and study of animals were performed according to Home Office
regulations (in pairs in standard cages and 12h light-dark cycles). Prior to and during any
experimental procedures, mice were given free access to water. For control animals and prior
to any experimental procedures, mice were given free access to standard commercial rodent
chow containing 0.27% sodium and 0.395% chloride (CRM, Special Dietary Services,
Witham, UK). Female C57/B16 and FVB/N mice were paired with males of respective
strains (in the afternoon before plug examination) and were examined for vaginal plugs the
following morning. The time of the plug detection was termed E0.5.
Control C57/B16 and FVB/N mice were housed in pairs and the embryos collected after
maternal cervical dislocation at E15.5, E16.5, El8.5, PI and P28. Only mice of C57/B16
strain were used for the experimental groups. For treatment groups 1 and 2, mice were
housed individually and placed on a low sodium (0.03%) or high sodium (3%) diet,
respectively and received the modified diet from El2.5 as to not interfere with implantation
and/or intrauterine early development. The modified diets were given in powder form.
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For treatment groups 3 and 4, mice were housed individually and received captopril
(30mg/kg/day) or enalapril (30mg/kg/day), respectively, by gavage. Due to previous reports
of foetal toxicity during maternal exposure, captopril and enalapril gavage was started at
E15.5. For the treatment groups 1-4, the embryos were collected at E18.5 and PI. For all
treatment and control groups, maternal plasma and foetal plasma was collected in EDTA
containing tubes, kept on ice, centrifuged at 9,300g for lOmins at 4°C and stored at -80°C
until needed. Maternal plasma was collected by cardiac puncture whereas foetal or newborn
plasma collection was performed by decapitation.
For captopril- and enalapril treated-mice, HPLC was performed to detect captopril and
enalaprilat (the metabolite of enalapril) in the plasma and whole embryo and to demonstrate
placental transfer. Enalaprilat was obtained from QMX laboratories (Thaxted, UK). Only
deuterium-labelled enalaprilat was available commercially and could therefore only be used
to construct a standard curve for HPLC and not mass spectrophotometry due to difference in
mass from enalapril (derived from enalapril given to mice).
2.4.4 Rats - General procedures
2.4.4.1 TGR(Cyplal-Ren2) transgenic rats - Maastricht
TGR(Cyplal-Ren2) animals were bred from a single breeding pair originally obtained from
the Molecular Physiology laboratory at the University of Edinburgh and identical to those
reported by Kantachuverisi et al. (2001).
The breeding, maintenance and study of the TGR(Cyplal-Ren2) animals at the University of
Maastricht (The Netherlands) were performed according to in-house established animal
handling guidelines. All animals were housed in pairs in standard cages except when placed
in metabolic cages (singly housed) with free access to tap water and standard commercial
rodent chow containing 0.25% sodium prior to experimental procedures (Ssniff, Germany)
and 12h light-dark cycles. The number of animals used was 10 per group except for the
metabolic cages where it was 2 and in the arteriograph where the number of controls was 9.
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2.4.4.2 TGR(Cyplal-Ren2) transgenic rats - Edinburgh
For experiments performed in Chapter 6, the TGR(Cyplal-Ren2) inducible hypertensive
rats were inbred at the University of Edinburgh. The breeding, maintenance and study of
animals were performed according to Home Office regulations (in pairs in standard cages
and 12h light-dark cycles). Prior to and during any experimental procedures, rats were given
free access to water. Rats were given free access to standard commercial rodent chow
containing 0.32% sodium and 0.395% chloride (CRM, Special Dietary Services, Witham,
UK) which was replaced by diet in powdered form containing 0.3% indole-3-carbinol (see
Chapter 2.3.11) for induction of the transgene.
2.4.5 Induction of transgene in TGR(Cyplal-Ren2) rats - Maastricht
For Chapter 4, TGR(Cyplal RenI) animals were fed either normal chow with (treated group
- 10 animals) or without (control group - 10 animals) 0.3% indole-3-carbinol (I3C) for 5
weeks. The inducer (I3C) was mixed in peanut oil, added to normal chow and reduced to
complete powder which was given to the animals ad libitum as a thick paste (mixed with
water) to avoid food wastage. The animals were housed in pairs for the duration of the study,
except for a period of 24h when the animals were placed in metabolic cages.
2.4.6 Blood pressure measurement in TGR(Cyplal-RenI) rats - Maastricht
and Edinburgh
Systolic blood pressure (SBP) was measured in conscious restrained animals by an indirect
tail-cuff method using a tail cuff inflating unit linked to a blood pressure transducer (IICT
Life Sciences, USA - Cf. Annex 4). The animals were trained for one week prior to the start
of the experiments. Training consisted of placing the animals in the heated (30°C) measuring
chamber for 15 minutes and then inflating the cuff to take 3-4 mock measurements. SBP was
then measured on day 0-3, 7-8, 14, 21, 28, 35. Three measurements were taken for each
animal on each recording day and then averaged. Blood pressure was also measured in
lightly anaesthesised animals during wall track procedures (described below) under
isofluorane anaesthesia in week 5 of treatment.
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2.4.7 Food consumption, fluid handling, body weight in TGR(Cyplal-Ren2)
rats - Maastricht
Food consumption was measured per cage at regular intervals throughout induction. The data
was calculated and plotted per rat. Body weight was measured prior to the start of the
induction and on day 1, 2, 7, 8, 14, 21, 28 and 35. The animals were individually caged in
metabolic cages for 12 hours and water intake and urine output were measured. Urine was
collected from 2 control and 2 treated animals house individually in metabolic cages.
Dipstick tests were carried out using Multistix 10SG (Bayer, Germany) to measure glucose
(mmol/L), ketones (mmol/L), urine density, blood trace, proteins (mg/dl) and the presence of
leukocytes.
2.4.8 Echocardiography in TGR(Cyplal-Ren2) rats - Maastricht
Echocardiography was performed under light isofluorane anaesthesia prior to the start of the
treatment, during week 1, 2 and 4 of induction. The animals were kept warm on a heat pad
(37°C) connected to a rectal probe. The left ventricle (LV) measurements were taken using a
15-Mhz linear array transducer (Hewlett-Packard, USA) interfaced with a Sonos 5500
echocardiography system (Philips, The Netherlands).
Two-dimensional B-mode echocardiograms were acquired from parasternal long axis views
and from mid-papillary short-axis views. Digital recordings were analysed off-line using
three cardiac cycles as to obtain measurements on both the long and short axis in three
systoles and three diastoles per animal per time point. Using long-axis images, left
ventricular area, aortic diameter, internal ventricular length and cardiac length were directly
measured whereas using short-axis images, wall and lumen thickness were measured
directly. Cardiac output, stroke volume and ejection fraction were calculated from the above
values.
2.4.9 Aorta wall track in TGR(Cyplal-Ren2) rats - Maastricht
Aorta wall track was performed under isofluorane anaesthesia during week 5 of induction.
Measurements were taken using a 10-Mhz linear array transducer linked to a AU4
echography system (Esaote, Italy) in combination with local aortic pressure measurements
(2F Millar probe). Images were sent to a software analysis which permitted manual detection
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of the aortic wall and automatic calculations of distension, compliance and pulse wave
velocity. Mechanical parameters were calculated at end-systolic blood pressure. An average
of 10 heart beats (and an average of 5 repeats) was used per animal. Heart beats during
breathing were discarded as the ultrasound signal was distorted due to diaphragm
movements.
2.4.10 Organ collection in TGR(Cyplal-RenI) rats - Maastricht
At the end of week 5 of induction, the animals were anaesthesised with pentobarbital
(intraperitonally) and exsanguinated for blood collection through the abdominal aorta. The
blood samples were treated in the same manner described in Chapter 2.3.6. The heart was
retro-perfused with saline to remove residual blood. The following tissues were collected,
rinsed free of blood, blotted dry, weighed and stored as described in Table 2.1.
Organ/vessel Measurement Snap frozen Fixed for histology in
formaldehyde
Whole Heart Weight N/A N/A
Atria Weight S X
Left ventricle Weight Cut longitudinally, 1 part S Cut longitudinally, 1 part S
Right ventricle Weight V X
Lungs Weight X X
Liver None ✓ X
Adrenals (x2) Weight 1 adrenal S 1 adrenal ^
Right kidney Weight Cut longitudinally, 2 parts S X
Left kidney Weight Cut longitudinally, 1 part S Cut longitudinally, 1 part V
Abdominal aorta None X V
Thoracic aorta None X S
Left renal artery None X V
Mesentery None X Small portion S
Mesentery artery None X S and used for arteriograph
Tibia Length X X
Table 2.1: Organ collection, processing and storage for Maastricht TGR(Cyplal-Ren2) animals.
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2.4.11 In vitro mesenteric artery arteriograph in TGR(Cyplal-Ren2) rats -
Maastricht
Mesenteric resistance arteries were isolated and cannulated in an arteriograph, filled with
calcium-free HEPES buffer containing 10p.mol/L sodium nitroprusside to insure maximal
dilatation. A pressure diameter curve was constructed by recording the lumen diameter
stepwise (lOmmHg) in intraluminal pressure from 20 to 140mmHg.
2.4.12 Pilot decoy peptide study in TGR(Cyplal-Renl) rats, Edinburgh
The animals were fed as described previously (Chapter 2.3.5) without addition of peanut oil
and weighed prior to the start of treatment, everyday for the first 3 days and every second
day thereafter. Three days before the start of the study, the diet was changed from pellet
form to powder form (RM1, Special Dietary Services, Witham, UK) and on the day of the
start of the dietary induction with 0.3% I3C, an osmotic mini-pump (Model 2002, 14-day
use, 0.5|il/hour, Charles River, Margate, UK) was implanted sub-cutaneously under
isofluorane anaesthesia with analgesia. The mini-pump was filled with a custom-made
peptide (Sigma-Genosys, UK) in saline, (NH2-RILLKKMPSV-COOH), at a concentration of
0.4mg/kg/day in saline or saline alone. Two animals were given powdered diet mixed with
0.3% I3C in addition to saline-filled osmotic mini-pump and two animals were given 0.3%
13C in addition to the decoy peptide-filled mini-pump.
Systolic blood pressure (SBP) was measured in conscious restrained animals by an indirect
tail-cuff method using a tail cuff inflating unit linked to a blood pressure transducer (IICT
Life Science, USA). The animals were trained for 5 days prior to the start of the experiments.
Training consisted of placing the animals in the restraining tube in a warm (30°C) chamber
for 15 minutes and then inflating the cuff to take 3-4 mock measurements. Immediately
before starting the induction diet of 0.3% I3C and during the 14 day experiment, 3
measurements were taken for each animal on each recording day and then averaged. SBP
and weight were measured on day 0, 1,2, 3, 5, 7, 9, 11 and 13.
The animals were sacrificed 14 days after mini-pump implantation and dissected for
pathological analysis. The tissues taken for pathology were: heart, kidney, and mesentery
which were fixed in formaldehyde. Due to the small sample group in this pilot study, only
qualitative analysis was performed and no gene expression investigation could be performed.
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For both rat and mouse tissues, a range of 60mg to lOOmg of tissue was used with the
exception of embryonic kidneys, adrenal glands and ovaries where the amount of tissue was
in the range of 5 to lOmg. Placed in Trizol™ (Invitrogen, UK) according to manufacturer's
instructions, the samples were homogenized with a bead mill (Mixer Mill MM 300, Retsch,
UK) previously optimised for each tissue type to achieve complete disruption (assessed
visually).
Subsequently, the samples were incubated at room temperature for 5 minutes after
homogenisation. 0.2 ml of chloroform (BDH, UK) per ml of Trizol was added, mixed
vigorously, then incubated at room temperature for 2-3 minutes. The mixes were then
centrifuged at 12,000g for 15 minutes at 4°C. The upper aqueous layer was transferred to a
fresh tube. At this stage, 5-lOpg of glycogen was added as a carrier to tissue samples of 1-
lOmg. The aqueous phase was added to 0.5ml of isopropanol (BDH, UK) per millilitre of
Trizol, mixed, incubated at room temperature and centrifuge at 12,000g for 10 minutes at
4°C. The supernatant was removed and the RNA pellet washed with 1ml of 70% ethanol.
The samples were mixed and centrifuged at 7,500g for 5 minutes at 4°C. The pellet was
allowed to dry for 5 minutes at room temperature and then was re-suspended in 50pl of
DEPC-treated water.
On some occasions, it was necessary to incubate the RNAs for 10 minutes at 55°C to
complete dissolution. Table 2.2 summarises the conditions used for the extracted tissues
listed above. The RNA samples were also DNase-treated using an RNase-free DNase kit
(Ambion, Texas, USA), then RNA concentration was determined by spectrophotometry at
wavelengths 260nm and 280nm. The RNAs were then stored at -80°C.
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Embryonic kidney (x2) 3 2x 120 30 0.1
Pre-wean kidney (x2) 3 2x 120 30 0.1
Ovary (x2) 3 2x 120 30 0.1
Adrenal gland (x2) 3 2x 60 30 0.1
Liver 6 2x 120 30 1
Brain 6 2x 120 30 1
Adult kidney 6 2x180 30 1
Heart 6 2x180 30 1
Lung 6 2x180 30 1
Placenta 6 2x180 30 1
Muscle 6 2x180 30 1
Table 2.2: Homogenisation conditions for RNA extraction from tissues.
2.5.2 Cultured Cells
RNA was extracted from cultured cells using an RNA preparation kit (RNeasy, Midi kit,
Qiagen, UK). The cells were grown to confluency, rinsed with PBS before being collected
using the lysis buffer provided and the RNA extracted as per manufacturer's instructions.
RNA samples were also DNase-treated using an RNase-free DNase kit (Ambion, Texas,
USA), then RNA concentration was determined by spectrophotometry at wavelengths
260nm and 280nm. The RNAs were then stored at -80°C.
2.6 Reverse Transcription
Two micrograms of RNA were used in a reaction containing random octamers (lpMol) and
dNTPs (ImM). This was incubated at 65°C for 5 minutes. Forty units of RNase Inhibitor
(Sigma, UK), lOmM DTT and 25 units of Superscript II Reverse Transcriptase (Invitrogen,
UK) were added and the samples were incubated under the following conditions: 25°C for
10 minutes, 42°C for 50 minutes, 70°C for 15 minutes. Negative controls were also made by
replacing the enzyme by 0.5pl of reaction buffer.
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2.7 Mouse (Pro)Renin Receptor Polymerase Chain Reaction
Polymerase chain reaction (PCR) was performed on the reverse transcribed samples using
the primers (MGW Biotech, Germany) described in Annex I.
The PCR conditions were as follows: Taq polymerase activation for 10 minutes denaturation
for 30 seconds at 94°C, annealing for 30 seconds at 60°C for mouse (pro)renin receptor
coding sequence primers or 61°C for mouse (pro)renin receptor whole cDNA primers and
polymerisation/extension for 2 minutes at 72°C. Using rat (pro)renin receptor primers, the
annealing temperature was 58°C for 45 seconds. Optimisation data for the mouse primers are
shown in Chapter 3. Two and a half units of a Taq polymerase (HotStartaq, AbGene, UK)
was used with 5pMol of each primer, 1.5mMMgCl2 and lOmM dNTP. The samples were
amplified for 30 cycles and analysed by agarose gel electrophoresis in lx Tris-acetate-EDTA
buffer.
2.8 Sequence Identity Analysis
A sequence identity search was conducted using BLAST (Basic Local Alignment Search
Tool; http://www.ncbi.nlm.nih.gov/BLAST/) which is a set of similarity search programs
designed to explore all of the available sequence databases with the human (pro)renin
receptor cDNA clone, N14F (Nguyen et al. 2002) (GenBank: AF291814). The resulting
mouse sequences were located in the mouse genome sequence using ENSEMBL
(http://www.ensembl.org/Mus_musculus/). Vector NTI 5.3.0 was used to translate cDNAs
into amino-acid sequence and ClustalW was used for sequence alignments (Chenna et al.
2003). Hydrophobicity prediction plots were obtained using TMHMM (Krogh et al. 2001).
A bacterial artificial chromosome (BAC - 12J18) containing the putative mouse (pro)renin
receptor gene of strain C57/B16 was purchased from Invitrogen, UK.
2.9 cDNA purification and TA cloning
PCR products were excised from a 0.8% agarose gel containing ethidium bromide under UV
illumination, and purified using a gel purification kit (QiaQuick, Qiagen, UK). Where
needed, the product was cloned using a TA cloning kit (pGEM-t easy kit, Promega, UK)
using the protocol described in Table 2.2. lpl of the resulting DNA was electroporated into
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electrocompetent E.coli DH5a and plated onto ampicillin (lOOpg/ml) agar plates containing
X-Gal (80pg/ml) and IPTG (0.5mM). Successful cloning of a PCR product using the
aforementioned kit interrupts the coding sequence of P-galactosidase, producing white
colonies. However, it remains possible that the PCR product may integrate in-frame with the
lacZ gene retaining p-galactosidase activity and producing blue colonies. Positive white
colonies were selected, grown in 25ml cultures and the DNA extracted with a Midi plasmid





lOx T4 ligase Buffer lpl lpl lpl
pGEM-T Easy Vector (50ng) lpl lpl lpl
PCR Product 2pi - -
Control Insert DNA - 2pl -
T4 DNA Ligase (3 units/pl) lpl lpl lpl
Deionised water to a volume of lOpl lOpl lOpl
Table 2.3: TA cloning protocol.
The plasmids were sequenced on an ABI Prism 377 DNA sequencer using BigDye 2
sequencing kit by N. Wrobel (Molecular Physiology, University of Edinburgh) and the
orientation and sequence of the PCR product examined by restriction mapping.
2.10 Real-time quantitative PCR
Quantitative PCR analysis in real time was performed using an Applied Biosystems 7000
sequence detector using SYBR green fluorescence with primers for the rat renin receptor
described in Annex I. The SYBR green results were normalised using a human 18S Taqman
assay (Applied Biosystems, UK). Reactions were performed in 25pi and cycling was for 2
minutes at 50°C, 15 minutes at 95°C and product amplification by 40 cycles of 95°C (15s)
and 60°C (1 minute). The tested samples were plated in quadruplicates and each five point of
the standard curve was plated in triplicates. The tested samples were read against their
respective standard curves and normalised with 18S. Standard curves for 18S with a slope of
-3.03 (representing optimal doubling efficiency of product being amplified) were used. An n
number of 5 or 6 (as detailed on each graph) was used per tissue/treatment and a Student t-
test was performed between respective treatment and control groups.
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2.11 Microsatellite marker PCR
Genomic DNA was extracted from liver samples (animals sampled in Maastricht) or ear/tail
biopsies (Animals sampled in Edinburgh) using phenol-chloroform organic phase extraction.
Polymerase chain reaction (PCR) was performed on genomic DNA. Using microsatellite
marker primers (See Annex I), PCR conditions were as follows: denaturation for 30 seconds
at 94°C, annealing for 30 seconds at 58°C and polymerisation/extension for 1 min at 72°C.
Half unit of a Taq polymerase (AbGene, UK) was used with 5pMol of each primer,
1.5mMMgCl2 and lOmM dNTP. Samples were amplified for 30 cycles, added Cresol red dye
for visualisation and analysed by acrylamide gel electrophoresis in lx tris-borate-EDTA
buffer (TBE). Gels were then stained in a solution of ethidium bromide (lmg/ml) in lxTBE.
2.12 Northern Blotting and Hybridisation
2.12.1 Agarose/formaldehyde RNA gel
400mls of agarose/formaldehyde gel mixture was prepared by melting 4g of agarose in
250ml of DEPC-treated water. 1.1 part of 5x running buffer and 1 part of formaldehyde were
added to the agarose. The gel was cast in an electrophoresis tray and allowed to set for at
least 30min.
2.12.2 Sample preparation
Up to 30pg of RNA in 4.5pl was mixed with 2pl of 5x gel running buffer, 3.5pi of
formaldehyde and 10pl of formamide and incubated at 65°C for 15 minutes. 2pl of DEPC-
treated gel loading buffer were then added to the samples. The samples were placed on ice
while the gel was pre-run 5V/cm for 5 minutes. The samples were loaded and separated on
the agarose gel at a voltage of 3-4V/cm until bromophenol blue had migrated 8cm. Half way
through electrophoresis, the running buffer was collected, mixed and returned to the tank.
2.12.3 Blot
The gel was placed up side down on a 20x SSC -soaked blotting paper and overlaid
successively with one sheet of nylon membrane (Hybond XL, Amersham-Pharmacia, UK), 3
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pre-soaked sheets of blotting paper and blotting paper towels. The blotting procedure was
performed overnight. The membrane was then baked at 80°C for 2 hours and stored between
two layers ofblotting paper until needed.
2.12.4 Pre-hybridisation and hybridisation
Na2HP04 (1M) and Modified Church and Gilbert buffer (0.25M Na2HP04. 7% SDS. 1mm
EDTA) were pre-warmed to 65°C. The membrane was placed in a roller bottle in a
hybridisation over and incubated in Na2HP04 (1M) and Modified Church and Gilbert buffer
at 65°C for 30mins each. While the membrane was pre-hybridising, the 32P labelled-probe
was prepared using Ready-to-use labelling beads (Amersham-Pharmacia, UK). 50ng of PCR
product (made with primers JJM515-516) was used. The probe was purified and eluted in
Tris-EDTA buffer. Church and Gilbert buffer was replaced by fresh pre-warmed buffer and
the probe added in the hybridisation buffer (not directly on the membrane) and incubated
overnight at 65°C.
2.12.5 Post hybridisation Washes
In the roller bottle, the nylon membrane was washed twice with pre-warmed 2xSSC, 0.1%
SDS for 20 minutes and twice with 0.2xSSC, 0.1% SDS for 20 minutes at 65°C. Higher
stringency (0.02% SSC) was performed if the membrane was still "hot" (i.e. counts per
second above 10). The membrane was pat dried, wrapped in cling film and exposed to X-ray
film with an intensifying screen at -80°C overnight.
2.13 In situ hybridisation on frozen tissue sections
2.13.1 35S-UTP RNA probes
Reagents were added to an RNase-free tube in the following order: 5x transcription buffer
(Promega, UK), ImM ATP, CTP and GTP, lOmM dithiothreitol, the linearised DNA
template [for the mouse putative (pro)renin receptor probes, the plasmid constructed by TA
cloning of RT-PCR product from mouse kidney with primers JJM 515-516 was restriction
digested with Spel for the anti-sense probe or with Apal for the sense probe], 40 units of
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RNase inhibitor (Promega, UK), RNA polymerase (20 units T7 RNA polymerase for the
anti-sense probe and 15 units SP6 RNA polymerase for the sense probe) and 160pCi 35S-
labelled UTP. The reaction was carefully mixed and incubated for 1 hour at 37°C for the T7
RNA polymerase or 40°C for the SP6 RNA polymerase. DNase treatment was then
performed using RQ1 DNase (Promega, UK) at 37°C for 10 minutes. The RNA probes were
then purified on a Nick column (Amersham-Pharmacia, UK) and eluted in 400pl of 1M Tris-
EDTA buffer and kept at -20°C.
2.13.2 Tissue sections
7mm frozen tissue sections were prepared in a cryostat microtome (Bright 5040 OTF, UK) at
-20°C on commercially purchased polylysine-coated slides (BDH, UK) and kept at -80°C
until needed.
2.13.3 In situ hybridisation procedure
The sections were fixed and dehydrated at room temperature in successful incubations of the
following solutions: 4% cold paraformaldehyde (10 minutes), lx phosphate buffered solution
(5 minutes, twice), 0.1M triethanolamine with 0.25% acetic anhydride (10 minutes), lx
phosphate buffered solution (3 minutes), 70% ethanol (2 minutes), 80% ethanol (2 minutes)
and 95% ethanol (2 minutes). The slides were then left to air dry for a minimum of 30
minutes.
Pre-hybridisation was performed in sealed containers lined with blotting paper soaked in 4x
SSC with 50% deionised formamide. The slides were placed in this environment covered
with 200pl of the following buffer: 0.12M NaCl, 2mM Tris (pH: 7.5), 0.2x Dehnardt's,
200pM EDTA, lOOpg salmon sperm DNA, 2mg yeast tRNA and 50% deionised formamide
and incubated at 50°C for 2 hours. The probe buffer was made of the same mix containing
the probe (40 million counts/minute) and 50% deionised formamide. This was heated up to
80°C for 10 minutes, cooled down on ice and DTT added to lOmM. The pre-hybridisation
buffer was replaced by the probe-containing buffer and incubated at 50°C for 16 hours.
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The slides were drained and rinsed in three 2x SSC washes for five minutes each. 200pi
RNase containing buffer (0.5M NaCl, lOmM Tris, ImM EDTA, 30pg RNase A) was added
to the sections and incubated at 37°C for 1 hour to remove unbound probe.
The slides were then washed through the following treatment: 2xSSC at room temperature
for 30 minutes, O.lxSSC at 60°C for 1 hour, O.lxSSC at 60°C (and cooled at room
temperature) for 1 hour. Dehydration was performed in successive washes of 50% ethanol in
0.3M ammonium acetate, 70% ethanol in 0.3M ammonium acetate and 90% ethanol in 0.3M
ammonium acetate. The slides were left to dry completely at room temperature and exposed
to X-ray autoradiography for 48 hours. When quantitative measurement was needed, the
slides were dipped into liquid silver chloride emulsion, exposed for two to three weeks in the
dark at 4°C and the image analysed for silver grain deposition.
2.14 Histology
These techniques were performed at the University of Edinburgh, Core pathology facilities
and the pathology assessment was performed by Dr. David Browstein.
2.14.1 Paraffin embedding and paraffin sections
After initial fixation in formalin (overnight for large adult tissues), the tissues were
processed using an automated paraffin wax embedder (Citadel 2000, Shandonn, UK). Firstly,
the dehydration steps were done at 35°C, each for 1 hour: 50% ethanol, 70% ethanol, 95%
ethanol, 99% ethanol (twice), 100% ethanol (twice), xylene (thrice).
The paraffin steps were then carried out at 60°C: wax (1 hour, 4 times). The tissues were
then placed in the correct orientation into moulds and covered in paraffin wax. The paraffin
blocks were kept at 4°C until sectioned. The tissues were sectioned with a microtome (Bright
5040, Bright, UK) and the resulting 3pm-sections were bound to pre-coated polylysine slides
(BDH, UK) before drying them at 37°C overnight.
2.14.2 Haematoxylin-Eosin staining of paraffin sections
All steps were performed at room temperature. The tissue sections were de-paraffinised and
re-hydrated by successive incubations in xylene (5 minutes), absolute ethanol (2 minutes),
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99% ethanol (2 minutes), 70% ethanol (2 minutes) and tap water (2 minutes). Staining was
performed by placing the sections into haematoxylin for 5mins, tap water (5 seconds), acid
alcohol (0.12M hydrochloric acid in 99% ethanol; 5 seconds), tap water (5 seconds) and
eosin for 2 minutes before a final rinse in tap water. The sections were then dehydrated in
95% ethanol, 99% ethanol and twice in absolute ethanol, each for 5 seconds. The sections
were stored in xylene until mounted with DPX (BDH,UK) and sealed with a glass coverslip.
2.14.3 Sirius Red staining of paraffin sections for collagen fibres
Sections were de-paraffinised and re-hydrated by a series of 5 minute-incubations as follows:
xylene (twice), 100% ethanol, 98% ethanol, 70% ethanol, 30% ethanol and distilled water
(twice). Slides were then incubated in saturated picric acid (aqueous solution of saturated
picric acid containing 0.1% Fast green FCF and 0.1% direct red 80) for 2 hours. A wash step
in distilled water was performed for 6 minutes before dehydrating the sections using a
reverse ethanol series. Slides were mounted using Permount and a glass coverslip.
2.14.4 Gomori's stain on paraffin sections for reticulin fibres
The sections were de-paraffinised and re-hydrated by a series of incubations as follows:
xylene (5 minutes - twice and 2 minutes once), absolute ethanol (5 minutes - twice), 90%
ethanol (2 minutes), 70% ethanol (2 minutes), 50% ethanol (2 minutes) and tap water (5
minutes). The sections were then treated as follows with 5 minute-washes in tap water
between each step: oxidisation using acidified potassium permanganate (1% in hydrochloric
acid), incubation in oxalic acid (1%), sensitisation in iron alum (2.5%), reduction in 10%
formalin, staining in gold chloride (0.2%), fixation in sodium thiosulphate (5%) and nuclei
counterstaining with safranin (1%). The section were then de-hydrated in the reverse
ethanol-xylene series and mounted in DPX and a glass coverslip.
2.15 Electron Microscopy
Embryonic kidneys were carefully isolated and one kidney per embryo was used for electron
microscopy examination. The rest of the procedure was performed at the Department of
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Pathology, University of Dundee and the presence or absence of renin granules was assessed
by Prof. Stewart Fleming.
The samples were fixed in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer at 4°C, for
a minimum of 4 hours. Tissues were cut into 1mm cubes for fixing, washed in 0.1M buffer
overnight at 4°C, post fixed in osmium tetroxide in 0.2M buffer for 1 hour and rinsed in
0.2M buffer before being dehydrated in an ethanol and propylene oxide series. The samples
were then gradually processed into epoxy resin and allowed to polymerise at 60°C for 48
hours. Several 1 pm sections were cut using glass knives and an ultramicrotome, then dried
onto a glass slide on a hotplate at 80°C to ensure adhesion. Staining with 1% toluidine blue
in 1% borax solution for 1 minute at 80°C was performed before mounting the sections with
a coverslip. Target areas of the sections were identified before thin sectioning was performed
using a diamond knife at around lOOnm. The sections were picked up onto 300 mesh (300
squares), thin-bar, copper grid.
2.16 Statistical analysis
All graphs show mean ± standard error. *: p>0.05; **: p>0.01; ***: p>0.001. Statistical
analysis consisted of Student's t-test for individual variables.
In the events of several time points (or pressure in the case of arteriography) being recorded
for the same animals, two batteries of statistical tests were used:
1) Repeated measure two-way Analysis ofVariance (ANOVA) was employed.
2) However, if data points were missing due to experimental procedures (such as animals
being restless during blood pressure measurements), Prism statistical analysis software
did not allow repeated measure two-way Analysis of Variance (ANOVA). For this
reason, a standard two-way Analysis of Variance (ANOVA) was undertaken as stated in
the text.
Bonferroni Post-test was deemed too stringent if a high number of repeated measurements
were recorded. It was used solely to examine differences at individual time points for
measurements such as cardiac output and stroke volume recorded on 4 different occasions.
Least significant difference Post test was employed if a high number of repeated
measurements, for example, blood pressure measured food consumption measured on 15
different occasions.
70
Due to weight loss in TGR(CyplaJ~Ren2) animals, organ weights were not expressed over




The Putative (Pro)Renin Receptor in the
Mouse
3.1 Introduction
Nguyen et al. (2002) recently described the cloning of a human (pro)renin receptor that was
found to be expressed in multiple tissues and was localised to the mesangium of glomeruli,
the coronary artery and the vascular bed of the placenta. Transfection of the cDNA into
human foetal mesangial cells (HMC) resulted in expression of a membrane-associated
protein that specifically bound to renin and prorenin but not other aspartyl proteases. Binding
resulted in a 5-fold increase in angiotensinogen cleavage (compared with renin or prorenin in
solution), the rapid phosphorylation of the receptor and the activation of ERK1 and ERK2
(MAP kinases).
A (pro)renin receptor has important implications in RAS biology in normal physiology and
in pathological situations and there are several ways in which it may play a pivotal role.
Firstly, a (pro)renin receptor may be involved in (pro)renin uptake. Mannose-6-phopshate
receptors are well known to play a role in this event in cardiac and vascular tissues (Peters et
al. 2002; Saris et al. 2002; van den Eijnden et al. 2001; van Kesteren et al. 1997) but this
process is limited to the glycosylated form of renin. The role of mannose-6-phosphate
receptors in cardiac and vascular hypertrophy has been extensively investigated (Saris et al.
2001a; Saris et al. 2001b; Saris et al. 2002). The data suggest that although this receptor can
bind and internalise prorenin (Saris et al. 2001b), this pathway may be a clearance pathway
for prorenin since proteolytic activation of prorenin was observed following receptor binding
(Saris et al. 2001a).
It was previously demonstrated in TGR(Cyplal-mRen2) that prorenin resulting from the
mouse Ren2 gene (hence non-glycosylated) is present in the heart prior to mouse renin
detection suggesting that a (pro)renin receptor may be involved in uptake and activation of
prorenin. Secondly, non-proteolytic reversible activation of prorenin has been shown to play
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a role in diabetic nephropathy in a diabetic rat model and it was demonstrated that a rat
(pro)renin receptor was involved (Ichihara et al. 2004).
In addition, putative (pro)renin receptor over-expression in smooth muscle cells of a
transgenic rat model resulted in increased heart rate and in progressive elevation of systolic
blood pressure (Burckle et al. 2006). It is also possible that a (pro)renin receptor may play
additional roles in normal (such as during gestation or in ovarian biology) or abnormal (such
as hypertension) physiology associated with prorenin secretion and non-proteolytic
activation of prorenin.
The aim of this chapter is to identify potential mouse homologues of the human (pro)renin
receptor reported by Nguyen et al. (2002) using bioinformatics tools and to clone the
cDNA(s) for future work. Sequence comparison of the human (pro)renin receptor with a
vacuolar proton-ATPase membrane sector-associated protein (M8-9 (Ludwig et al. 1998)) in
a variety of species including mouse, chicken and C.elegans is also reported. The findings
suggest that the (pro)renin receptor is conserved between these species. The protein
identified as the (pro)renin receptor may also function as part of a vacuolar ATPase protein
complex and is the product of a single gene. In addition, we studied the mouse homologue
and found that at the cDNA and protein levels, mouse and human sequences are highly
similar. Transcripts were found (using RT-PCR) in all adult tissues examined and in the
kidney from E9.5dpc indicating that the molecule is ubiquitously expressed in the mouse. It
was not possible to identify a tissue or cell line negative for the mouse putative (pro)renin
receptor and expression was also detected in embryonic stem cells.
Once the existence of a murine homologue of the human (pro)renin receptor was established,
the mRNA expression patterns in mouse adult and foetal tissues were investigated, as well as
the cellular localisation of this putative receptor. In all other tissues, the receptor expression
was ubiquitous. In the kidney, results suggest that the receptor is expressed differentially and
that it is present in the renal cortex but not the medulla and more precisely in smooth muscle
cells of the arterioles.
3.2 Results
3.2.1 Genomic structure and homology searches
Three mouse cDNA sequences were found by BLAST using the human (pro)renin receptor
cDNA sequence N14F [(Nguyen et al. 2002), GenBank accession no: AF291814)]. The first
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was from a mammary tumour library generated from a mouse of FVB/N strain. The other two
clones were from an 8-day mouse embryo whole body and from a mouse neonatal head library,
both of C57/B16 origin (GenBank: AKO17482 and AK029405, respectively). The cDNAs were
all approximately 2Kb in length and had a stop codon located within exon 9 producing a long 3'
untranslated region of approximately 800bp (Figure 3.1).
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Figure 3.1: (Pro)renin receptor gene and cDNA structure. A) Genomic structure of the putative mouse
(pro)renin receptor. Roman numerals represent the exons. The striped area indicates the coding region of
exon 9 while the plain area indicates the 3' untranslated region of exon 9. B) Alignment ofmouse putative
(pro)renin receptor with human rennin receptor cDNAs. The orange arrow denotes the coding region of
the cDNA while the blue line denotes the 3' untranslated region. Note the position of the conserved
BamHI restriction site at the 3' end of the coding region between human and mouse cDNAs.
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The mouse cDNAs mapped to chromosome X in the mouse genome, more precisely at locus
A1.2 (Figure 3.2). From this locus, a C57/B16 BAC clone (12J18) was identified using
ENSEMBL.
The BAC sequence by comparison with cDNA sequence predicts that the mouse putative
(pro)renin receptor gene is 25Kb in length and has 9 exons and 8 introns (Figure 3.1). Another
genomic match was obtained by ENSEMBL on chromosome 1. However, no identified gene,
cDNA or ESTs are present in this region. This may be evidence for a pseudogene, the function
ofwhich is unknown.
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Figure 3.2: Putative (pro)renin receptor Contig from Ensembl. The sequence was from Chromosome
X of the mouse genome. The cDNA clone BC014706 (57304E06Rik) is found within this contig.
3.2.2 Sequence alignments
DNA sequences of the three murine putative (pro)renin receptor cDNA clones found by BLAST
were aligned and compared with the human (pro)renin receptor clone (Figure 3.3). Very few
differences in sequence were observed between mouse strains with an average of 83% sequence
identity between all 3 cDNAs. The mouse putative (pro)renin receptor protein has two
hydrophobic regions located at amino acid position 219-235 and amino acid position 336-350.
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Mouse cDNA Whole cDNA Coding Region 3' Untranslated Region
BC014706 82.9% 88.8% 75%
AKO17482 81.6% 88.2% 73.2%
AK029405 82.8% 88.1% 80.2%
Figure 3.3: Nucleotide sequence alignment matching of putative (pro)renin receptor. Three mouse
cDNA clones, BCO14706, AKO17482 and AK029405 were aligned against the human (pro)renin
receptor nucleotide sequence. Results are expressed as a percentage of nucleotides matching the human













Figure 3.4: Alignment of amino acid sequences between human (pro)renin receptor and mouse
putative (pro)renin receptor. Shaded sequences indicate identity. Bold amino acids indicate
conservative substitution while unshaded amino acids denotes a non-conservative substitution.
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The data clearly show that the mouse sequences are highly similar to the human sequence
reported by Nguyen et al. (2002). At the amino acid level, human and mouse proteins also
displayed sequence identity. Only 22 of the total 350 amino acids differed between the two
species (Figure 3.4), 10 of them being conservative substitutions. The 3' untranslated region
of the (pro)renin receptor showed the lowest identity sequence between mouse and human
suggesting it may not be as important for gene function.
When carrying out the BLAST search, a truncated vacuolar ATPase protein called M8-9
(Ludwig et al. 1998) from adrenal chromaffin cells (co-purifying with V-ATPases) was
found to have homology with the human and mouse (pro)renin receptor cDNA and also the
mouse cDNA. Amino acid alignment between the bovine M8-9 V-ATPase sub-unit (30
amino acids) and the human (pro)renin receptor translation showed a high degree of
sequence homology (Figure 3.5A). Eight out of the 30 amino acids differed between the two
sequences, 3 of which were conservative substitutions. Similar analyses revealed that 10
amino acids differed between the murine and the bovine sequences (Figure 3.5B), 3 of which
were conservative substitutions.
Nucleotide sequence identity was also demonstrated between the human (pro)renin receptor

















Figure 3.5: M8-9 alignments. A) Alignment of amino acid sequences between human (pro)renin
receptor and bovine M8-9 vacuolar ATPase sub-unit B) Alignment of amino acid sequences between
mouse (pro)renin receptor and bovine M8-9 vacuolar ATPase sub-unit. Shaded sequences indicate
homology. Bold amino acids within the shaded sequence indicate conservative substitution while






















Figure 3.6: CLUSTAL alignment of human amino acid sequences. (Pro)renin receptor (GenBank
accession AF291814) and M8-9 (GenBank accession NM 005765). In addition, the shorter sequence
described as M8-9 (VATN; Swissprot accession 075787) was aligned manually to show extent of its
identity with the other sequences. Figure compiled with the help ofDr D. Dunbar.
3.2.3 (Pro)renin receptor phylogenic conservation
Conservation of the putative (pro)renin receptor in several species was studied using the
homologous sequences available in the ENSEMBL database. A multi-species protein sequence
comparison (Figure 3.7A) revealed homologues to the human receptor in a variety of species
including rat, mouse (as already mentioned), chicken, frog, zebrafish, mosquito or drosophila
suggesting that the putative (pro)renin receptor gene is highly conserved between a large number
of species. The multi-species sequence alignment (Figure 3.7B) shows homologues in species as
remotely related to humans as C.elegans.
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Human VGNLFHRPRATVMVMVKGVNKLALPPGSVISYPLENAVPFSLDSVANSIHSLFSEETPVVLQLA 128
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2 2* ****,2* **.;?** • 2 * • • * II.
Human PSEERVYMVGKANSVFEDLSVTLRQLRNRLFQENSVLSSLPLNSLSRNNEVDLLFLSELQVLHD 192
C_elegans FDQDMALIFGADR ENVQVSAGGITGSMLALAAQQEAVDATVIKTKR STLVKELEAVYQ 160
• •• • • *•••*• J a a Z a a a a a a a a a !Sa**aaaaa
Human VDALQKFADDMYSLYGGISSLLSRHKHLAKDHSPDLYSLELAGLDEIGKRYGEDSEQFRDASKI 256
C_elegans KAAIEALTASINNAYGGLAAAIKSAG-VQMDNNADVFRVSITGLVGI TESAQKEEAVAD 218
*aa aa a a a ***J55 a a S *taa*Sa Saa!** * a* * a *a *
Human LNAVVELVTVKSFDTSLIRKTR TILEAKQAKNPASPYNLAYK YNFEYSVVFN 30 8
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^ , *; .5. J* t** Z » S*aal*
Human MVLWIMIALALAVIITSYNIWNMDPGYDSIIYRMTNQKIRMD 348
C_elegans IFLGLVVILVVALIYIVVGMASIDPEKDSIIYRMTTTRMKKD 322
Figure 3.7: Conservation of amino acid sequence of (pro)renin receptor/M8-9. A) Sequence identity
matrix showing percentage identity of amino acid sequence between nine species. B) Hydrophobicity plots
for human (pro)renin receptor and C.elegans M8-9 generated by TMHMM program. "+" denotes
transmembrane regions and "§" denotes highly conserved intracellular/vacuolar domains. C) CLUSTAL
alignment of amino acid sequence for human (pro)renin receptor and C.elegans M8-9. = identity, =
conserved substitution, = semi-conserved substitution. Figure compiled with the help of Dr D. Dunbar.
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It is worth noting that the regions showing greater homology between the human sequence
and C.elegans encompass the transmembrane region of the protein and the predicted
intracellular/intravacuolar portion of the molecule as shown on the hydrophobic prediction
plot (Figure 3.7C). Analysis of the database showed that the genomic structure described
above (Figure 3.1) is the only sequence that encodes a functional gene and therefore this
gene must encode both the (pro)renin receptor and the truncation products (M8-9) which are
associated with the V-ATPase.
3.2.4 Reverse Transcriptase Polymerase Chain Reaction
3.2.4.1 Optimisation ofRT-PCR reaction
Optimisation of the RT-PCR reactions with primer pairs encompassing the coding region
and the complete cDNA of the mouse putative (pro)renin receptor were performed on kidney
and AS4.1 cell RNA. Figure 3-8A&B shows the effects of an annealing temperature gradient
(59-64°C) and of magnesium chloride concentration on the efficiency of the RT-PCR on
kidney RNA with primers designed to amplify the coding region of the cDNA (JJM 515-
516). Figure 3-8C shows the effects of the same temperature gradient with primers designed
to amplify the whole cDNA (JJM 515-517).
Both PCR reactions were found to be efficient along the temperature gradient (only up to
62°C for JJM 515-517 primers). An annealing temperature of 60°C for JJM 515-516 primers
and 61°C for JJM 515-517 primers was used thereafter. The product band was sharper at a
concentration of 1,5mM MgCl2 than at a concentration of 2.5mM and this condition was
adopted as standard for further RT-PCR reactions of the mouse putative (pro)renin receptor.
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Figure 3.8: Optimisation of reverse transcriptase (RT) PCR primers for mouse putative
(pro)renin receptor. Electrophoresis on agarose gels.
A) Coding region primers, Temperature gradient (59-64°C) and magnesium chloride concentration
1.5mM. Lanes 2, 4, 6, 8, 10, 12, 14: mouse putative (pro)renin receptor PCR product of 1.2kB. The
PCR reaction is efficient at all temperatures tested. An additional band was observed in lane 2
representing an unspecific product due to low annealing temperature. Lanes 3, 5, 7, 9, 11, 13, 15:
negative PCR reaction with RT reaction lacking the reverse transcriptase enzyme. Lanes 1 and 16:
DNA ladder of 500bp increments.
B) Coding region primers, Temperature gradient (59-64°C) and magnesium chloride concentration
2.5mM. Lanes 1-8: mouse putative (pro)renin receptor PCR product of 1.2kB. The PCR reaction
resulted in a product of correct size at all temperatures tested. The reaction appears less efficient at
both ends of the temperature range. Lanes 9-10: negative PCR reaction with RT reaction lacking the
reverse transcriptase enzyme. Lane 11: DNA ladder of 500bp increments.
C) Whole cDNA primers, Temperature gradient (59-64°C) and magnesium chloride concentration
2.5mM. Lanes 1-4: negative PCR reaction with RT reaction lacking the reverse transcriptase enzyme.
Lanes 5-11: mouse putative (pro)renin receptor PCR product of 2kB, the PCR reaction resulted in a
product of correct size only at lowest temperature of tested range.
For all three gels the small "fuzzy" band at the bottom of the gel represents unincorporated
oligonucleotides.
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3.2.4.2 TA cloning ofthe mouse putative (pro)renin receptor PCR products
The same reactions were performed with RNA extracted from AS4.1 cells and from kidney
tissue. Products from AS4.1 RNA were named AS516 if amplified with JJM 515-516 and
AS517 if amplified with JJM 515-517. Products from kidney RNA were named K516 if
amplified with JJM 515-516 and K517 if amplified with JJM 515-517. The products were
cloned into pGEM-T easy vectors as described in Chapter 2.8 on the day of purification
(after electrophoresis and size check) so as not to risk loss of the 3' poly-A tail addition by
Taq polymerase. The cloning procedure used does not allow for directional cloning. The
resulting plasmids were named pGRenRec (and the name of PCR product), sequenced using
universal primers recognising T7 and SP6 promoter sequences to confirm identity, checked
for orientation and used in further experiments including Northern blotting and in situ
hybridisation.
3.2.5 Adult and foetal tissue expression and cell line screening
RT-PCR was performed using optimised conditions reported above. Murine RNA was
processed to examine the expression of the putative mouse putative (pro)renin receptor
transcripts in a variety of tissues and embryonic/postnatal stages (Figure 3.10). Primers
encompassing only the coding region were used for RT-PCR and the PCR product was
found in two strains of mice: C57-B16 which possess one-renin gene (data not shown) and
FVB/N which harbour two-renin genes (Figure 3.9A). Putative (pro)renin receptor
expression was detected in all tissues examined, namely, brain, heart, kidney, liver, lung,
submandibular gland, adrenal gland, muscle, mesenteric fat, ovary, suggesting the molecule
may be expressed ubiquitously (Figure 3.9A). The PCR reaction was highly efficient and
specific as no additional bands were obtained in the positive reactions and no bands were
produced in the negative reactions in which PCR was performed on reverse transcriptase
mixes in which no reverse transcriptase was added. Using the same RT-PCR protocol as for
adult tissues, (pro)renin receptor was detected in kidneys ofmouse pups of post-natal day 1
stage (Figure 3.9B). Similarly, embryonic expression of the putative (pro)renin receptor was
examined in mouse embryonic kidneys (Figure 3.9C). RT-PCR analysis was performed on
RNA extracted from embryos from E9.5dpc to E18.5dpc. Putative (pro)renin receptor
expression was detected at all stages examined (Figure 3.9C) suggesting that this receptor








Figure 3.9: Agarose gel electrophoresis of mouse putative (pro)renin receptor reverse
transcriptase PCR. A) Female mouse tissue of FVB/N strain. (Pro)renin receptor product (1.2kB) is
present in all tissues. Lane 1: brain, Lane 2: heart, Lane 3: kidney, Lane 4: liver, Lane 5: lung, Lane 6:
submandibular gland, Lane 7: adrenal gland, Lane 8: muscle, Lane 9: mesenteric fat, Lane 10: ovary;
Lanes a-j = corresponding negative PCR with RT reaction lacking the reverse transcriptase enzyme.
B) Post-natal day 1 (PI) kidney from mouse of FVB/N strain. (Pro)renin receptor product of 1.2kB
size is present only in positive reactions. Lanes 1-2: PI kidney, Lanes 3-4: negative PCR with RT
reaction lacking the reverse transcriptase enzyme. C) Developmental profile of (pro)renin receptor
expression of embryonic kidneys from mouse of FVB/N strain. (Pro)renin receptor product of 1.2kB
size (arrowhead) is present at all stages examined but only in positive reactions. Lanes 1: E9.5, Lane
2: El 1.5, Lane 3: E12.5, Lane 7: E14.5, Lanes 9-10: E16.5, Lanes 12-13: E18.5; Lanes 4-6, 8, 11, 14-
15: negative PCR with RT reaction lacking the reverse transcriptase enzyme. For all gels, the second
band at the bottom of the gels is unincorporated oligonucleotides. The DNA marker is a lkB ladder.
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Additional analysis showed that the mouse putative (pro)renin receptor was expressed in two
murine cell lines: AS4.1 (from mouse kidney) and E14TG2a (an embryonic stem cell line)
and that the human (pro)renin receptor was expressed in HMC by RT-PCR and Northern
blot analysis (Figure 3.10). The results with the HMC are in disagreement with previous
published data (Nguyen et al. 2002) which reported that HMC did not express the human
(pro)renin receptor.












Figure 3.10: Cell line expression of the putative (pro)renin receptor. A) Schematic representation
of the mouse (pro)renin receptor cDNA as cloned from kidney preparations highlighting the Northern
blot probe (fragment Xbal-RsaT). B) Autoradiography of a Northern blot with Xbal-Rsal fragment of
the (pro)renin receptor as a probe. The highlighted bands (boxed area) represent the putative
(pro)renin receptor (approx. 2kB). Lane 1: AS4.1 cells ; Lane 2: ES cells; Lane 3: human mesangial
cell line. The ribosomal bands are indicated by the arrows, 28S and 18S accordingly and used as size
markers. C) (Pro)renin receptor RT-PCR on human mesangial cell line RNA: with primers designed
on the human renin receptor (N14F) sequence, Lanes 1, 3 and 5: positive RT reactions; lanes 2, 4 and
6: negative RT-PCR reactions. (I), expected band size 65bp, DNA ladder = lOObp; with primers
designed for housekeeping gene GAPDH (II), expected band size 480bp, DNA ladder = lkB; with
primers designed on the human (pro)renin receptor sequence (III), expected band size 1200bp, with
primers designed on the putative mouse (pro)renin receptor sequence; DNA ladder = 500bp.
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Figure 3.11. In situ 35S hybridisation of mouse (C57/B16) tissues with (pro)renin receptor probes.
Dark and light field photographs of frozen tissue sections (4pm).
Photographs no 1 = Dark field photographs of sections hybridised with anti-sense probe, Photographs no 2
= Corresponding haematoxylin and eosin (H&E) staining photograph of sections hybridised with anti-
sense probe, Photographs no 3 = Dark field photographs of sections hybridised with sense probe
(background control), Photographs no 4 = Corresponding (H&E) staining photograph of sections
hybridised with sense probe. A) Longitudinal sections of kidney, arrows indicate the cortex-medulla
delimitation; note the staining solely in the cortical region. This pattern was specific to anti-sense probe
hybridisation. B) Sections of skeletal muscle note the overall increased staining with the anti-sense probe
(B-l) compared with sense probe (B-3). C) Sections of liver; note the overall increased staining with the
anti-sense probe (C-l) compared with sense probe (C-3).
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In situ hybridisation (ISH) showed that the mouse putative (pro)renin receptor is not expressed
uniformly within the kidney. Higher levels of expression were found in the cortex (Figure 3.12)
which suggests that the putative (pro)renin receptor is expressed in the vasculature rather than in
tubular structures. Although, no expression could be detected in the renal medulla, it is possible that
mRNA levels are low and undetectable by ISH. Gross examination of liver and skeletal muscle
sections revealed no particular pattern and the hybridisation appears to be widespread throughout
these two tissues. Hybridisation of the (pro)renin receptor riboprobe to heart and placenta did not
reveal any signal above background. This may be due to low mRNA amounts which could not be
detected by in situ hybridisation. Hence, prorenin/renin uptake may not be mediated through the
(pro)renin receptor in the heart under normal physiological conditions but may be up-regulated
during stimulated conditions.
Additional ISH assays were performed at the College de France in Paris on paraffin embedded
embryonic kidney, heart and lung sections provided by myself. The results were provided and
interpreted by Dr Gasc and Dr NGuyen. These revealed that the staining was strongest in the kidney
at E15.5 compared to later embryonic stages of E16.5 and E18.5. This indicates that the mouse
putative (pro)renin receptor may not play a role in late nephrogenesis. The riboprobe labelling
showed a similar pattern to the adult in post-natal (PI) kidneys with an intense signal in the external
and internal cortices, (stronger in the external cortex). In the heart, labelling was only evident at
E16.5, other embryonic stages, namely El5.5 and El 8.5 showed very faint staining. At these stages,
the heart and the kidney are structurally fully developed suggesting that the mouse putative
(pro)renin receptor may play another role than establishing cardiac and renal organogenesis. It may
indeed function to mediate prorenin actions independent or dependent on downstream Angll
production such as homeostatic balance. In accordance with the results obtained with adult cardiac
tissues, very weak labelling was detected in the heart of post-natal mouse pups. The (pro)renin
receptor may again be expressed at low levels, not detectable by in situ hybridisation. Indeed, in the
adult, mouse putative (pro)renin receptor can be detected by RT-PCR, a more sensitive technique.
3.3 Discussion and conclusions
3J.1 Cloning of the mouse putative (pro)renin receptor
This chapter describes the existence of a putative homologue of the human (pro)renin receptor in
the mouse. Three complete putative (pro)renin receptor cDNA clones were identified by BLAST
search using a human cDNA sequence recently reported to be the (pro)renin receptor as template
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[GenBank number: AF291814 (Nguyen et al. 2002)]. The cDNA sequences of these three
mouse putative (pro)renin receptor clones are highly similar, two of the clones being from
the C57/B16 strain and one being from the FVB/N strain. Alignment with the human
(pro)renin receptor sequence indicated an average of 83% identity at the nucleotide level. At
the protein level, only 21 out of the 351 amino acids of the predicted sequence differed
between the mouse and the human proteins and of those 21 amino acids, 10 were predicted
to be conservative substitutions which may imply functional homology. Phylogenic studies
revealed that the (pro)renin receptor is highly conserved between species, including D.rerio
(67% identity with mouse sequence) and C.elegans (21% identity with mouse sequence). Rat
(pro)renin receptor nucleotide sequence displayed 91% and 96% identity with the human and
mouse sequence respectively. This mouse putative (pro)renin receptor was then cloned,
sequenced and used for further study. The cDNAs obtained from kidney and AS4.1 cells (a
mouse kidney tumour cell line) were identical to the nucleotide sequences of the cDNA
identified by BLAST and were homologous to the human cDNA identified by Nguyen et
a/(Nguyen et al. 2002). A BAC clone (12J18) was identified containing the putative
(pro)renin receptor gene ofmouse strain C57/B16. The gene was localised to chromosome X,
locus Al .2 and predicted to possess 8 introns and 9 exons. However, additional exons may
be present since expressed sequence tags were obtained during the BLAST search
aforementioned that differed significantly at the 3' end.
3.3.2 Homology of the putative (pro)renin receptor to a membrane sector
associated subunit
Surprisingly, however, the translated human cDNA (GenBank accession no AF291814) as
well as the translated mouse cDNAs (BC014706, AK017482 and AK029405) exhibited
sequence identity with a small protein that co-purifies with a bovine vacuolar ATPase (V-
ATPase) called M8-9 (Ludwig et al. 1998). M8-9 is a membrane sector associated portion of
V-ATPase. Human M8-9 has been mapped to the same chromosomal region as the human
(pro)renin receptor (locus: Xpll.4) which also contains the critical region of a rare
progressive visual disease called X-linked cone-rod dystrophy (COD1) (Demirci et al. 2001).
The authors reported that the M8-9 gene is not responsible for the disease. This gene may,
however, undergo alternative splicing and/or have multiple sites of transcription start. It is
worth noticing that the amino acid sequence identified as the human M8-9 is 316 amino acid
in length compared with the bovine form which is 30 amino acid in length. This may be the
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result of post-transcriptional processing, possible alternative splicing, post-translational
modifications or proteolytic cleavage occurring within the cell or when M8-9 was purified. It
is not known whether the human M8-9 cDNA is the same length as the human (pro)renin
receptor or if it is indicative of a cDNA with an alternative transcription start. It may suggest
that M8-9 and the (pro)renin receptor are the same gene or that two proteins are produced
from the same gene. V-ATPases contain 6-10 subunits divided into two domains: a
transmembrane proton-conducting sector and an extramembrane catalytic sector responsible
for ATP hydrolysis (Harvey and Wieczorek 1997; Stevens and Forgac 1997). Moreover,
individual V-ATPase subunit null mutants are lethal and yeast models have to be used.
In mammalian cells, V-ATPases play important roles in energy conservation and secondary
active transport, acidification of intracellular compartments and cellular pH homeostasis
(Nelson 2003; Nelson and Harvey 1999). The gene encoding the (pro)renin receptor was
conserved between species including organisms from lower orders such as C.elegans.
Phylogenic conservation indicates that it is physiologically important and a second protein
arising from the same gene would explain the homology with the vacuolar ATPase subunit,
M8-9. Indeed, the human (pro)renin receptor described by Nguyen et al and the vacuolar
ATPase subunit M8-9 must the product of the same gene since only one gene was found
identified in ENSEMBL database. Additional investigations designed to elucidate whether
these proteins are functionally related remains to be undertaken.
3.3.3 Developmental and tissue expression profile
The RT-PCR results reported in this chapter demonstrate the robustness of the PCR reaction
developed to amplify the mouse putative (pro)renin receptor and optimised in Chapter 3.
The PCR reaction was performed successfully on a variety of tissues and it was
demonstrated that the mouse putative (pro)renin receptor is expressed in all tissues
examined. No negative tissues or cell lines have been identified to date. This could be
explained if the mouse putative (pro)renin receptor was expressed in the microvasculature
since the blood vessels were not microdissected out. In the present work, the mouse putative
(pro)renin receptor was also expressed throughout development from E9.5. This raises the
question of the role of a mouse (pro)renin receptor in embryonic stages independently of
renin/prorenin. As mentioned in Chapter 1, components of the RAS are present in foetal
tissues and Angll is known to be involved in cell growth/differentiation (Unger et al. 1996).
It is therefore possible that uptake of renin or prorenin occurs in these tissues to initiate the
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RAS cascade and the production of Angll. Whether, renin or prorenin themselves have a
direct role in development is, however, not known.
The function of the putative (pro)renin receptor in kidney and heart development remains
unclear but expression of this gene is evident throughout embryogenesis in these tissues with
highest expression detected at El5.5 and El6.5, respectively. The mouse putative (pro)renin
receptor is expressed in early embryogenesis, i.e. before the need for and the establishment
of a functional RAS. It suggests that it may have a role independently of renin/prorenin and
ofAngll generation and may have functions relating to its homology with a V-ATPase sub-
unit. It is worth noting that ES cells (which are not smooth muscle cells) express the mouse
putative (pro)renin receptor which are not smooth muscle cells and that one of the cDNA
identified was from an E8.5dpc embryo library (when blood vessels are at a blood island
stage. Taken together, this suggests that the protein identified as a (pro)renin receptor may
have "housekeeping" functions and have a more basic biological role than thought.
The results above demonstrate messenger RNA (mRNA) expression and it cannot be
excluded that protein expression pattern may differ from that of mRNA due to post-
transcriptional modification. In an attempt to rectify this, a mouse (pro)renin receptor
antibody was made from two mouse peptides homologous to those used by Nguyen et al. in
their publication on the human (pro)renin receptor. Chicken was the species chosen for
immunisation with these peptides (performed by a commercial manufacturer). The rationale
behind this was that an anti-mouse renin antibody raised in rabbit was available in the
laboratory. This would allow for double labelling without species cross-reactivity between
the two antibodies. The aim was to use the antibody in binding and immuno-precipitation
studies to confirm the results ofNguyen et al. using mouse cell/tissues. The titer of the anti-
sera collected after the different immunisations was very low and no difference were
observed between pre-immune serum and post-immunisation sera when tested on AS4.1 cell
lysate on a dot blot. This is possibly due to the high homology of the mouse peptides with
the chicken corresponding protein resulting in low/no production of anti-bodies against the
injected peptides.
3.3.4 Comparison of putative (pro)renin receptor expression between two
mouse strains
The use of two different strains ofmice, one-carrying one renin gene (C57/B16) and the other
carrying two renin genes (FVB/N) highlighted the fact that there is no differences in
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expression of the mouse putative (pro)renin receptor in the tissues examined. It is not
possible, however, from the data shown to say whether levels of expression are similar in
both strains. Quantitative investigations may help identify those tissues that express the
receptor abundantly, e.g. tissues which do not express renin but show renin activity (such as
the heart) require uptake of renin or prorenin
3.3.5 On the relationship between M8-9 and the (pro)renin receptor
A mouse putative (pro)renin receptor could therefore be a very important tool to understand
(pro)renin uptake in the heart/vascular tissues and the direct roles of (pro)renin
independently of angiotensin II formation. However, it is easy to be confused when trying to
disentangle the available information relating to M8-9 and the (pro)renin receptor. It is
important to remember that the name 'M8-9' refers to a group of short peptides of
overlapping sequence, believed to be the truncation products of a larger, as yet unpurified,
protein. In 2001, the encoded cDNA sequence and genomic structure of a gene encoding the
M8-9 peptides was reported [24]. Although there is no biochemical evidence to prove that
the M8-9 peptides are derived from the protein encoded by this cDNA, the fact that there are
no other such sequences in the genome suggests that this must indeed be the precursor. It is
not known whether the encoded protein is itself associated with the V-ATPase, or how its
truncation products, which do associate with the V-ATPase, are formed. What seems clear is
that this gene, termed the 'M8-9' gene, encodes sequences that co-purify with the V-ATPase.
Independently, in 2002, the sequence of the human (pro)renin receptor was reported
(Nguyen et al. 2002). The authors commented on the homology between the peptide
sequence encoded by the (pro)renin receptor cDNA and the M8-9 peptides. However, on
further comparison it is clear that the (pro)renin receptor cDNA sequence must the product
of the gene referred to in the database as the 'M8-9' gene. Perhaps until we understand more
fully the relationship between the (pro)renin receptor and the V-ATPase-associated peptides
this gene should be referred to as the 'M8-9/(pro)renin receptor gene. There is clearly much
work to do in elucidating the role(s) of the product(s) of this gene and clarification of the
function(s) of the encoded protein(s) has important implications for cell function (via the V-
ATPase function) and the cardiovascular system (via its role as a renin receptor).
The (pro)renin receptor was recently described as a trigger for pro-fibrotic genes and
hypertrophic response of mesangial cells exposed to stimulus (Huang et al. 2006). The
authors used the technique of siRNA inhibition against the (pro)renin receptor. This may
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result in inhibition of the M8-9 portion of the (pro)renin receptor and the results may
therefore not be representative of the receptor involvement in the phenotype. It is worth
noting, however, that the stimulus used was renin rather than prorenin. One may question the
validity of this study since 1) renin does not have a prosegment which is recognised as the
binding region, 2) the authors did not exclude that mesangial cells may produce AOGEN and
ACE and hence the effects seen reflects a RAS stimulation, 3) M8-9 may be involved.
Similarly, the work of Nguyen et al. describes binding to the described human (pro)renin
receptor to both renin and prorenin. No common sequence between the two proteins was
identified as a binding region to the receptor and it is important to consider how in the
absence of "pro" sequence renin may interact with the putative (pro)renin receptor. More
studies are required to shed the light on the biology on the putative (pro)renin receptor and to
remove any controversy concerning its importance in several pathophysiological events. The
results described in this chapter (and the subsequent chapter) cast doubts over the role of this
molecule as "the" (pro)renin receptor. It cannot be excluded that other molecules may act as
"(pro)renin receptor" and this discussed in more detail in Chapter 4.
In addition, since the role of this gene may prove to be critical for cell survival and
considering that my data differs results from Nguyen et al. (2002) it was felt more
reasonable not to attempt to produce mice lacking this gene through the use of gene
targeting. For the present thesis, it was, therefore, decided to investigate whether this
molecule has indeed any pathophysiological role in a transgenic model of high circulating
prorenin which is characterised by malignant hypertension (Kantachuvesiri et al. 2001) (See
Chapter 4 and 5). Two studies looking at inhibition of the (pro)renin receptor by a prorenin
decoy peptide (Ichihara et al. 2004) and at overexpression of the (pro)renin receptor
(Burckle et al. 2006) have demonstrated a physiological role for the (pro)renin receptor/M8-
9 and for non-proteolytic activation ofprorenin.
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Chapter 4
Vascular Injury in an Inducible Rat Model of
Hypertension Characterised by High
Prorenin
4.1 Introduction
Transgenic models have become widely used in the field of cardiovascular science and three
different transgenic models characterised by high prorenin have been produced to study the
involvement of circulating and local renin-angiotensin system (RAS) genes and pathways in
the pathophysiology of hypertension. TGR(mRen2)27 animals were the first transgenic rats
used for cardiovascular and hypertension research. These animals carry the mouse Ren2 gene
(Mullins et al. 1990) and they display fulminant hypertension from 5 weeks of age
(230mmHg). The animals suffer from malignant hypertension (MH) injuries leading to heart
failure unless treated with ACE inhibitors (Mullins et al. 1990). The TGR(mRen2)27 animals
displayed suppressed concentrations of active plasma and renal renin, low or unchanged
levels of plasma Angll but increased levels of circulating prorenin compared to controls (Lee
et al. 1995). A second rat model carrying a "Ren2 transgene" was generated to study the
effects of high levels of circulating rat prorenin by directing the expression of the transgene
exclusively to the liver (Veniant et al. 1996). Endogenous renin expression in the kidney was
similar to wild type, unlike in the previous model in which renal renin was decreased, but the
animals displayed characteristic MH lesions in the heart and in the kidney suggesting a direct
effect of circulating prorenin in the pathophysiology of hypertension. A third and inducible
rat model of hypertension was recently developed in this laboratory. It carries an mRen2
transgene which is under the control of cytochrome P450 Cyplal promoter (Kantachuvesiri
et al. 2001). Expression of the prorenin transgene is restricted to the liver and small intestine
where no malignant hypertension lesions occur. The promoter is induced when the animals
are fed a diet containing the natural xenobiotic indole-3-carbinol (I3C). Upon chronic
induction, TGR(Cyplal-Ren2) animals displayed a rapid increase in blood pressure
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accompanied by weight loss and polyuria, as a result of salt and water depletion. The animals
exhibited hypertensive injuries in several vascular beds and organs. Microinfarctions,
inflammatory cell infiltration and fibrinoid necrosis were observed in the heart. The latter
was also present in the mesentery. In the kidney, distal tubule hyperplasia was consistent
with polyuria, intrarenal arteries displayed a thickening of the media layer but the glomeruli
were unaffected. There was a distinct difference in the response to injury, the heart and the
mesentery exhibiting greater sensitivity whereas the kidneys appeared to be affected to a
lesser extent. Involvement of a locally activated renin-angiotensin-system, in particular
prorenin and/or inflammation may play an important role in the mechanisms underlying
vascular and end-organ injury due to hypertension (Collidge et al. 2004). The aims of this
chapter were to characterise the pathological and haemodynamic changes to the heart and to
the vasculature in this rat model using echography techniques and correlating these findings
with histological studies. Presence and expression of the putative (pro)renin receptor in rat
tissues was studied using PCR. Potential regulation of the (pro)renin receptor in the




4.2.1.1 Bloodpressure and heart rate
Systolic blood pressure and heart rate were measured using a photoelectric sensor for pulse
detection in rat tail. Following tail cuff inflation to a pressure superior to the systolic blood
pressure, the pulse waveform becomes indistinguishable from baseline. Observation of the
return of the pulse signal during progressive (automated) deflation of the tail-cuff blood
pressure could be done visually from the trace as exemplified below in Figure 4.1. The tail
cuff pressure at which the pulse wave form returns after maximal inflation identifies systolic
blood pressure.
Transgene induction resulted in a distinct but gradual increase in blood pressure (Figure 4.2)
in treated TGR(Cyplal-Ren2) animals from 24h after treatment started. Statistical analysis
showed that blood pressure from treated animals was significantly increased compared to
controls throughout the experimental period starting at day 1. This difference in blood
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Figure 4.1: Examples of tail cuff plethysmography recordings. A) From hypertensive animals,
systolic blood pressure measurements were: 150mmHg (I), 165mmHg (II) and 170mmHg (III). Tail-
cuff pressure scale in shown on the right of the tracing while an example of a pressure point at which
the pulse waveform return is highlighted in boxed area. B) From normotensive animal, systolic blood
pressure measurements were: 115mmHg (I), 1 lOmmHg (II) and 115mmHg (III).




Two days before transgene induction and at day 0, the blood pressure was slightly elevated in
both groups compared to day 1 in the control group (data not shown) which may reflect a stress
effect of the methodology. This did not, however, reach significance and blood pressure
remained in the normal range for the control group throughout the experimental period.
I Day
Figure 4.2: Systolic blood pressure (mraHg) in conscious TGR(Cyplal-Ren2) rats. The arrow
indicates the start of the 0.3% indole-3-carbinol-containing diet for the treated group. Standard two-way
ANOVA with post test showed that systolic blood pressure is significantly elevated compared to control
from 24h after starting the induction.
J Day
Figure 4.3: Heart rate (beat per minute) in conscious TGR(Cyplal-Ren2) rats. Standard two-way
ANOVA confirmed the heart rate was unaffected by treatment N=10; n.s = non-significant. The arrow
indicates the start of the 0.3% indole-3-carbinol-containing diet for the treated group.
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The heart rate, however, remained unchanged in the treated animals compared to controls
throughout the treatment period (Figure 4.3).
4.2.1.2 Body weight, food consumption, fluid intake
Increased blood pressure was accompanied by gradual weight loss from day 1 of the experiment
in the treated animals which only became evident from controls from day 14 (Figure 4.4). As a
result, repeated measure two-way ANOVA revealed that the difference in body weight between
the two groups was almost significant (p= 0.052) over the entire experimental period.
The total average weight loss for the treated group at the end of the experiment was 12.1 g.
However, considering that the animals were young and that the control animals gained
approximately 44g over the experimental period, the weight loss can be regarded as fairly
severe.
J Day
Figure 4.4: Body weight (g) in TGR(Cyplal-Ren2) rats. The arrow indicates the start of the 0.3%
indole-3-carbinol-containing diet for the treated group. Note the weight gain in the control group due to
growth while the effect was absent in the treated group due to body mass loss.
Over the entire experimental period, increased food consumption was observed in the treated
animals compared to the control group (Figure 4.5). Repeated measure two-way ANOVA also
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identified a significant effect over time suggesting that the treated animals are increasingly
consuming more food than the control animals. Polyuria and polydypsia (Figure 4.6) were also
noted but due to technical and ethical protocol restrictions, fluid intake and urine production
measurements were only taken from two animals at a unique time point during week 4 of
treatment. There was no indication of diabetes as demonstrated by the absence of glucose in the
urine of treated animals (Table 4.1). The reasons for the presence of ketones, the increased
detection of proteins (in two animals) and nitrite (in one animal only) in the urine of the control
animals are unknown. It is possible that the increased fluid loss through urine output diluted this
parameters in the treated animals and therefore does not represent an accurate reading. It is
worth noting that the dipstick method is a rapid but crude method. Flowever, leucocytes were
detected in the urine of treated TGR(Cyp 1a 1 -Ren2) animals suggesting renal inflammation
potentially linked to hypertensive injury.
J Day
Figure 4.5: Food consumption (g/day) per TGR(Cyplal-Ren2) rats. N=10; Repeated measure two-way
ANOVA analysis showed an increased food consumption of the animals in the treated group throughout
the experimental period. The arrow indicates the start of the 0.3% indole-3-carbinol-containing diet for the
treated group.
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A similar procedure was repeated using urine samples collected from a previous experiment with
TGR(Cyplal-Ren2) animals at the University of Maastricht (data not shown). When blinded to
the treatment, it was possible to identify those animals which received control diet, those animals
that received the inducer, and those in which the transgene had been induced for several weeks
and subsequently allowed to recover, simply on the basis on the leucocyte detection system on
the dipstick.
Figure 4.6: Urine output and fluid consumption (ml) in 2 TGR(Cyplal-Ren2) rats. Measurement
were performed over 12h during week 4 of the study. Only two treated (Red bars) and two control (Black
bars) animals were used and for clarity, results are presented per animal.
Treated 1 Treated 2 Control 1 Control 2
Glucose (mmol/L) ND ND ND ND
Ketones (mmol/L) ND ND ++ ++
Blood ND ND ND ND
Protein (mg/dL) ++ ++ +++ +++
Nitrite ND ND ND +
Leucocytes + + ND ND
Table 4.1: Urine dipstick results. Readings were obtained visually against standard colorimetric
measurement provided by the manufacturer (Bayer, Germany). ND : Not detected. + : indicates low
amounts ++ : indicates moderate amounts and +++ : indicates high amounts. Leucocyte detection was
based on esterase activity and given arbitrary units.
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4.2.2 Echocardiography and aorta wall track
Echocardiography data shows an increase in left ventricular area suggesting development of
ventricular hypertrophy in treated TGR(Cyplal-Ren2) animals (data not shown). This was
confirmed by an increase in left ventricle weight (Figure 4.9).
time
Figure 4.7: Echocardiographic measurements of TGR(Cyplal-Ren2) rats. Results were calculated
from parasternal long axis B-mode echocardiograms A) Cardiac output (in cm3/min) B) Stroke volume (in
cm3). Red bars represent the treated animals and solid black bars represent the control animals. Standard
two-way ANOVA analysis with Bonferroni post-test showed a decrease in cardiac function from 2 weeks
after start of induction. N=10, *: p>0.05, **: p>0.01, ***: p>0.001.
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Cardiac output and stroke volume (Figure 4.7A&B) were markedly reduced compared to
control, which may be indicative of heart failure. This event was only significant from two
weeks after the start of the treatment with indole-3-carbinol. Since blood pressure is a
function of cardiac output and peripheral resistance, a decrease in cardiac output would
represent an adaptative response from the heart.
Aorta wall track echography demonstrated a stiffening (calculated as compliance and
distensibility - Figure 4.8) of the abdominal aorta. This effect is likely to be a result of blood
pressure increase and vascular remodeling.
MAP Compliance Distensibility Aorta Diameter Pulse wave PP
(mmHg) a (mmZ/kPa) (Pa-1) (mm) velocity (m/s) (mmHg)
Mean Treated 99.512 2.424 0.106 34.582 1.989 5.473 43.093
S.d Treated 13.306 0.473 0.022 6.990 0.156 0.665 11.552
Mean Control 83.007 1.524 0.142 60.126 1.746 4.183 35.711
S.d Control 8.547 0.334 0.027 7.767 0.128 0.301 3.494
p value ** *** ** *** ** ***
*
Figure 4.8: Aorta wall track echography in anaesthetized TGR(Cyplal-Ren2) animals. Direct
(MAP, PP and diameter) and calculated measurements (a, compliance, distensibility, PWV). a is a
pressure independent measurement of aorta wall compliance. N=10, *: p>0.05, **: p>0.01, ***:
pXXOOl.
The lumen diameter (Figure 4.9) of mesenteric arteries of TGR(Cyplal-Ren2) animals was
significantly smaller (inward remodeling) as compared to controls. Response to intraluminal
pressure was significantly reduced in the vessels isolated from the treated animals even at
low pressure (20mmHg). Whether this inward remodeling is hyper/hypo-eutrophic depends
on the cross-sectional area of the tunica media.
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Figure 4.9: Pressure (mmHg)/diameter (mm) curve of first order mesentery arteries. Arteries from
treated and control TGR(Cyplal-Ren2 rats) were mounted on an arteriograph in relaxed state in a
physiological buffer with nitroprusside after week 5 of the study. N = 10 for treated animals. N = 9 for
control animals *: p>0.05, **: p>0.01, ***: p>0.001.
4.2.3 Organ weights and Histopathology
Histology processing was carried out at the Core Pathology unit. Histopathological analysis and
photographs were supplied by Dr David Brownstein.
In accordance with the echocardiography and echography data, the left ventricle (expressed as
weight/tibial length) was consistently larger in the treated animals than in the control (Figure
4.10). The weight of kidneys from treated animals was higher than in control animals which may
be caused by several factors such, hyperplasia enlargement of capillaries and tubules or as
increase fibrotic tissue formation. The latter was observed after macroscopic examination of
sections stained for collagen and also in after microscopic analysis which revealed fibrinoid
necrosis. The adrenal gland of induced animals only displayed a slight increase in weight
compared to control (data not shown) which may indicate hyperplasia. No histological changes
were, however, detected in this tissue.
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Figure 4.10: Organ weights normalised to tibial length of TGR(Cyplal-Ren2) rats. LK = Left
Kidney, RK = Right Kidney, TL = Tibial Length, LV = Left Ventricle, RV = Right Ventricle. Treated
animals (dotted bar); control animals (striped bar). N=10, n.s = not significant, *: p>0.05, **: p>0.01, ***:
p>0.001.
4.2.3.1 Heart
Left ventricular hypertrophy was also evident under histopathological investigation (Figure
4.11). Cardiac hypertrophy was observed which correlated with the echocardiography data. No












Figure 4.11: H&E stained sections of paraffin embedded hearts. A) Treated TGR(Cyplal-Ren2) rat
left ventricle wall. B) Control TGR(Cyplal-Ren2) rat left ventricle wall. Bars: imm. Dashed lines
indicate the thickness of the ventricular wall. Sections: 4pm.
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Figure 4.12: H&E stained sections of paraffin embedded hearts of TGR(CyplaI-Ren2) rats. Left
ventricle: A-B) Treated heart, C) Control heart. Septal branch of the left coronary artery (arrow). Bar:
1mm. Arterial lumen area size: D) Control and E) Treated left coronary artery, Area measured = lumen




Kidneys were undergoing hypertrophy as demonstrated by the increased weight to tibial length
ratio in treated animals. This is not obvious histopathologically. The kidney however displayed
glomerular sclerotic areas which may be consistent with the increase weight (Figure 4.13).
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Figure 4.13: H&E stained section of paraffin embedded kidneys of TGR(Cyplal-Ren2) rats.
Glomeruli of treated animals. A) Severe phenotype due to loss of podocyte attachment (p) to the
Bowman's capsule. A-E) Note the segmental appearance of the injuries (indicated by the dashed line) B)
No loss of podocyte attachment, presence of inflammatory infiltrating cells. C-E) Mild loss of podocyte
attachment, presence of inflammatory infiltrating cells. F) Normal glomerulus. Bar represents 25pm,
sections: 4pm, the arrow indicates the Bowman's capsule.
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In 50% of glomeruli in the treated group, fibrinoid necrosis affected the afferent arteriole
Segmental glomerulosclerosis was present {i.e. only parts of the glomerulus were affected)
characterised in some glomeruli by a loss of podocytes causing adhesion to the Bowman's
capsule (Figure 4.13). Increased collagen deposition was present over the whole kidney (Figure
4.14).
Figure 4.14: Sirius red staining for collagen staining of renal cortices. A) Control TGR(Cyplal-Ren2)
rat, B) Treated TGR(Cyplal-Ren2) rat. Note the increased collagen deposition (arrows), sections: 4pm.
Figure 4.15: H&E stained sections of paraffin embedded kidneys. Arcuate arteries. A) Control
TGR(Cyplal-Ren2) rat, B) Treated (Cyplal-Ren2) rat. Bar represents 100pm, sections: 4pm, arrow
indicates the infiltrating inflammatory cells.
Minimal changes were observed in the interlobar-arcuate arteries (size: 120-250pm - Figure
4.15) finding which again differs from previous reports. Profound changes become apparent in
the interlobular arteries, more markedly in the peripheral vessels (Figure 4.16 B&D).
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Figure 4.16: H&E stained sections of paraffin embedded kidneys TGR(CypIal-Ren2) rats. Intra-
renal vasculature. A) Control interlobular artery, vessel size approx 80pm. B) Treated interlobular artery,
vessel size approx 80pm. Note the thickening of the adventitia indicated by the arrow. C) Control
interlobular artery, vessel size approx 40pm, D) Treated interlobular artery, vessel size approx 40pm.
Note the "onion skin" appearance indicated by the asterisk, E) Control (Cyplal-Ren2') rat interlobular
artery, vessel size < 40pm, F-G) Treated TGR(Cyplal-Ren2) rat interlobular artery, vessel size < 40pm.
Note the marked "onion skinning" and loss of intimal space indicated by an asterisk. Sections: 4pm.
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The media was thickened; the lumen decreased in thickness and collagen deposition was
increased in adventitia. The cross-sectional area was increased due to smooth muscle cells
hypertrophy and the nuclei of the smooth muscle cells appeared to be more numerous in the
treated animals, which may be due to diploidy. In smaller vessels (60-40pm), intimal
proliferation (as demonstrated by the presence of proliferative endarteritis) was present
(Figure 4.16). The demarcation of the vascular layers was lost and the vessels had an "onion
skinning" appearance which is associated with malignant hypertension. In the smallest
vessels (<40pm), this was even more marked (Figure 4.16 F&G) with near complete loss of
luminal space.
4.2.3.3 Mesentery
Mesentery artery pressure-diameter data are in accordance with gross and microscopic
findings:
The morphology of the isolated first order mesenteric arteries may be different from ante-
mortem because the vessels were used for constructing a pressure-diameter curve and were
therefore pressure-inflated (up to 220mmHg). They displayed an apparent increased medial
area and a decreased vascular lumen (Figure 4.17). This was common to all calibres of
mesentery arteries. Despite the pressure diameter curve, the cross-sectional area would not
have changed with pressure. The vessels also had a thickened adventitial layer due to
increased collagen deposition. It was estimated than an increase of 25% in cross-sectional
area was present. This event is most likely due to hypertrophy and/or an increased
extracellular matrix production.
Histopathological stains for elastin, collagen and reticulin were performed and only collagen
staining was higher in treated animals than in controls notably in the media (data not shown).
Proliferative endarteritis was seen in mesentery arteries of size 40pm or lower (Figure 4.17
E&F). Inflammatory cell infiltration was not present in this vascular bed.
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Figure 4.17: H&E stained sections of paraffin embedded mesenteric vessels of TGR(Cyplat-Ren2)
rats. A) Control and B) treated first order artery, vessel size 250- 120pm, Area measured represents the
areterial wall surface areabar represents 50pm. C) Control and D) Treated second order artery, vessel size
120- 100pm, measured area = lumen area, bar represents 50pm. E-H) Control and I-L) treated third order
arteries, vessel size 100-40pm, bar represents 25pm. Note the thickening of the adventitia and the reduced
luminal area in all treated vessels. Sections: 4pm.
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4.2.4 (Pro)renin receptor expression in wild type rat tissues and regulation
during induction of transgene in TGR(Cyplal-Ren2) animals
Considering that, in TGR(Cyplal-Ren2) rats, prorenin is derived from the mouse gene Ren2
and therefore unglycosylated, the mannose-6-phosphate receptor is an unlikely candidate for
prorenin uptake. An alternative pathway may be through the (pro)renin receptor described by
Nguyen et al. The upregulation of the rat putative (pro)renin receptor was examined in
TGR{Cyplal-Ren2) tissues. For this reason, expression of the homologous (pro)renin
receptor in rats was first verified in a wide range of tissues.
4.2.4.1 RT-PCR on Fischer (F344) female adult tissues
Standard RT-PCR was used to study the expression pattern of the putative (pro)renin
receptor in Fischer (F344) adult rat and compare it to the pattern obtained in the mouse
0Chapter 3.2.4). As for the mouse, the (pro)renin receptor was detected in all tissues
examined showing that, in this species, the (pro)renin receptor is ubiquitously expressed
(Figure 4.18).
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Figure 4.18: Reverse Transcriptase PCR of putative rat (pro)renin receptor (RR) and GAPDH.
Agarose gel electrophoresis. Female adult tissue samples from two rats of Fischer (F344) strain.
Bands of the correct sizes (RR : 900bp; GAPDH : 480bp) were obtained in all tissues except muscle
for which only one repeat reaction was positive. The two PCR reactions were performed
independently but electrophoresis was done simultaneously. DNA marker (M) : lkB ladder. Lane 1-2
= Brain, Lanes 3-4 = Mesenteric Fat, Lanes 5-6 = Heart, lanes 7-8 = Kidney, Lanes 9-10= Liver,
Lanes 11-12 = Lung, Lanes 13-14 = Muscle, SMG = Submandibular Gland, Sp = Spleen.
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4.2.4.2 Regulation ofexpression of the (pro)renin receptor in TGR(Cyplal-Ren2) rats
A SYBR green real-time RT-PCR assay was designed to measure differences in (pro)renin
receptor expression in treated and control TGR(Cyplal-Ren2) animals. Optimisation of the
method was performed to obtain the optimal primer concentrations. Three concentrations of
primers, 300nM, 600nM and 900nM, were tested with a cDNA mastermix (made up of all RNAs
to be tested) at a concentration of lOOng/pl to obtain the lowest CT with the lowest primer
concentration pair. The results showed that a concentration of 300nM for the forward primer and










y = -2.8556x + 27.388
-1.0
y = -2.9014X + 27.157
y = -3.0879X + 14.538
y = -3.2071X + 14.034
Linear (18S 1)
Linear (18S 2)
Linear (SYBR RR 1)
Linear (SYBR RR 2)
-0.5 0.0 0.5 1.0
Log [C]
1.5 2.0 2.5





SYBR RR Plate 1
(Mean Ct)
SYBR RR Plate 2
(Mean Ct)
100 2.0 8.1 8.5 21.8 22.1
20 1.3 9.4 10.4 22.9 23.3
4 0.6 12.0 12.6 25.1 25.4
0.8 -0.1 14.2 14.9 27.6 27.7
0.16 -0.8 16.9 17.0 29.6 29.9
Figure 4.19: Standard curves for rat (pro)renin (SYBR green) and 18S (VIC) quantitative PCR
measurements. A) A standard curve was incorporated to each sample plate to avoid plate to plate
variation. The standard curve for each gene was reproducible and the efficiency of the each assay was high
(slope = 2.85 and 2.9 for SYBR green; 3.08 and 3.2 for VIC). B) Table of individual standard curve value
points.
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For future investigations, the highest value of the standard curve was selected to be 100ng/pl
as used for the optimisation step. Using the SYBR green optimised assay, a standard curve
was constructed with the cDNA mastermix described above at 100, 20, 4, 0.8, 0.16 and
Ong/pl (Figure 4.18). Three animals per group were used for each tissue analysed, namely
heart (left ventricle), kidney, adrenal gland. In order to normalise the data and to account for
pipetting errors, an endogenous gene assay (Taqman 18S-VIC) was also performed using the
same standard curve and the same samples. Each plate with samples contained its own
standard curve to account for plate to plate variation. Hence, due to the number of samples
used in the present experiment two plates for each assay were needed to accommodate PCR
reactions on left ventricle, adrenal gland and kidney samples from TGR(CyplaJ -Ren2)
animals. Standard curves for each assay, Taqman with 18S primers and SYBR green with rat
putative (pro)renin receptor primers were reproducible from plate to plate. The slopes of the
standard curves showed that the assay performed with 18S primers was more efficient than
with rat putative (pro)renin receptor primers, although the slope was close to optimum (3.03)
for each primer set (Figure 4.19). It was found that no differences between the treated and
the control groups could be observed in terms of prorenin receptor expression (Figure 4.20)
in all three tissues examined, namely left ventricle, kidney and adrenal gland. Expression of
the rat putative (pro)renin receptor was higher in the left ventricle than in the kidney and the
adrenal gland, although this was not statistically significant.
Figure 4.20: Analysis of the putative (pro)rcnin receptor expression in TCR(Cyplal Rcn2) rats
by real-time RT-PCR. Data is expressed as a ratio of CT for (pro)renin receptor (RR) with SYBR
green dye and ofCT for 18S (Taqman probe labelled with VIC). P value was determined by Student's
t-test. LV = left ventricle.
3 □ LV s Kidney ■ Adrenal
Control Treated
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4.3 Discussion and conclusions
This study demonstrates the advantages of this recently developed transgenic rat model of
hypertension, notably the fact that the severity and length of exposure to high blood pressure
can be modulated at will. This allows the study of chronic as well as acute effects and
mechanisms of hypertension but also to investigate recovery mechanisms when treatment
has ceased. Echocardiography techniques used in this report has been shown to be powerful
non invasive tools to evaluate the extent of cardiovascular damages in hypertensive animals.
Transgene induction resulted in a rapid increase in blood pressure in treated TGR(Cyplal-
Ren2) animals. This was accompanied by weight loss, polyphagia, polyuria and polydypsia
without indication of diabetes. Leucocytes were detected in the urine of treated
TGR{Cyplal-Ren2) animals suggesting renal inflammation potentially linked to
hypertensive injury.
4.3.1 Cardiac and aortic phenotype
Echocardiography data shows an increase in left ventricular area suggesting development of
ventricular hypertrophy in treated TGR(Cyplal-RenI) animals. This was confirmed by an
increase in left ventricle weight. The increase in blood pressure may also be responsible for a
stiffening (calculated as compliance and distensibility) of the abdominal aorta. It is possible
that, in turn, aortic stiffening may aggravate vascular and organ remodeling by increasing
shear stress. The molecular mechanisms triggering this process remain unknown but
histological investigations (namely collagen and elastin staining) have revealed that an
increase in the number of collagen fibres as well as hypertrophy in smooth muscle cells
which is likely to be responsible for the aortic stiffening. Whether this response is causative
of or caused by hypertension is unclear. However, due to the rapid increase in blood pressure
after two days of transgene induction, one may speculate that arterial stiffness is the result of
increased blood pressure and shear stress. In turn, a decrease in the compliant, blood
pressure-dampening properties of the aorta could contribute towards the gradual blood
pressure elevation after the initial period of hypertension due to the transgene activation.
Cardiac output (CO) and stroke volume were markedly reduced compared to control after
two weeks of treatment which may also be an adaptative response to increased blood
pressure (BP) and increased peripheral resistance (PR) since blood pressure is dependent on
both factors (BP=CO*PR). Indeed, it was shown that mesenteric arteries developed
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increased stiffness and this could be the case in other vascular beds. Stroke volume was
reduced from week 2 in the treated group. Although a clear reduction in stroke volume was
also observed in week 4, this was not significantly significant compared to controls.
Decreased cardiac function was, however, not observed in older (24 weeks) treated
TGR(Cypla1 -Ren2) animals (B. Janssen, personal communication). Hence, the timing and
onset of the hypertension are important determinants of hypertrophy and cardiac failure.
Dilation of the coronary arteries was obvious which is likely to be an compensatory response
in order to decrease local blood pressure and to prevent increased shear stress-mediated
injury to the cardiac tissues. In contrast with the results published in (Kantachuvesiri et al.
2001), no inflammatory injury to cardiac tissues could be observed. It may explain why the
rats survive/handle exposure to increased blood pressure for such a prolonged period of time
compared with rats available in Edinburgh (as investigated in Chapter 5).
4.3.2 Renal phenotype
The renal phenotype consisted of general but subtle fibrosis in the cortex as evidenced by a
small increase in collagen staining, segmental glomerulosclerosis, profound changes to the
interlobular arteries and fibrinoid necrosis of smaller renal vessels and afferent arterioles.
The "onion skinning" appearance was gradually more marked with decreasing vessel size.
There are two forms of hypertensive injury to the kidney. Firstly, the afferent arterioles
constrict until the high blood pressure is not carried on to the glomerulus, hence preventing
exposure to high blood pressure in the glomerulus and the efferent arteriole which can
become ischaemic. This causes severe arteriolar nephrosclerosis. Secondly, increased arterial
pressure is transmitted through the afferent arteriole to the glomerulus which is the most
affected. In most rat models and in the present one, no global sclerosis was observed
suggesting that the afferent arterioles had recently lost control of high blood pressure
dampening to the glomerulus leading to fibrinoid necrosis and segmental glomerulosclerosis.
This, however, differs from the original publication (Kantachuvesiri et al. 2001) which
presented this model in which normal glomerular histology was reported. The renal arteries
were unaffected by treatment and minimal changes to interlobar-arcuate vessels was noted.
Mild inflammatory cell infiltration was observed in the latter which may explain the
leucocyte detection in the urine. The absence of injuries to these vessels suggest, however,
that inflammation at earlier stages of transgene induction did not occur.
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4.3.3 Mesenteric phenotype
A reduction in the lumen diameter was observed in mesenteric resistance arteries (inward
remodelling) of TGR(Cyplal-Ren2) animals compared to controls. Whether this inward
remodelling is hyper/hypo-eutrophic depends on the cross-sectional area of the tunica media.
Inward eutrophic remodelling and hypertrophic remodelling are observed in small and large
arteries in humans, respectively (P. Schiffers, Personal communication). Indeed, in this
study, histopathology revealed that both a reduction in lumen diameter and an increase in
vascular wall thickness are present. The wall thickness of the mesentery arteries was
increased due to remodelling of the tunica media and the tunica adventitia, the latter
displaying a small increase in collagen deposition. As for the aorta, vascular remodelling
involving the production of extracellular matrix is likely to be the mechanism involved in the
stiffening of small arteries since collagen was increased in the mesenteric bed. No changes in
the amount of elastin or reticulin were also observed. In contrast to the aorta, changes in
smooth muscle cells were not detected in the mesenteric arteries.
4.3.4 (Pro)renin receptor
Increased local and circulating levels of prorenin may have triggered these remodeling
events. Binding of prorenin to the human (pro)renin receptor was shown to trigger
intracellular signaling cascades linked to MAP kinases ERK1 and ERK2. Although ERK1
and ERK2 have been demonstrated to initiate hypertrophic events in cardiomyocytes, the
involvement of the (pro)renin receptor in hypertrophic responses has not been reported. The
remodeling events observed in TGR(Cyplal-Ren2) animals are, in fact, not due to increased
expression of (pro)renin receptor in left ventricle, kidney or adrenal since quantitative PCR
revealed no differences in (pro)renin expression between treated and control rats.
It is possible that increased expression of (pro)renin receptor in the vasculature plays a role
in haemodynamics as demonstrated in a (pro)renin receptor over-expressing transgenic rat
model by Burckle et al. Quantitative expression of the (pro)renin receptor in isolated vessels
was not measured in the present study. Basal levels of the receptor may be normally high and
increased prorenin may result in increased binding to the receptor followed by non-
proteolytic activation. It is worth noting that the vasculature was not microdissected out of
the tissues examined in the present study. However, an increase in the expression of the
(pro)renin receptor solely in the vasculature is unlikely to be the major contributor in the
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pathogenesis of TGR(Cyplal-ren2) animals since overexpression of the receptor did not
trigger malignant hypertensive injuries (Burckle et al. 2006). The author also used a anti-
human (pro)renin receptor antibody(kindly provided by Dr Nguyen) in an attempt to localise
the protein in several tissues such as the heart, the kidney and the brain. Paraffin sections
from TGR(Cyplal-Ren2) animals were tested for efficiency of antibody binding to rat
tissues. However, this proved to be unsuccessful and resulted in non-specific binding and
high background levels. It also made impossible the comparison ofprotein levels by Western
blotting which would have complemented the real-time PCR data. It cannot be excluded that,
although the putative (pro)renin receptor mRNA levels were not different between control
and transgenic animals, post-transcriptional up-regulation is occurring.
Overexpression of the putative (pro)renin receptor in transgenic rats (Burckle et al. 2006)
results in increased blood pressure and heart rate but does not trigger any end-organ damage
or inflammatory events, arguing for a role of this molecule in blood pressure -dependent
mechanisms. The prorenin pathway of non-proteolytical activation is, however, thought to be
linked to hypertrophic and inflammatory responses independently of blood pressure. This is
also in contradiction with the work of Ichihara et al. on the involvement of the putative
(pro)renin receptor in diabetic nephropathy. In addition, the increased levels of aldosterone
reported by Burckle et al. may be related to the M8-9 function of the putative (pro)renin
receptor. The work of Nguyen et al. reports binding of prorenin, non-proteolytic activation
and intracellular signalling cascade upon binding to the human (pro)renin receptor. However,
the mechanism of prorenin uptake is neither addressed nor discussed in these studies. This is
of great importance, in particular for the transgenic rat model Cyplal-Ren2 and this is
further investigated using a decoy peptide as inhibitor of the putative (pro)renin receptor.
In order to clarify the involvement of the putative (pro)renin in the malignant hypertension
phenotype, inhibition of the putative (pro)renin receptor in TGR(Cyplal-ren2) animals was
studied in a pilot study (Chapter 6). A decoy peptide showed to competitively bind the
putative (pro)renin receptor in a rat model of diabetic nephropathy (characterised by an




Genetic, Environmental and Experimental Factors
in the Phenotype ofTGR(Cyplal-Ren2) animals
5.1 Introduction
For this chapter, the phenotype of TGR(Cyplal-Ren2) rats studied at the University of
Maastricht was compared with the phenotype described in the original publication
(Kantachuvesiri et al. 2001) which described the TGR{Cyplal-Ren2) produced at the
University of Edinburgh. Differences in phenotype were noted from the previous data as
highlighted in Chapter 4.2.3. Although, infiltrating inflammatory cells were noted in the
large arteries of the kidney (arcuate arteries) and in the glomerulus, the expected significant
inflammatory response in the kidney and in the heart was absent which differed from the
previously published data (Kantachuvesiri et al. 2001). Glomerulosclerosis was observed in
the treated "Maastricht" TGR(Cyplal-Ren2) after 5 weeks of transgene induction which was
not observed previously in the "Edinburgh" TGR(Cyplal-Ren2) after 2 weeks of treatment.
Glomerulosclerosis may be an adaptative response to the prolonged exposure to high blood
pressure although it would be expected to be a rapid, early rather than a chronic phenotype.
In addition, no signs of cardiac tissue infarctions were observed despite an obvious
hypertrophic effects in the left ventricle of induced TGR{Cyplal-Ren2) rats.
Another striking feature of the "Maastricht" TGR(Cyplal-Ren2) is their apparent reduced
sensitivity to the traiisgene inducer (indole-3-carbinol) as observed by the very low mortality
rate in this colony. Except for the excess micturition and increased food and water intake, the
animals did not display any signs of illness such as reduced activity, cessation of grooming,
hunch back or unkempt appearance and they appear to thrive as illustrated by the lack of
weight loss showing that the growth of the young animals was not inhibited.
The reasons for these discrepancies were examined, namely genotypic and environmental
differences. In order to address these issues, a questionnaire was designed to compare
dietary, experimental and general animal care in all 5 populations of TGR(CyplaJ-Ren2)
rats existing round the world. In addition, extensive genotyping of the two "Edinburgh"
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populations of TGR(Cyplal-Ren2) and of the "Maastricht colony" was undertaken using
microsatellite markers to determine if strain background has a role in these phenotypic
differences. Other TGR(Cyplal-Ren2) were not examined in terms of genetic background
since they were not re-derived and are believed to be identical from the original strain. It
may, however, be useful to undertake genotypic screening of other lines since the genetic
background could account for differences in the sensitivity to hypertensive injuries.
The aim of this chapter was, therefore, to identify potential contamination with rat strains
other than Fischer (F344) which may account for the phenotypic differences observed during
the experiments carried out in Maastricht and described in Chapter 4. Genetic background is
of great importance considering the hypertensive rat model TGR(mRen2)21, which expresses
the mouse Ren2 gene and displays severe malignant hypertension accompanied by high
circulating prorenin concentrations and by elevated tissue RAS levels (Mullins et al. 1990).
Ciosses of TGR(mRen2)21 to different rat strains have showed that malignant hypertension
is linked to the strain genetic background, TGR{mRen2)21 rats on a Fischer (F344)
background displaying the most extensive injuries whereas TGR(mRen2)27 rats on a Lewis
background exhibited less striking lesions (Mullins and Mullins 2003).
5.2 Results
The re-derivation, environmental, dietary and experimental information was compiled by
myself for the two Edinburgh colonies and by myself from the colony held in Maastricht
University (The Netherlands) with the help of Dr Ben Janssen (University of Maastricht)
who had performed earlier work on the animals. Dr. Kenneth Mitchell and Prof. Jorg Peters
kindly provided information relating the transgenic animals held in Tulane University (New
Orleans, USA) and in the University of Greifswald (Germany), respectively.
5.2.1 Transfer and re-derivation of different TGR(Cyplal-Ren2) rat colonies
The "Maastricht" TGR{Cyplal-Ren2) rats were re-derived by caesarian section from the
animals examined in this publication. As part of a department re-structuring in 2004, the
"Edinburgh" TGR(Cyplal-Ren2) rats were also re-derived by embryo transfer to a separate
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Table 5.1: Comparison of re-derivation procedures used to establish TGR(Cyplal-Ren2)
colonies at the University of Edinburgh and in collaborating laboratories.
The only other colony which was re-derived was the colony established at the University of
Maastricht. This was performed by for the caesarian section procedure and the rationale for
re-derivation was that the original animals from Edinburgh were found to have pinworms,
and, in addition, S.aureus which is not routinely screened as part ofHome Office regulations
in the UK but required in the Netherlands.
5.2.2 Indole-3-Carbinol and diet preparation
Indole-3-carbinol is the compound used to induce the cytochrome P450 1A1 (Cyplal)
promoter under which control the mouse Ren2 gene is. It is therefore an important factor in
the transgene activation and the downstream production and release of prorenin in the
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Table 5.2: Comparison of indole-3-carbinol (I3C) preparation used in TGR(Cyplal-Ren2)
colonies at the University of Edinburgh and in collaborating laboratories. I3C = Indole-3-
carbinol.
The concentrations of I3C used routinely for transgene induction were consistent between
the laboratories, namely 0.3% although other I3C concentrations have been tested (Table
5.2). The exception is in Greifswald where the standard concentration used is 0.15%. In
Maastricht, due to a low number of animals developing cardiac failure, higher concentrations
of 1% (which was discarded as a working dose due to the pungent smell of I3C preventing
the rats from eating the diet) and 0.6% (which did not yield significant results from 0.3% in
terms ofmortality or phenotype) . In Edinburgh, a lower dose of 0.15% was used previously
resulting in a phenotype which developed more slowly and which was less severe than with
0.3% (A. Ryding, University of Edinburgh, 2005, PhD thesis). The amount of vegetable
derivatives i.e.: potentially containing I3C may vary between batches/supplies of normal
chow.
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In addition, it was noted that peanut oil was used to mix I3C before adding it to the diet in
Maastricht. Another striking difference was the sodium contents between the rodent chow
used in all different animal holding facilities, the highest being in Greifswald and New
Orleans.
5.2.3 Transgene induction duration and protocol
The exposure time to the inducer varied greatly between laboratories due to a variable
mortality (Table 5.3). The shortest routine length of exposure is 12 days at Tulane University
































































Table 5.3: Comparison of transgene induction procedures used to establish TGR(Cyplal-Ren2)
colonies at the University of Edinburgh and in collaborating laboratories.
However, the "Greifswald" animals displayed high mortality when fed a diet containing a
low concentration of 0.1% for 6 weeks. It is worth noting that the diet used at Tulane
University and at the University of Greifswald contain the highest amount of sodium.
The animals from Maastricht appear to be the least sensitive to the transgene induction as
reflected by very few (if any at all) animals dying although their blood pressure is increased
to a level comparable to the treated animals from Edinburgh and from the other colonies. In
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addition, the amount of sodium in the diet purchased in Maastricht was the lowest compared
with all the other animal holding facilities (Table 5.3). If the results are extrapolated, it
appears that dietary sodium contents are correlated with the severity of the phenotype, the
time course of phenotype progression and with the mortality rate.
5.2.4 Blood pressure measurement
The blood pressure measurements are similar between all the laboratories when measured by
higher, except in Greifswald where the 13C doses were lower and one would expect the
transgene induction to be reduced compared to that of animals from other colonies (Table
5.4). The values obtained in New Orleans differ depending on the blood pressure sampling
method, namely, tail-cuff or radiotelemetry. This is thought to be due to the restraining
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Table 5.4: Blood pressure measurements obtained with TGR(CypIa I-Ren2) animals from all the
different holding facilities. Blood pressure was measured in for all animal population after induction
of the transgene with indole-3-carbinol. T.C. = Tail cuff.
5.2.5 Histopathology
It is difficult to assess whether histopathology data is comparable between the TGR(Cyplal-
Ren2) colonies since different length of exposure, dosage are used and the organ of












































Not done Not done Yes Not done Not done
B Is the observed pathology correlating with the original results
published in Kantachuvesiri et al. (2001) ?
Edinburgh
WGH
N/A - original work
Edinburgh
LF
Microinfarctions, fibrinoid necrosis, inflammatory cells in heart and similar
injuries to kidneys: intrarenal vascular thickening without glomerulosclerosis
Maastricht No, reduced inflammatory component. No microinfarction, fibrinoid necrosis in
heart. Fibrinoid necrosis of small intra-renal vessels with glomerulosclerosis.
New
Orleans
In kidney: vascular and interstitial cell proliferation. Segmental
glomerulosclerosis and tubular cell proliferation.
Greifswald Lower doses were used so less severe phenotype. However, hypertrophy and
fibrosis present. Inflammatory cell infiltration in the heart.
Table 5.5: Table comparing establishment of phenotype, inflammatory response and
histopathology between TCR(Cyplal Rcnl) animals from all the collaborative laboratories and
from the "Edinburgh" facility. A) Description of the histopathological phenotype, B) Comparison
of the phenotype of each colony with the previously published results (Kantachuvesiri et al. 2001)
N/A = not applicable, MH = malignant hypertension.
The comparison of the phenotype between treated animals from all 5 existing colonies is
summarised in Table 5.5. The rise in blood pressure was rapid in all treated TGR(Cyplal-
Ren2) rats except for "Maastricht" animals for which it was more progressive, did not reach
a plateau and continued to increase throughout the 5-week experiment (Cf. Chapter 4.2.1.1).
The common phenotype between all the animals was cardiac hypertrophy accompanied by
fibrosis although the latter may be a very subtle response as observed in the "Maastricht"
rats, despite longer exposure to inducer. Inflammatory cell infiltration was not a significant
feature of the heart, mesentery or kidney, except around the large intra-renal arteries in the
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"Maastricht". This was also less prominent in the "Greifswald" which may be due to a lower
I3C dose. All the other treated animals displayed infiltration of inflammatory cells. No
information was obtained about renal histopathology for the "Greifswald" animals. The
overall phenotype (renal and cardiac) was considered to be less severe with these animals
due to the lower dosage used but to follow a similar pattern of end-organ damage (J. Peters,
personal communication).
Segmental glomerulosclerosis was demonstrated in the "New Orleans" and the "Maastricht"
animals although, in the latter, the severity of the glomerular injuries was not homogeneous
and normal glomeruli were found when examining the same section. Vascular remodeling of
the intra-renal vessels was common to the treated animals from all colonies. However, only
the "Maastricht" animals displayed fibrinoid necrosis in interlobular arteries and the afferent
arterioles which may be due to longer exposure to the transgene induction (five weeks). The
"Edinburgh" and the "Maastricht" animals differed again in terms of the lesions in
mesenteric bed which were shown to be more severe in the "Edinburgh" animals which
displayed vascular remodeling characterised by fibrinoid necrosis (Cf Chapter 4). The
mesenteric phenotype consisted of apparent increased medial area and a decreased vascular
lumen without fibrinoid necrosis or presence of inflammatory cells in the "Maastricht" rats.
What is clear from this questionnaire is that there is a multitude of factors to consider when
attempting to evaluate endpoints of the same models used by different experimenters.
5.2.6 Genetic screening
Another important factor in hypertensive phenotypic differences is the genetic background of
the animals. Forty-nine microsatcllite markers were used and PCR analysis was performed.
The original TGR(Cyplal-Ren2) rats were produced on a Fischer (F344) background and all
the re-derived animals (namely Edinburgh-LF and Maastricht) were re-derived on this
background. It was, however, decided to verify the genetic strain as it is known to affect
cardiovascular phenotypes.
Two animals from Maastricht, two animals from Edinburgh-WGH and 3 animals (from three
different breeding pairs) from Edinburgh-LF were analysed using microsatellite markers.
The results are summarised in Table 5.6 and examples of genotyping and evidence of genetic
contamination are shown in Figure 5.1.
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Animal WGH WGH Maastricht Maastricht LF LF LF
Marker 6015 6031 4 6 182 170 199
DlMgh2 FF FF FF FF FF FF LL
MT1PA FF FF FF FF FF FF FF
DlRat51 FF FF FF FF FF FF FF
D2Mgh 14 FF FF FF FF FF FF FF
D2Mit6 FF FF FF FF FF FF FF
D2Rat83 FL FL FF FF FF FL FF
D3MU10 FF FF FF FF FF FF FF
D4Mit2 FF FF FF FF FF FF FF
D4Mitl 7 FF FF FF FF FF FL FF
D5Mghl3 FF FF FF FF FF FL FF
D5MH4 FF FF FF FF FF FF LL
D5MU13 FF FF FF FF FF FL FF
D6Rat24 FF FF FF FF FF FF FL
D7Mit4 FF FF FF FF FF FF FF
D7Rat24 FF FF FF FF FF FF FF
D8Ratl6 FF FF FF FF FF FF FF
D8Rat77 FL FL FF FF FF FF FF
D9MU2 FL FL FF FF FF FL FF
D9Rat81 FL FL FF FF FF FF FF
D10MU9 LL LL FF FF LL FF FL
PPY FF FF FF FF FF FF FF
D10Ratl42 FF FF FF FF FL FF FF
D10Rat32 FF FF FF FF FF FF FF
735-736 FF FF FF FF FF FF FF
DllMgh4 FF FF FF FF FF FF FF
D1 lRat52 FF FF FF FF FF FF FF
D12MH4 FF FF FF FF FF FF FF
D12Rat59 FF FF FF FF FF FF FF
D13MU1 FF FF FF FF FF FF FF
D13Uwml FF FF FF FF FF FF FF
D14Mgh2 FF FF FF FF FF FF FF
D14MU2 FF FF FF FF FF FF FF
D15Mgh2 FF FF FF FF FF FF FF
D15Rat71 FF FF FF FF FF FF FF
D15Ratl23 FF FF FF FF FL FF FF
D16Rat53 FF FF FF FF FF FF FF
D16Rat90 FF FF FF FF FF FF FF
D17Mit4 FL FL FF FF FL FL FF
D17Rat85 FF FF FF FF FL FL FF
D17Rat89 FL FL FF FF FL FL FF
D18Mgh2 FF FF FF FF FF FF FF
D18MH1 FL FL FF FF FF FL FF
D18MU3 FL FL FF FF FF FF FF
Table 5.6: continues overleaf
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D19Rat30 FF FF FF FF FF FF FF
TAT FF FF FF FF FF FF FF
D20Mgh I FF FF FF FF FF FF FF
D20Rat21 FF FF FF FF FF FF FF
DXRatl5 FF FF FF FF FF FF FF
DXRat31 FF FF FF FF FF FF ND
Table 5.6: Table summarising the genotype of TGR(Cyplal-Ren2) rats from animal facilities in
Edinburgh (WGH, LF) and Maastricht. Animal numbers were generated as a unique identifier. Each animal
is from a different litter or breeder pair. FF = homozygous Fischer for the named marker, FL = heterozygous
Fischer for the named marker, LL = homozygous for another strain for the named marker. The number
following "D" indicates chromosome number. MT1PA: chromosome 1 marker. PPY and 735/736: chromosome
10 markers. TAT: chromosome 19 marker. ND = not determined.
The results revealed that the Maastricht rat colony was of pure inbred Fischer (F344) origin which
shows that the strain of the population from which they were derived was indeed pure Fischer (F344).
It can therefore not account for the phenotypic differences between the Maastricht rat colony and the
Edinburgh rat colony and other factors, unidentified to date, must be involved. Surprisingly, however,
the Edinburgh-WGH (the descendants of the original TGR(Cyplal-Ren2) rat population) animals
displayed contamination with what appeared to be of Lewis strain origin although this is difficult to
ascertain as information about band size for other strains with the markers used was not available.
Figure 5.1: Acrylamide gel electrophoresis of microsatellite markers genotyping on genomic rat DNA. A)
Microsatellite marker D10Ratl42 on chromosome 10, B) Microsatellite marker DI0Mit9 on chromosome 10,
C) Microsatellite marker D2Rat83 on chromosome 2, D) Microsatellite marker D17Rat89 on chromosome 17.
Lane 1 is from Fischer DNA, lane 2 is from Lewis DNA, lane 3 is from animal WGH 6015, lane 4 is from
animal WGH 6031, lane 5 is from animal Maastricht 4, lane 6 is from animal Maastricht 6, lane 7 is from
animal LF 182, lane 8 is from animal LF 170 and lane 9 is from animal LF 199. '#' indicates homozygosity for
a loci of strain different from Fischer, indicates heterozygosity, circles show the genotypic contamination.
125
As a result of this contamination, the TGR(Cyplal-Ren2) rat population from the new
animal holding facility which was re-derived by embryo transfer from Edinburgh-WGH
animals was also contaminated. Studies evaluating the correlation between dietary sodium
and the severity of the phenotype were infeasible and will require further analysis.
5.3 Discussion and Conclusions
As presented in Chapter 4, histopathological data using TGR(Cyplal-Ren2) showed a
reduced inflammatory response normally associated with the vascular injuries compared
with the original work in this model (Kantachuvesiri et al. 2001). Despite an obvious
hypertrophic remodeling and a longer length of exposure to the inducer, no signs of
microinfarctions or infiltration of inflammatory cells were observed in the heart, which
differs from the original publication (Kantachuvesiri et al. 2001). Although the direct
comparison between this study and the original data is difficult to assess due to the different
exposure length, two main observations were made regarding response of the "Maastricht"
TGR(Cyplal -Ren2) to transgene induction following indole-3-carbinol (I3C) administration.
Firstly, it appears that the "Maastricht" rats are less sensitive to the I3C treatment and
although a five-week exposure resulted in a distinct histopathological and physiological
phenotype, the mortality rate was not increased which is in contrast with the "Edinburgh"
TGR(Cyplal-Ren2) rats (A. Ryding, personal communication), with the "New Orleans" and
the "Greifswald" animals. Secondly, in the present study, the arcuate-interlobar arteries were
unaffected and it would appear that no severe overall renosclerosis was observed. Segmental
glomerulosclerosis suggests that the afferent arterioles had recently lost control of high blood
pressure dampening to the glomerulus leading to fibrinoid necrosis which again differs from
the original publication (Kantachuvesiri et al. 2001) which reported normal glomerular
histology. The mesentery displayed similar hypertensive injuries, albeit less severe and no
infiltration of inflammatory cells was noted in the Maastricht rats.
Due to these findings, investigations were carried out in order to identify the factors involved
in the different phenotypes between the "Maastricht" rats described in (Chapter 4) and the
"Edinburgh" rats studied in (Kantachuvesiri et al. 2001). Re-derivation, environmental,
dietary and genetic information was collected for all the TGR(Cyplal-Ren2) rat colonies
existing in the world. The reasons for the discrepancies may be multiple: different
investigators, diet preparations and housing may be involved. The "Maastricht" animals were
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re-derived by caesarian section after veterinary screening which revealed a dual commensal
infection (pinworms and S. aureus). Although a carry over of certain pathogens during this
procedure cannot be excluded, the immunologically stimulated state of the "Edinburgh"
TGR(Cyplal-Ren2) rats may be a factor in the phenotypic differences. The testing of this
hypothesis was hampered by a genetic contamination in the "Edinburgh-LF" animals. These
animals had recently been re-derived by embryo transfer but no histopathological
comparison was possible since these were not of pure Fischer (F344) origin. A difference in
genetic background may have been responsible since we know that the Fischer (F344) and
Fewis strains differ in ACE activity levels associated with a quantitative trait locus on
chromosome 10 in the vicinity of the ACE gene. Genetic background was investigated and
was shown, as for the original publication that the "Maastricht" animals were on a pure
Fischer (F344) background. While it is not impossible that untested animals in the
"Maastricht" colony may also display genetic contamination, the animals used for the
present study were from the same breeding pair and can therefore be considered to be of pure
Fischer (F344) origin. Hence, the discovery of the genetic contamination in the "Edinburgh"
animals was not the key factor accounting for the differences in phenotype between the
"Maastricht" animals and the original "Edinburgh" TGR(Cyplal-Ren2). The reasons for a
genetic contamination were traced to the commercially purchased stock. It demonstrates that
regular in-house genetic screening may be necessary to insure the strain purity of transgenic
lines and in particular, when producing congenic lines.
Another explanation could be the levels of dietary sodium given to the animals.
TGR(Cyplal -Ren2) animals have been shown to develop salt-sensitive hypertension
following a two-week exposure to the inducer (Howard et al. 2005). The present study
revealed that the "Maastricht" rats were fed the lowest sodium amounts compared with
animals from the other laboratories holding this model. It is unlikely that a 0.07% difference
in sodium levels with the "Edinburgh" diet is responsible for the phenotypic divergences. It
has been previously reported that the induced TGR(Cyplal -Ren2) animals fed a high salt
diet (4%) or offered saline solution did not display exacerbated end-organ pathology to the
kidney, heart or mesentery although cerebrovascular injuries were detected (Collidge et al.
2004). It could be that the levels of dietary sodium in the laboratory in Maastricht are below
a threshold which is suggested by the increased mortality rate at 12 days in the "New
Orleans" population (greater than that of the "Edinburgh"), which are fed a diet with higher
sodium contents (K. Mitchell, Personal communication). The shape of the blood pressure
curve may have been affected by dietary sodium levels which would explain why the
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"Maastricht" animals develop a more gradual hypertension rather than a rapid, severe
increase in blood pressure. Adaptative mechanisms to progressive blood pressure elevation
may be likely to play a physiological role and to prevent mortality amongst treated
"Maastricht" TGR(Cyplal-Ren2) animals. Furthermore, the lack of inflammatory cell
infiltration in the "Maastricht" rats correlates with a possible decreased pathogen load in
these animals following caesarian section re-derivation. Studies designed to investigate the
effects of dietary sodium in different strains and pathogen load including the recently re-
derived "Edinburgh-LF" TGR(Cyplal-Ren2) animals are required but further experiments
were hampered by the discovery that these animals were no longer of pure Fischer (F344)
origin. Careful diet content verification should be undertaken as to enable comparison
between publications addressing the same model and to ensure an accurate interpretation of
the data.
Another consideration to address phenotypic differences between different TGR(Cyplal-
Ren2) colonies housed in several laboratories may be to measure the level of transgene
induction following induction with I3C treatment. Prorenin plasma concentrations are in
direct correlation with transgene activation as a result of the mouse Ren2 gene expression.
This measurement could be used to avoid variations from diet and to exclude an effect from
sodium contents in the diet as well as from possible pathogen load. Plasma prorenin levels
were not measured for the present thesis due to the lack of prorenin substrate availability
(i.e.: plasma containing angiotensinogen and devoid of renin/prorenin. Home office license
restriction prevented the preparation of nephrectomised mouse or rat plasma and the prorenin
assay could not be performed. This and the other environmental/genetic factors described
above are of considerable importance for further studies TGR(Cyplal-Ren2) and for future
research dealing with animal models of hypertension/cardiovascular diseases.
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Chapter 6
Inhibition of Cardiovascular Injuries in
TGR(Cyplal-Ren2) using a Prorenin Decoy
Peptide
6.1 Introduction
After prorenin secretion, the mechanisms of downstream prorenin activation/conversion are,
to date, unclear. Evidence is accumulating in favour of a non-proteolytic activation of
prorenin. An alternative pathway for prorenin conversion is now known resulting in the pro
enzyme to be activated without changes in molecular weight and with the ability to return to
an inactive conformation by heat treatment or following binding a (pro)renin receptor (Derkx
et al. 1987; Leckie and McGhee 1980). The physiological regulation and relevance of non-
proteolytic prorenin activation remain unclear in malignant hypertension.
The aim of the present chapter is to assess whether the prorenin handle region peptide
described by Ichihara et al., (2005) abolishes the malignant hypertension cardiovascular
lesions in the TGR(Cyplal-Ren2) model. This will evaluate the involvement of non-
proteolytic activation of prorenin and of its receptor in the pathophysiology of malignant
hypertension. Due to the genetic contamination uncovered in the animals held at the
University of Edinburgh, a full scale study including renin gene expression, plasma
prorenin/renin levels and tissue prorenin/renin amounts was unachievable. A pilot study was
therefore undertaken concentrating on histopathology in key organs, namely heart, kidney
and mesentery, having been shown to exhibit malignant hypertension end-organ damage in
the original publication on TGR(Cyplal-Ren2) animals (Kantachuvesiri et al. 2001).
Animals from the Edinburgh-LF colonies were used, despite their mixed genetic




Previous research (Ichihara et al. 2004) reported the use of the peptide (NH2-RILLKKMPSV-
COOH) which abolished diabetic nephropathy in streptozotocin-treated rats. The dose used was
O.lmg/kg. The peptide was used as a competitive inhibitor of prorenin for its receptor. Comparing
the levels of prorenin in the plasma between the streptozotocin-treated rats and the TGR(Cyplal-
Renl) rats, it was decided to use a higher dose (0.4mg/kg) of decoy peptide for the present
experiment.
6.2.1 Body weight and blood pressure
Animals 1 and 2 received the inducer and the decoy peptide in saline whereas animals 3 and 4
received the inducer and saline only. The animals were weighed prior to the start of transgene
induction with 0.3% I3C, everyday for the first 3 days and every second day thereafter. All 4
animals displayed weight loss which was progressive over 14 days (Figure 6.1). The total weight
loss was between 36.1g and 52.4g (Figure 6.1). The highest and smallest weight loss did not



















Figure 6.1: Body weight and weight loss in TGR(Cyplal-Ren2) animals. A) Body weight (g) of individual
animals, B) Total weight loss over 14 day-experiment of each animal.
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The blood pressure was measured in conscious restrained animals and was shown to increase
progressively over the experimental time from day 3 (Figure 6.2). The range of blood pressure
values was more widespread between animals in the first 5 days and may be due to difference in
adapting to the restrain conditions between each individual animal. At the end of the study, the
increase in blood pressure was between lOOmmHg and 48.3mmHg (Figure 6.2). These differences
in blood pressure increase may be due to the methodology which can trigger stress in the animals.
However, the blood pressure changes do not appear to be different with decoy peptide treatment
compared with animals receiving saline only and do not correspond to weight loss. The decoy
peptide overall does not seem to affect or ameliorate the weight loss or increase in blood pressure in












Figure 6.2: Blood pressure measurement in conscious restrained TGR(Cyplal-Ren2). A) Blood pressure
(mmHg) of individual animals measured by indirect tail-cuff method. B) Total blood pressure increase over
14 day study.
6.2.2 Histopathology
Considering the histopathology data reported by Kantachuverisi et al. (2001) and in this thesis gross
and microscopic examination of the key tissues affected by end-organ damage was undertaken to
identify the effects of the prorenin decoy peptide of end-organ damage in TGR(CypJal-Ren2)
animals.The results presented represents data from each of the four rats sampled during this study.
All four animals displayed homogeneous increase in left ventricular (LV) wall thickness indicative
of concentric LV hypertrophy (Figure 6.3). No difference was noted between the animals on I3C
alone or the induced rats which were implanted with mini-pumps containing the prorenin decoy
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peptide. Another striking feature similar to all the animals was the presence of infarction in the
right ventricle (RV), including in the RV free wall (Figure 6.3 A-D)
Figure 6.3: Scanned images of H&E stained cross sectioned hearts of TGK(Cyplal-Ren2). A) Rat 1
(I3C and decoy), B) Rat 2 (I3C and decoy), C) Rat 3 (I3C alone), D) Rat 4 (I3C alone). All animals
displayed the same degree of concentric LV hypertrophy, boxed areas indicate sites of infarct. Bar = 2mm,
LV = left ventricle, RV = right ventricle. E) Superimposed intraventricular septa of rat 4 (width 3.3mm)
and of control rat from Chapter 4 (wall width 2.1mm).
Infarction in the RV wall accompanied by fibrotic lesions in the right coronary artery was seen
in all four rats (Figure 6.4). Reduction in lumen size and fibrinoid necrosis of intramural right
coronary arteries generally found in or near areas of infarction (Figure 6.5) was observed. No
other coronary vascular lesions were found.
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Figure 6.4: Localisation of infarcts and microscopic examination of heart sections stained with H&E
and Sirius Red (for collagen) of TGR(Cyplal-Ren2). Each horizontal panel groups photographs from
individual animals. A) Whole heart sections as shown in Figure 6.3. (*) indicates the position of the RV
infarct, Bar = 2mm. B) H&E staining of the right ventricular infarcts showing inflammatory cell
infiltration and fibrotic areas. Boxed areas represent regions shown in (C). Bar = 200pm. C) Reverse
photographs of Sirius Red stained RV infarcts showing collagen deposition (white staining) indicative of
fibrosis and tissue scaring. I-C and 4-C: bar = 50pm, 2-C and 3-C: bar = 100pm.
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Figure 6.5: Right coronary artery branches from TGR(Cyp1a 1-Ren2) animals. A) Rat 4 (I3C alone),
Bar = 25pm, B) Rat 2 (I3C and decoy), Bar = 25pm, C) Rat 3 (I3C alone), Bar = 50pm. All calibres of
right coronary artery branches were affected by fibrinoid necrosis.
In the kidney, hypertrophy of the tunica media and a decrease in lumen size suggested
hypertrophic remodelling of the interlobular arteries of all calibres (Figure 6.5). Segmental
fibrinoid necrosis as indicated by unilateral loss of smooth muscle cells was observed in some
vessels. There are no discernible differences between the treated rats which received the decoy
peptide (rats 1 and 2) and the ones which did not (rats 3 and 4).
fflltfour animals showed glomerular enlargement and fibrinoid necrosis of the vascular pedicle
(Figure 6.7). Glomerular enlargement appears to result primarily from capillary distension.
Glomerular cellularity did not appear to be increased nor was sclerosis evident. Agam, this
phenotypic characteristics were common to all four rats and no improvement or inhibition of
these injuries were noted as a result of decoy peptide administration.
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Decoy and ISC
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Figure 6.6: H&E stained sections of paraffin embedded kidneys TGK(CypIal-Ren2) rats. Intra-
renal vasculature. For each of the 5 photograph series presented interlobular arteries of decreasing
calibre are shown from top to bottom. A) Rat 1, B) Rat 2, C) Rat 3, D) Rat 4, E) Untreated TGR(Cyplal-
Ren2) rat from study presented in Chapter 4. (*) indicates vessels affected by segmental fibrinoid
necrosis. Medial hypertrophy and decreased lumen size are present in the vessels of all rats.
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Figure 6.7: H&E stained sections of paraffin embedded kidneys TGR(Cyplal-Ren2) rats.
Glomerular phenotype. Glomerulus from A) Rat 1 (DC and decoy peptide), B) Rat 2 (DC and decoy
peptide), C) Rat 3 (DC alone), D) Rat 4 (DC alone), E) Control rat from study presented in Chapter 4.
The boxed area highlights the vascular pedicle of the glomerulus affected by fibrinoid necrosis. Note the
glomerular enlargement compared to control. Bar = 25pm.
Mesenteric vessels from all four animals showed medial hypertrophy and small lumens
suggestive of hypertrophic remodelling (Figure 6.8). Only vessels from rats 3 and 4 which had
not been administered with the prorenin decoy peptide show segmental fibrinoid necrosis or
hyperplastic arteriosclerosis (onion skinning).
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This was not seen in rats 1 and 2 which had received the decoy peptide suggesting that this
peptide may have prevented development of vascular remodelling and injuries. Histopathology
analysis was performed by an independent pathologist who was blinded to the treatment. It is
worth noting that the animals were grouped correctly by the pathologist.
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Figure 6.8: H&E stained sections of paraffin embedded mesentery TGR(Cyplal-Ren2) rats. For each
of the 5 photograph series presented mesenteric arteries of decreasing calibre are shown from proximal at
the top to distal at the bottom. A) Rat 1 (I3C and decoy peptide), B) Rat 2 (I3C and decoy peptide), C) Rat
3 (I3C alone), D) Rat 4 (I3C alone), E) Untreated JGR(Cyplal-Ren2) rat from study presented in Chapter
4. (*) indicates vessels affected by fibrinoid necrosis. Note that fibrinoid necrosis was only present in
vessels ofanimals treated with I3C alone.
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6.3 Discussion and conclusions
All four animals used in this pilot study displayed weight loss starting 2 days after transgene
induction and increase in blood pressure beginning 3 days after transgene induction. The
initial weight loss may have been due to the change of diet from pellet to powder form,
although the animals were given powdered food prior to the addition of the inducer to the
diet. The weight loss was progressive throughout the experimental period and all animals
followed the same trend regardless of the administration of the decoy peptide. The blood
pressure elevation was also gradual which, surprisingly, corresponded to the hypertensive
profile in the animals described in Chapter 4 rather than in the original report on the
TGR(Cyplal-Ren2) model (Kantachuvesiri etal. 2001).
Histopathological analysis revealed the classical injuries associated with malignant
hypertension. In the kidney, hypertrophic remodelling of the interlobular arteries of all
calibres with occasional segmental fibrinoid necrosis, glomerular enlargement and fibrinoid
necrosis of the vascular pedicle were observed. Vascular remodelling was present in all three
tissues examined. The prorenin decoy peptide did not prevent the development of the renal
lesions. Left ventricular hypertrophy was present without, however, the presence of
microinfarctions. Unexpectedly, infarcts were found in the right ventricle of all animals,
including in the right ventricular free wall. This shows again that, in this study, progression
of cardiac remodeling was not alleviated by the decoy peptide. In humans, right ventricular
(RV) infarction occurs when there is an occlusion of the right coronary artery proximal to the
acute marginal branches. Isolated RV infarction is extremely rare representing 2% of
autopsies. In animal models RV hypertrophy and infarcts are generally associated with
surgical ligation of the right coronary artery. Indeed, luminal size decrease was noted in all
calibres of right coronary artery branches found in the vicinity of the infarct. The
mechanisms by which right ventricular infarction developed in TGR(Cyplal-Ren2) animals
are unknown. It cannot be excluded that it may be a consequence of the mixed genetic
background identified in Chapter 5. Further investigations would be required to understand
the factors involved in this particular phenotype.
An interesting result was the amelioration of the lesions in mesenteric vasculature following
treatment with the prorenin handle region peptide. Although mesenteric vessels from all four
rats developed medial hypertrophy and reduction of lumen size, there was a distinct absence
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of fibrinoid necrosis in the animals receiving the peptide. This isolated effect in the
mesentery may reflect differential access of the peptide to this tissue and hence, an enhanced
protective outcome. What is not known from this study is whether the injuries developed and
their progression was subsequently delayed or if the lesions were prevented from developing.
In contrast with the work of, Ichihara et al. (2004) my experimental procedures did not
include administration of the decoy peptide several weeks prior to the expected vascular
phenotypic changes to occur. Using TGR(Cyplal-Ren2) animals, the inhibitor was applied
at the same time as the transgene, indole-3-carbinol, which triggers malignant hypertension
injuries from day 3 of exposure. Hence my study represents an attempt to ameliorate the
lesions as they are developing. This differential dosage strategy may explain why little
improvement in the histopathology findings was detected. A dose of decoy peptide four-fold
higher that used by Ichihara et al. (2004) was expected to be sufficient to counterbalance the
shorter length of treatment. This was, however, not observed.
The "handle" region of prorenin, i.e.: the portion of the protein thought to interact with
binding molecules and/or receptors to trigger non-proteolytic/reversible activation of
prorenin has been previously been used and described as a "decoy" peptide (Ichihara et al.
2004). It may be more accurate to describe it as a competitive inhibitor of prorenin,
preventing this molecule from binding to potential receptor(s). While this peptide has been
shown to bind the (pro)renin receptor reported by Nguyen et al., it cannot be excluded that it
may bind additional receptors or converting enzymes. Hence the effects obtained by Ichihara
et al. may reflect these direct or indirect mechanisms which have not been described. It is, in
addition, possible that the peptide acts as a chaperone rather than having a true effect on the
putative rat (pro)renin receptor.
Huang et al. (2006) showed that expression of pro-fibrotic genes such as TGF-p induced by
renin in cultured mesangial cells could be inhibited by short interfering RNA (siRNA)
corresponding to the putative (pro)renin receptor mRNA. Although recent evidence
suggesting a strong interaction between components of the renin-angiotensin system and
fibrosis is available, it is attractive to hypothesize that renin may be carrying out its effects,
independent of its enzymatic action to produce angiotensin II. However, the data arising
from siRNA inhibition of the (pro)renin receptor mRNA in mesangial cells (Huang et al.
2006) may reflect a more general effect on these cells which have altered pro-fibrotic
proteins synthesis. As noted in chapter 3, the mesangial cell cultures were exposed to renin
rather than prorenin to trigger the fibrotic response, hence raising the question of an
involvement of the putative (pro)renin receptor in the process. Data presented in Chapter 3
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showed that the (pro)renin receptor is homologous with a sub-unit (M8-9) of a vacuolar-
ATPase. It cannot be excluded that inhibition of (pro)renin receptor mRNA translation may
also result in interferences with this system involved in cell survival. In contrast with the
above results, competitive inhibition for the prorenin binding site of the (pro)renin receptor
did not inhibit fibrotic injuries in interlobular arteries and in the vascular pole on glomeruli.
In addition, inhibition of the (pro)renin receptor binding to prorenin for several weeks in
control animals by Ichihara et al. did not have any effect on blood pressure or body weight
(Ichihara et al. 2004) suggesting that the protein does not have an important role in normal
physiological situations.
"Three studies have used the prorenin handle region of prorenin to reduce vascular/cardiac
injuries. Firstly, Ichihara et al. (2004) showed amelioration of vascular injuries in a model of
diabetic nephropathy and this study is discussed above. Secondly, reduction of cardiac
fibrosis and blood pressure upon "decoy peptide" administration was noted in the very
severe model of SPSHR (Ichihara et al. 2006a). Thirdly, prevention of the development of
glomerulosclerosis was achieved in diabetic AT la null mice and MAPK activation was
abolished (Ichihara et al. 2006b). All three systems used have a common pathway linked to
disturbances in sodium and/or glucose homeostasis. In addition, TGF-P activation is
involved in the pathophysiology of these all models and the "decoy" peptide effects on the
putative (pro)renin receptor may be linked to this pathway rather than having a direct
inhibitory effect on prorenin. This could explain why minimum effects were observed in
TGR(Cyplal-Ren2) animals when administered with the peptide. The "decoy" peptide used
in the present study was identical to that used by Ichihara et al. and therefore the amino-acid
sequence was from rat. Prorenin expressed by TGR(Cyplal-Ren2) animals is of murine
origin. Rat and mouse prorenin are, however, highly homologous and it is unlikely that
species differences can account for the lack of effect in this study. Additionally, since the
decoy peptide administration in TGR(Cyplal-Ren2) did not result a significant amelioration
of the phenotype, it can be concluded that the putative (pro)renin receptor does not play a
role in this high prorenin model ofmalignant hypertension. No evidence has been published
to suggest that the (pro)renin receptor is involved in uptake of prorenin, a major component
of the phenotype in TGR(Cyplal-Ren2) rats. Therefore, it could be hypothesised that
additional, unknown receptors and/or binding proteins may be involved in this pathogenesis.
A separate protein (i.e. M8-9) originating from the same gene than the putative (pro)renin
receptor may be produced to carry on basic cell biology functions. The lack of evidence for
regulation of the (pro)renin receptor in TGR(Cyplal-Ren2) animals suggests that the
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function of this protein may need to be re-assessed. The work reported in the present chapter
indicates that non-proteolytic activation of prorenin through the recently published
(pro)renin receptor does not play a crucial role in malignant hypertension in the inducible
transgenic rat model of high prorenin. Further studies are needed to understand alternative
physiological roles for this newly identified gene.
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Chapter 7
Prorenin Maturation and the Regulation of
Renin Granulation during Mouse
Development
7.1 Introduction
Pro-hormones such as pre-pro-renin are synthesized in the rough endoplasmic reticulum and
sorted into the constitutive pathway or the regulated secretory pathway from which they are
released after extracellular stimulation. The regulation of granule biogenesis is poorly
understood but Kim et al. demonstrated that chromogranin A is essential for dense core
granule formation and for storage of hormones directed to the regulated secretory pathway
(Kim et al. 2001). The formation of epitheloid renin granules has been described although
some information remains hypothetical (Hackenthal et al. 1990). Schematic representation of
all stages of granule formation is shown in Figure 7.1. In summary, immature granules first
appear as the result of "budding" of the Golgi resulting in small spindle-shaped granules
which may round off to form rhomboid granules. These granules may become larger when
coalescing with other immature granules resulting in intermediate granules. It has been
hypothesized that immature granules may be more fusogenic than other types of renin
granules (Taugner et al. 1987; Taugner and Metz 1986). Immature granules (containing
prorenin) may be trafficked to the cell membrane to release inactive renin as part of the
constitutive secretory pathway. Intermediate granules are also produced when the material
contained in them is condensed into a para-crystalline structure and then appears as an
electron dense product. As a result polymorphous intermediate granules can be found in
different size and shape but often contain (pro)renin material which can be para-crystalline in
appearance. The final form of these storage cisterns contain dense renin material (the so-
called dense core mature renin granules) and have the ability to release renin upon calcium
influx (Hackenthal et al. 1990). Secreting granules and intermediate polymorphous granules
can be difficult to differentiate as the outside of the secretory granule may appear "fuzzy" if
releasing renin resembling either late stages of immature/intermediate granule coalescence or
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non-homogeneous material contained within intermediate granules. Fusion of granules
appears to be present only in higher vertebrates suggesting a relatively recent evolutionary
physiological adaptation (Kon 1999). In Cyprinidae (e.g. carps), only three types of granules
can be detected since no coalescence occurred resulting in granules smaller in size
(approximately 200nm) compared with mouse granules which can be 1pm or greater in
diameter (Kon 1999). Examples of the main types of granules in the mouse are shown in the
result section of this chapter. Renin granules can be mistaken from lysosomes and stains
such as cresyl violet can detect both types of secretory granules. Electron microscopy is, to
date, the most reliable technique for identifying dense core renin granules and for isolating
the different types ofjuvenile and immature (pro)renin granules.
Figure 7.1: Diagram representing renin granulogenesis in the regulated secretory pathway from
Golgi to mature granule formation. Reproduced and adapted from Hackenthal et al. (Hackenthal et
al. 1990).
As discussed in Chapter 1.3.1.1, renin synthesized as the pro-enzyme, prorenin, by the JG
cells in the kidney, can then either be, a) packaged into low density granules ("juvenile") or
b) converted intracellularly to active renin (40kDa) and stored in dense core/mature granules
before secretion when required (Friis et al. 2000), both in humans and mice. In humans, the
kidney is the only known organ to release active renin, other extra-renal sites of renin
production secreting prorenin exclusively (Sealey and Rubattu 1989). After secretion, the
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mechanisms of downstream prorenin activation/conversion are, to date, unclear. In the
plasma, in the presence of protease inhibitors, the conversion of pro-renin is much slower
than in the kidney (Leckie 1981) and prorenin is known to have "renin-like" enzymatic
activity (Skinner 1987).
Renin expression in the foeto-placental tissues namely, placenta, amnion, chorion and foetus
has been reported previously (Carretero et al. 1972; Poisner 1998) in humans and in mice.
During renal development, renin expression in the developing mouse kidney essentially
follows the formation of the arcuate and interlobar arteries (Gomez et al. 1990a) suggesting a
physiological role for renin in nephrogenesis before blood pressure regulation. Renin
expression then becomes localised to the JG cells. In addition, the smooth muscle cells
(SMC) of the afferent arterioles are capable, under stimulation to undergo reversible
metaplastic transformation (Taugner et al. 1984). Renin secretion from granules may be
triggered by a variety of stimuli such as a decrease in blood pressure or sodium depletion
(Atlas et al. 1977). JG cells are considered to be terminally differentiated from SMC since
they possess SMC characteristics and produce the hormone renin. Renin expression has been
detected in the kidney from El4 (Kon 1999).
Although, post-natally the presence of renin granules is unequivocal (Bruhl et al. 1974), few
reports demonstrate the presence of renin granules in JG cells during renal development. In
the pig, studies showed the presence of granules in the mesonephros and metanephros
(precursors of the mature kidney) (Tiedemann and Egerer 1984). In the sheep, granulated
(putatively with renin granules) peripolar cells are the most numerous at the newborn stage
but the identity of the enzymes contained in this granules and their role in the
juxtaglomerular apparatus is unclear. In addition, the presence of juxtaglomerular renin
granules was observed in E18 Wistar rats (Bruhl et al. 1974). Minuth et al., reported the
presence of renal renin granules in NMRI mice (Minuth et al. 1981). In the latter, it is worth
noting that the transmission electron microscopy data was not shown. In human foetuses, a
juxtaglomerular index (the number of granules/number of cells) of zero or below one was
recorded (Ljungvist and Wagermark 1966). It appears, therefore, important to clarify
whether renin dense core granules are present pre-natally. The presence of renin JG granules
in pre- and post-natal stages in the mouse was investigated by electron microscopy. In
addition, the potential involvement of the presence of two renin genes in different foetal
renin granulation profiles was addressed. This allowed the phenotypic comparison of the
granulation phenotype in the adult and in the foetus. Some of the stimuli involved in the
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control of renin granulation were assessed using maternal dietary manipulations and late
gestation angiotensin-converting enzyme (ACE) inhibition.
7.2 Results
Embryos from control C57/B16 and FVB/N mice were sampled at gestational age E15.5,
E16.5, E18.5, PI and P28. For dietary manipulation and ACE inhibition experiments only
mice of C57/B16 strain were used. The mice were divided into 4 treatment groups. For
treatment groups 1 and 2, mice were placed on a low sodium (0.03%) or high sodium (3%)
diet, respectively and received the modified diet from El2.5. For treatment groups 3 and 4,
mice received captopril (30mg/kg/day) or enalapril (30mg/kg/day), respectively, by gavage.
Due to previous reports of foetal toxicity during maternal exposure, captopril and enalapril
gavage was started at El5.5. For the treatment groups 1-4, the embryos were collected at
El8.5 and PI.
7.2.1 Peri-natal renin granulation in mice.
Because the kidney vasculature develops centrifugally, both deep and peripheral arteries
were studied at stages where the renal vasculature may not be fully developed. No granules
were detected pre-natally at embryonic day E15.5 (data not shown), E16.5 (Figure 7.2) or
El 8.5 (Figure 7.3). Post-natally, the presence of granules was clearly observed in JG cells
(Figure 7.4). At post-natal day 1 (PI), each SMC contained approximately 5-6 granules
whereas at weaning (P28), 20-25 granules could be detected showing that the kidneys are
still maturing after birth (Figure 7.5). Renin expression (which starts prior to vessel
formation in the kidney - [19]) preceded the appearance of renin granules and it appears that
renin granulation does not overlap with renin expression along the vasculature.
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Figure 7.2: TEM photographs of embryonic pre-natal mouse kidneys (C57/B16) at embryonic day
16.5. A) Peripheral interlobular artery, B) Deep interlobular artery, C) Vascular pole of JGA including
afferent arteriole. Note the absence of renin dense core granules in SMC of the interlobular arteries and
afferent arterioles of the juxtaglomerular apparatus. "E" denotes the embryonic day. AA = afferent
arteriole, E = endothelial cells, G = glomerulus, MD = macula densa, SMC = smooth muscle cell.
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7.2.2 Comparison between one renin- and two renin gene mouse strains.
Considering the differences in processing between renin from Renld and Ren2, we investigated
whether differences in granulation could be detected between one renin- (C57/B16) and two
renin (FVB/N) gene mice. An identical pattern of renin granule formation was observed in
FVB/N (a 2-renin gene mouse strain) embryonic and neonatal kidneys (Figure 7.6). Juvenile
(also called "rhomboid") granules containing para-crystalline material characteristic of renin as
well as intermediate and mature granules were all observed post-natally (Figure 7.6) but not pre-
natally.
Figure 73: TEM photographs of embryonic pre-natal mouse kidneys (C57/B16) at embryonic day
18.5. A) Interlobular artery, B) Afferent arteriole. Note the absence of renin dense core granules in SMC
of the interlobular arteries and afferent arterioles of the juxtaglomerular apparatus. AA = afferent arteriole,
E = endothelial cells, G = glomerulus, MD = macula densa, SMC = smooth muscle cell.
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Figure 7.4: TEM photographs of post-natal PI mouse (C57/BI6) kidneys. A) Vascular pole of JGA
showing afferent arteriole. B) Higher magnification of (A) showing the renin granule-containing cells
along the afferent arteriole. C) Higher magnification of (B) showing individual dense core granules in
JGC. The presence of renin granules is clearly observed. Arrowheads indicate the dense core renin
granules. MD = macula densa, SMC = smooth muscle cell, JGC = juxtaglomerular cell.
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Figure 7.5: TEM photograph of post-natal P28 mouse (C57/B16) kidneys. Note the presence of renin
granules in SMC of the afferent arterioles. Arrowheads indicate the dense core renin granules. MD =
macula densa, SMC = smooth muscle cell.
a.
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Figure 7.6: TEM photographs of mouse FVB/N kidneys during peri-natal period. A) Peripheral
interlobular artery, embryonic day 16.5. B) Interlobular artery, embryonic day 18.5, C) Afferent arteriole,
post-natal day 1, D) Afferent arteriole, post-natal day 28, inset: intermediate granule showing para-
crystalline renin material. Arrowheads indicate the dense core renin granules. SMC = smooth muscle cell,
E = endothelial cell, G = glomerulus, AA = afferent arteriole, MD = macula densa.
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7.2.3 Effect of sodium depletion on granulation (Experimental group 1).
Contrary to the absence of prenatal granulation in control animals, renin granulation was
detected at El8.5 when the mothers were fed a low sodium (0.03%) diet until giving birth.
(Figure 7.7). Low sodium diet is well known to up-regulate renin expression and production in
the adult and it is demonstrated here that it also has an effect on the foetal RAS regulation. The
number ofgranules was approximately 5-6 granules per JG cell.
Figure 7.7: TEM photographs of pre-natal mouse (C57/B16) kidneys at embryonic day 18.5 after
maternal low sodium diet. A) Vascular pole of JGA including renin-containing juxtaglomerular cells
(JGC), B) Immature amorphous (pro)renin granule in JGC containing para-crystalline material, C)
Afferent arteriole containing JGC, D) Immature spindle-shaped (pro)renin granules in JGC containing
para-crystalline material. Note the presence of renin dense core granules in JGC of the afferent arterioles,
arrowheads indicate the dense core renin granules. JGC = Juxtaglomerular cell. (*) immature (pro)renin
granules.
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7.2.4 Effect of sodium loading on granulation (Experimental group 2).
To reinforce the results obtained with the low sodium, we studied the effects of salt loading on
foetal renin granulation. High sodium diet (3%) is known to inhibit the RAS and in particular
renin release. As expected high sodium diet did not stimulate any renin granule formation pre-
natally (Figure 7.8) and may have suppressed it further and this may need to be investigated in
more detail.
Figure 7.8: TEM photographs of pre- and post-natal mouse (C57/B16) kidneys at embryonic day
18.5 after maternal high sodium diet. A) Interlobular artery, B) Afferent arteriole. Note the absence of
renin dense core granules in SMC of the interlobular artery and in the afferent arterioles of the
juxtaglomerular apparatus. AA = afferent arteriole, SMC = smooth muscle cell.
7.2.5 Effects ofACE inhibition on granulation.
7.2.5.1 Captopril (Experimental group 3)
In the adult, pharmacological angiotensin-converting enzyme (ACE) inhibition up-regulates
renin expression and production [34] as part of a feedback loop response. The physiological
regulation of pre-natal granule absence was therefore studied by inhibiting maternal ACE.
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Captopril (30mg/kg/day) was administered to pregnant C57/bl6 mice from day 15 of gestation
until birth. As demonstrated with salt depletion, captopril ACE inhibition was found to be a
stimulus for foetal renin granulation. It is worth noting that the number of renin granules in the
foetus were elevated (30 granules per JG cell) after captopril ACE treatment compared with low
sodium diet. The number of dense core granules compared to immature granules appeared to be
higher after captopril ACE inhibition than after maternal sodium depletion. The data underline
that maternal captopril ACE inhibition (and hence a reduction in circulating Angll), similar to
low sodium diet, promotes the formation of renin granules in the foetal kidney before birth
(Figure 7.9).
Figure 7.9: TEM photographs of C57/B16 embryonic and post-natal kidneys after maternal
captopril treatment. A) Afferent arteriole with renin granule-containing smooth muscle cell, embryonic
day 18.5, B) Higher magnification of (A) showing numerous dense core granules in smooth muscle cell,
C) Afferent arteriole showing smooth cells containing dense core granules, post-natal day 1, D) Immature
granule containing para-crystalline material. Arrowheads indicate the dense core renin granules. AA =
afferent arteriole, SMC = smooth muscle cell.
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7.2.5.2 Enalapril (Experimental group 3)
Due to potential cross-placental crossing of captopril, another ACE inhibitor, enalapril, was used
to study the control of foetal kidney renin granulation. Pregnant C57/B16 mice were treated with
enalapril (30mg/kg/day) from day 18 of gestation until birth. It has been shown that enalapril
does not cross the placental barrier in the sheep and it may therefore enable differentiation
between direct maternal or combined foetal/maternal effects ofACE inhibition when comparing
the consequences of captopril and enalapril treatment on prenatal renin granulation.
Figure 7.10: TEM photographs of pre- and post-natal mouse (C57/B16) kidneys after maternal
captopril treatment. A-C) Afferent arterioles with smooth muscle cells containing dense core renin
granules, embryonic day El8.5. D) Afferent arterioles with smooth muscle cells containing dense core
renin granules, post-natal day 1. Arrowheads indicate the dense core renin granules. AA = afferent
arteriole, SMC = smooth muscle cell.
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As with captopril treatment, enalapril stimulated the formation of renin granules in the foetal
kidneys (Figure 7.10) which do normally contain renin secretory granules before birth.
Smooth muscle and JG cells contained fewer dense core granules than after captopril
treatment and had more apparent immature granules resembling the granulation profile
caused by maternal low sodium diet.
7.3 Discussion
7.3.1 Absence of renin dense core granules in foetal kidney
The data presented in this chapter clearly shows the complete absence of dense core renin
granules in mouse kidneys before birth suggesting that renin was neither stored or packaged
as observed in the adult. Prorenin maturation in the kidney results in packaging of the pro¬
hormone in secretory granules which are processed into dense core granules following the
conversion of prorenin to renin and condensation of renin material within these granules If
prorenin is the only "renin species" in mouse foetal kidney, its role in kidney development
may be essential. Measurement of foetal plasma and foetal kidney renin/prorenin contents
would confirm the electron microscopy results and ascertain prorenin as a pivotal protein in
nephrogenesis independently or as part of a local RAS system. This assay was not carried
out in this thesis due to the unavailability of nephrectomised plasma to be used as a substrate
for prorenin/renin. Similarly, the identification of renin granules could be confirmed by
immunogold procedures. However, this was deemed unnecessary since the electron
micrographs were processed and analysed by Prof. Stewart Fleming (University of Dundee)
an expert in this area. The alternative pathway by-passes dense core granulogenesis and
results in the release of the protease in its "inactive" form via the constitutive pathway.
Surprisingly, this is in contradiction with Minuth et al. who reported the presence of renal
renin granules in NMRI mice (Minuth et al. 1981). In this study, it is worth noting that the
transmission electron microscopy data were not shown and that the mouse strain differences
may be an important factor as well as the renin granule detection methodology. In addition,
other electron dense micro-vesicles may have been observed and mistaken for dense core
renin granules. Our results also differ from reports in the pig which showed the presence of
granules in the mesonephros and metanephros (Tiedemann and Egerer 1984) and studies in
Wistar rats (Bruhl et al. 1974). These differences may reflect the fact that renal maturation in
mice continues after birth. Renin granules appeared post-natally in their "adult" location, the
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juxtaglomerular cells. The number of renin granules was showed to increase from birth to
weaning indicating that the kidneys were still maturing after birth and gradually adapting to
independent feeding and RAS/blood pressure or salt balance regulation.
No differences could be observed between the two mouse strains used, FVB/N possessing 2-
renin genes (Renld and Ren2) while C57/B16 have only one renin gene (Renlc). All three
murine renins share 97% homology at the protein levels and show differences, at the
nucleotide levels, at 3 asparagine-linked glycosylation sites found exclusively in the "Ren-1"
genes (Sigmund and Gross 1991). Ren-ld null mutants (Clark et al. 1997) displayed a distinct
phenotype in which no dense core granulation was observed in the juxtaglomerular (JG)
cells, indicative of absence of storage vesicles for renin and the inability to package renin
originating from Ren2. These mice also have a modified macula densa morphology (the cells
appear more columnar and numerous). The granulation and macula densa phenotype were
rescued by crossing the Ren-ld knock-out animals with a bacterial artificial chromosome
(BAC) clone encompassing both Ren-2 and Ren-1 genes (BACN10). This was not observed
when the mice were crossed with transgenic mice carrying BACN10 in which Ren-ld has
been replaced by a gene conferring (3-galactosidase activity. This confirms that Ren-ld is
important in the granulation process. Over-expression of Ren-2 (from BACN10) did not
compensate for the renal phenotype but did participate in the regulation of blood pressure as
male Ren-ld null mutants have normal pressure (Mullins et al. 2000).
In the adult, the number of renin-positive cells along the afferent arterioles varies. It has been
shown that when homeostasis is threatened (as it may happen during haemorrhage or
hypotension), smooth muscle cells of the renal arterioles can be recruited and they undergo
the metaplastic differentiation events mentioned above (Gomez et al. 1990b; Pentz et al.
2001). Using a G¥V-RenI reporter system, Sequeira-Lopez et al. followed the fate of renin-
expressing cells from their embryonic location in normal physiological conditions to their
location under salt depletion conditions in the adult (Sequeira Lopez et al. 2004). They
demonstrated that it was the same renin-producing cells which line the afferent and efferent
arterioles during nephrogenesis which become SMC in the adult but retain the "memory" of
becoming renin producing when needed. My studies, however, revealed that the embryonic
phenotype for JG cells in the mouse was characterised by a complete absence of renin
granules suggesting that the adult and embryonic juxtaglomerular cells differ in their
prorenin/renin storage capacity (Figure 7.11).
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Prorenin is now known to be activated without changes in molecular weight through an
alternative activation mechanism. This process possibly involves a (pro)renin receptor which
gives prorenin the ability to return to an inactive conformation after unfolding of the
prosegment to reveal the catalytic site (Derkx et al. 1987; Leckie and McGhee 1980)
Figure 7.11: Schematic representation of the fate of JGC and SMC during development and
during episodes of RAS activation in terms of granulation according to the results presented.
7.3.2 Stimulation of foetal renin granulation
Two different ACE inhibitors, captopril and enalapril, were used to stimulate the foetal
kidney to generate renin granules. Both ACE inhibition and low salt diet triggered renin
granule production in the foetal kidney at embryonic day El 8.5 (El 8.5). It is not known if it
is the distinct result of maternal homeostasis stimulation or if it is a combined effect on both
the foetal and the maternal RAS. The response to captopril treatment appears to be enhanced
compared with sodium depletion in terms of the number of granules produced. This could be
due to the difference in administration route or to a difference in the degree of action which
these two conditions have on the foetal kidney. Similarly, the number of renin granules in the
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prenatal kidney was higher during captopril treatment than enalapril treatment. This may
reflect a different drug metabolism for enalapril. It may also be that both low salt treatment
and enalapril have isolated effects on maternal homeostasis resulting in a less widespread
stimulation of the foetal kidney. Captopril has been shown to cross the placental barrier in






Enalapril Rats (SHR) - No (Jouquey et al. 1995)
Enalapril Sheep No - (Broughton Pipkin and
Wallace 1986)
Enalapril Sheep No - (Stevenson et al. 1995)
Enalapril Human (in
vitro)
Yes - (Reisenberger et al.
1996)
Captopril Rat - No (Barry et al. 1984)
Captopril Sheep Yes - (Broughton Pipkin et
al. 1982)
Captopril Rabbit Yes - (Broughton Pipkin et
al. 1982)
Captopril Sheep Yes - (Stevenson et al. 1995)
Trandolapril
(lipophilic)
Rat - Yes (Tan et al. 2005)
Lisinopril
(hydrophilic)
Rat - Yes (but higher dose
than trandopril)
(Tan et al. 2005)
Table 7.1: Placental and blood-brain barrier transfer of ACE inhibitors.
The differences in foetal granulation after captopril and enalapril treatment may reside in the
transplacental transfer of one drug and not the other. It may, indeed, not reflect what occurs
in the mouse due to different placental structures. However, foetal renin granule stimulation
may be accounted for as a response to maternal ACE inhibition but also as a direct result of
foetal RAS modulation. This is illustrated by the detection of granules with both drug
treatments and salt depletion. In addition, enalapril is not the active drug and after intestinal
absorption needs to be hydrolysed to its active metabolite, enalaprilat. Captopril, on the other
hand, does not require activation to exert its effects. Considering both drugs were
administered at the same dose, the available active inhibitor may differ in amount between
the two treatments and may have a different influence on renin granulation.
Quantitative analysis of the number of granules in foetal kidneys from captopril- and
enalapril-treated mothers as well as from animals receiving a low sodium diet may be useful
to compare the different regimen. The manner in which the sections were obtained and the
micrographs examined does not allow statistical significance. This considered for future
studies and work.
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In summary, the present study demonstrated that the processes involved in prorenin
maturation are different in the embryo and in the adult. Renin expressing cells during
nephrogenesis differ from adult JG cells in their ability to package prorenin/renin in
secretory granules although they retain the "memory" of renin production in the adult. The
mechanisms governing the processing of renin granules appear to be under a dual protective
system of maternal and of foetal origin. This study suggests that the maternal and foetal RAS
may have very separate roles during foetal development pertaining to blood pressure
regulation and to nephrogenesis, respectively. Further investigations are required to dissect




The results presented and discussed in this thesis contribute to a large body of work
pertaining to newly identified functions of the renin-angiotensin system (RAS) within
tissues. Recent reports have demonstrated that prorenin, rather than being solely an inactive
precursor of renin, is itself part of the RAS enzymatic cascade and may also carry out
functions independently of angiotensin (Ang) II production. Considering the potential
importance of prorenin and renin in the development of vascular and cardiac injuries in
animal models of hypertension and diabetes and in patients exhibiting hypertension, diabetes
and pre-eclampsia, the general aim of this thesis was to examine the pathophysiology of
prorenin and renin in malignant hypertension and to investigate (pro)renin maturation during
embryogenesis as well as its regulation.
For this purpose, the identification, characterisation and localisation of a prorenin/renin
receptor homologous to the human (pro)renin receptor in mouse and rat tissues as well as
extensive phylogenic studies and foetal expression profiles were performed. Expression of
the mouse putative (pro)renin receptor was detected in all tissues and cell lines examined
including human mesangial cells previously reported to be negative for (pro)renin receptor.
Mouse putative (pro)renin receptor was also present during development from E9.5, hence
before renin expression begins. The mouse and rat (pro)renin receptor cDNA were found to
be highly homologous (92% and 91%, respectively) to the human cDNA. Surprisingly, the
translated human, mouse and rat cDNAs exhibited sequence identity with a small protein co-
purifying with a bovine vacuolar-ATPase called M8-9 which had not been reported
previously. V-ATPases are critical for cell survival. Phylogenic studies revealed (pro)renin
receptor is highly conserved between species, including those as distant as C.elegans. This
molecule is, therefore, likely to be important physiologically. The role of (pro)renin receptor
was investigated in a rat model in which (pro)renin triggers malignant hypertension (MH).
TGR(Cyplal-Ren2) animals carry a mouse renin gene under the control of the Cyplal
promoter inducible by dietary indole-3-carbinol. A rapid rise in blood pressure was
accompanied by weight loss and polyuria. The animals exhibited microinfarctions,
inflammatory cell infiltration and fibrinoid necrosis in the heart. In the kidney, distal tubule
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hyperplasia and thickening of intra-renal arterial wall without glomerulosclerosis were
observed. High prorenin plasma concentrations due to expression of the mouse Ren2
transgene were reported and uptake of this non-glycosylated prorenin by the heart,
previously demonstrated in this model, may be mediated by (pro)renin receptor. In the
present study, the animals, from a separate colony, developed hypertension in a more
progressive manner. Cardiac remodeling and vascular stiffening were measured using
echo(cardio)graphy techniques. Despite an obvious hypertrophic response of the heart and
longer exposure to the inducer, no signs ofmicroinfarctions or inflammatory infiltration cells
were observed. Fibrinoid necrosis of small intra-renal vessels with glomerulosclerosis and
mesenteric artery remodeling were also observed. The phenotype, therefore, differs from the
original work. Surprisingly, the (pro)renin receptor expression was not up-regulated in this
model. Phenotypic differences between TGR{Cyplal-Ren2) colonies were examined and
two main observations were made: dietary sodium levels appear to correlate with the severity
ofMH and TGR(Cyplal -Ren2) animals reported in this thesis had a lower pathogen load.
To investigate the possible role of the putative (pro)renin receptor, a prorenin decoy peptide
was used to attempt to ameliorate the MH phenotype in TGR(Cyplal-Ren2) animals. This
peptide which competes with prorenin for binding to the (pro)renin receptor has been
showed to improve vascular injuries in diabetic nephropathy. In TGR(Cyplal-Ren2),
however, no changes in the MH phenotype could be observed, except in the mesentery in
which less severe fibrinoid necrosis developed. To complement work on the putative
(pro)renin receptor, prorenin maturation and renin storage were studied during development.
The data showed the complete absence of renin granules in mouse kidneys before birth. This
indicates that renin was not stored and may not be processed through the regulated pathway
as observed in the adult. Low sodium diet and ACE inhibition triggered (pro)renin granules
to be produced in the foetal kidney. Two ACE inhibitors differing in their ability to cross the
placenta were used. The data suggest that foetal renin granule formation is under the control
of both foetal and maternal RAS.
8.1 Local renin-angiotensin system
The renin-angiotensin system (RAS) is not just an endocrine/circulating system and two
decades of research have provided strong evidence for the presence of a tissue RAS and its
functional role in health and disease. It is only in the late 1970s that the term "local RAS"
first appeared and that the notion of independent RAS systems was brought forward. In
160
support of this hypothesis, all components of the RAS have been found in tissues such as
kidney, brain, heart and feto-placental tissues. However, it remains, to date, unclear whether
these tissues produce RAS components such as renin and angiotensinogen de novo or
whether these are taken up by the tissues. The role of the local RAS has been strongly linked
to localised effects of Angll on blood pressure, salt and electrolyte balance and
vasoconstriction as a result of local production. Indeed, in the kidney, Angll and AngI levels
are found are higher amounts than expected from equilibration with plasma levels and are
not solely a result of uptake from the circulation (Navar et al. 2002). Angll located in the
juxtaglomerular cells may constitute a link connecting distal tubular fluid to resistance of
glomerular arterioles, hence regulating tubulo-glomerular feedback in addition to a macula
densa-driven mechanisms. Furthermore, locally produced Angll through a proximal tubule
RAS may provide a rapid response able to modulate fluid and salt reabsorption preceding
that of the circulating RAS in response to homeostatic changes. In the heart, what would
Angll function be in cardiac physiology? Locally produced Angll and activated RAS may
contribute to the homeostatic response and vasoconstricting actions may participate in the re-
establishment of normal blood pressure. In normal physiological situations, Angll may be
involved in vasoconstriction of intra-cardiac vessels (and hence the blood supply to cardiac
tissues) and possibly in the regulation of cardiac inotropy.
8.2 Prorenin
Direct and separate actions of the enzyme catalyzing the first rate-limiting step of the RAS
cascade, renin, have been hypothesized together with a role for prorenin, the "inactive" form,
of the protease. The rationale behind this hypothesis originated from the fact that: 1) prorenin
is present at high concentrations in the plasma where they remain elevated after bilateral
nephrectomy although plasma renin almost but not completely disappears (Sealey and
Rubattu 1989; Sealey et al. 1977; Weinberger et al. 1977). 2) Elevated plasma prorenin
levels have been found during pregnancy and in conditions such as diabetic nephropathy. 3)
Prorenin is found in large amounts in the amniotic fluid and in the ovary. Additional sites of
prorenin production include the adrenal, the pituitary and the uteroplacental complex,
namely myometrium, placenta, and chorio-decidua (Carretero et al. 1972; Lumbers 1993;
Poisner 1998; Skinner 1987). These tissues have been shown to produce renin and prorenin
but it is unclear whether prorenin produced at those sites is converted to renin and released in
the circulation or taken up as prorenin prior to conversion in tissues. Several possibilities for
161
the origin of amniotic fluid prorenin have been proposed such as the chorion, the foetal
kidney/urine, maternal circulation or the maternal ovaries.
Since prorenin can be found in these tissues and in the plasma, one question which remains
to be elucidated is the potential role for prorenin and its mode of action. Null mutants for the
renin gene Ren Id produced in a two-renin gene strain of mice displayed normal blood
pressure in males only (Clark et al. 1997). Females animals were characterised by
hypotension. This is explained by the fact that a second renin gene Ren2 is expressed in the
sub-maxilliary gland (SMG) in a sexually dysmorphic fashion. In males, renin and prorenin
are released by the SMG under testosterone control. This suggests that Ren2 does participate
in the maintenance of blood pressure in the absence of Renld in two renin gene-mice. The
gene Ren2 is known to give rise predominantly to prorenin and a decrease in prorenin in
Ren2 null mutants (Sharp et al. 1996) was demonstrated suggesting that prorenin can play a
role in blood pressure maintenance. This process is likely to occur through the formation of
Angll. Hence, prorenin may result in localised production of Angll leading to Angll-
associated physiological events such as inflammation as observed in the ovary, vascular
remodelling as seen in the heart and blood vessels and steroid secretion from the adrenal
gland.
Are tissue and plasma prorenin converted to renin by removal of the prosegment? This
process occurs normally during prorenin maturation through the regulated pathway and other
mechanisms must therefore be involved in tissues or in the plasma. Prorenin conversion to
renin was identified experimentally as a two-step process, most likely to be associated with
an acidified microenvironment such as that of secretory granules (Derkx et al. 1987).
Proteases are also present in the plasma and in tissues such as the utero-placental complex
and may be responsible for enzymatic removal of the prosegment. However, Brechler et al,
identified a sequence signal in the prorenin associated with protease processing of prorenin
occurring during the regulated pathway, excluding a contribution to the conversion of
secreted prorenin. Prorenin is taken up by cardiac tissues in the inducible high prorenin
transgenic model (Kantachuvesiri et al. 2001). Since prorenin is originating from the mouse
Ren2 gene and therefore unglycosylated, uptake must result from binding to another receptor
which may activate prorenin. Similar to the glycosylation states of renin from mouse Renl
and Ren2 genes, differences exist in humans between prorenin of renal and extrarenal origin
[Hosoi et al, 1992], Although the existence of a (pro)renin receptor had not been
demonstrated and was still a matter of debate, binding to this receptor was hypothesized to
trigger unfolding of the prosegment to expose the catalytic site and conferring it the ability to
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convert angiotensinogen. [(Sealey et al. 1987; Sealey and Rubattu 1989); Figure 8.1]. This
was proposed to happen without removal of the prosegment and to be reversible. Indeed,
Suzuki and colleagues demonstrated that prorenin possessed a "gate region" necessary for
the unfolding of the prosegment and a "handle region" which binds to a putative (pro)renin
receptor resulting in reversible non-proteolytic activation of prorenin (Suzuki et al. 1999;
Suzuki et al. 2003).
Prosegment
Figure 8.1: Schematic representation of prorenin and binding to a putative receptor. Binding of
prorenin results in unfolding of the protein without removal of the prosegment. This process is similar
to the non-proteolytic activation described by Suzuki et al. (2003). Figure reproduced from (Sealey
and Rubattu 1989).
8.3 Putative (pro)renin receptor
The present report was first aimed at studying the biology of prorenin through its putative
(pro)renin receptor. Recently, a specific (pro)renin receptor was identified in human tissues
(Nguyen et al. 2002). Binding of this receptor to (pro)renin caused increased cleavage of
angiotensinogen and stimulation of an intracellular signalling pathway (Nguyen et al. 2002).
This is of importance for a physiological role of prorenin since prorenin may participate in





identified, cloned and shown to be expressed in all mouse tissues examined. Although,
expression in the microvasculature of these tissues may explain this widespread presence, it
was also detected in cell lines including human mesangial cells previously reported to be
negative for (pro)renin receptor (Nguyen et al. 2002). The conclusion from these findings
was that this gene was ubiquitously expressed and not differentially regulated in different
tissues. Phylogenic studies revealed that the mouse and rat putative (pro)renin receptor
cDNAs are highly homologous (92% and 91%, respectively) to the human cDNA and that
the receptor is highly conserved between species as unrelated as D.rerio and C.elegans.
Surprisingly, the translated human, mouse and rat cDNAs exhibited sequence identity with a
small protein co-purifying with a bovine vacuolar-ATPase called M8-9 which had been
previously overlooked (Chapter 3). Considering that binding of renin to the receptor also
resulted in increased AOGEN conversion to AngI, it appears that the receptor identified by
Nguyen et al. does not match the previously proposed model described in Figure 8.1 and one
may wonder how activated renin i.e. without a prosegment may bind this receptor since it
does not possess a "handle region". Although the (pro)renin receptor may be important
physiologically, the data and in particular homology with a vacuolar ATPase subunit
presented in this thesis suggest a more fundamental role in cell biology than had previously
been recognised.
In mammalian cells, V-ATPases play important roles in energy conservation and secondary
active transport, acidification of intracellular compartments and cellular pH homeostasis
(Nelson 2003; Nelson and Harvey 1999).The functions of both the (pro)renin receptor and
M8-9 subunit are therefore not incompatible. However, my studies have shown that the
human (pro)renin receptor described by Nguyen et al (2002) and the vacuolar ATPase
subunit M8-9 must be the product of the same gene since only one gene was found in the
database. Whether these proteins are functionally related remains to be investigated. For
example as a transporter of renin/prorenin from the circulation into tissues, an activator of
prorenin, an initiator of a intracellular pathway upon binding to (pro)renin and secretory
granules acidification, the latter via potential differential exon usage and post-translational
modifications which give rise to the M8-9 sub-unit of a V-ATPase. In the kidney, notably,
plasma membrane V-ATPases play a major role in homeostatic processes of several nephron
segments (Schoonderwoert and Martens 2001). Furthermore, V-ATPases are closely
involved in the process of dissociation of receptor to ligand and receptor recycling by
creating an acidic environment after internalization of the complex (Nelson 2003) suggesting
that V-ATPases and a (pro)renin receptor may interact in the cell. It is attractive to speculate
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that renin may be transported/taken up [by a (pro)renin receptor mediated mechanism] in the
mitochondria where V-ATPases are responsible for cytoplasmic acidification (Nelson and
Harvey 1999). A truncated non-secreted form of prorenin termed renin 1A has, now, been
identified in the mitochondria and uptake of prorenin through a receptor may therefore not
be needed for an interaction with V-ATPase in the mitochondria.
While intracellular pathway activation following binding of prorenin to the receptor is an
important mechanism for cardiac hypertrophy and vascular remodelling in hypertension and
diabetes, it is worth noting that only one publication (Nguyen et al. 2002) reported up-
regulation of second messenger pathways. This publication contained two major
discrepancies: no expression of the human (pro)renin receptor in human mesangial cells
which I found to be erroneous (and is now recognised by the author as an error) and
homology with the V-ATPase subunit which was previously overlooked and was described
in this thesis. The latter is of considerable importance in terms of a putative role for this
protein in basic cell function maintenance. Due to these findings, it was decided that
attempts at producing null mutants of this receptor would potentially be unfeasible. The
expression of a (pro)renin receptor in murine embryonic tissues may be linked to its putative
functional homology with the V-ATPase subunit as discussed in Chapter 3.
In mammalian cells, V-ATPases play important roles in energy conservation and secondary
active transport, acidification of intracellular compartments and cellular pH homeostasis
(Nelson and Harvey 1999). These V-ATPase functions are likely to be essential in
development. A gene trap cell line was available commercially in ES cells of female origin
(http://baygenomics.ucsf.edu/cgi-bin/BavSearch.pv. Genetrap reference RST307) in which it
caused no lethality. The position of the gene trap between exon 8-9 (upstream of the
transmembrane region) suggests that the transmembrane region is essential for protein
function and that a soluble form of the (pro)renin receptor is unlikely to be functional. It has
come to my attention that attempts at creating (pro)renin receptor/M8-9 null mutants in
laboratories of collaborators using this gene trap were indeed unsuccessful (Nguyen G.,
Personal communication).
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8.4 TGR(Cyplal~Ren2) - a high prorenin transgenic inducible model
ofhypertension
Several rat models of hypertension are available for investigations of hypertensive end-organ
damage, genetic influences and pharmacological intervention benefits in this pathological
condition. Genetic rat models (SHR, Dahl, Milan) and transgenic models such as
TGR(mRen2)27 and dTGR(hAOGENxhRen) have allowed researchers to study
pathophysiological factors involved in hypertension, notably the (local) renin-angiotensin
system or oxidative stress and inflammation. However, these animals do not provide a
controllable system for the timing of the development or severity of hypertension. The
importance of having a non-surgical inducible model is further highlighted by the fact early
events in malignant hypertension are largely unknown. Indeed, a large group of patients with
malignant hypertension are diagnosed once the injuries have developed which prevents
investigations of early hypertensive mechanisms. It is important to be able to trigger
hypertension at different stages of the lifespan in animal models since foetal and neonatal
programming may play a crucial role in the pathogenesis. In addition, hypertension in young
animals may not represent a relevant physiological situation to that seen in humans. Hence,
the inducible hypertension model TGR(Cyplal-Ren2) provides researchers with a flexible
and adaptable model. Previous publications (Collidge et al. 2004; Howard et al. 2005;
Kantachuvesiri et al. 2001) and the present thesis highlight the fact that can be used for
separate areas of research and shows that this model is of use and in use in several
laboratories all studying aspects of hypertension biology. Unique endpoints and assays are
used but careful interpretation of the data when comparing previous published work must be
taken as found in my experiments using a separate transgenic colony.
The experiments described in this thesis provided extensive study of the haemodynamic
response in this strain (Chapter 4). Echocardiography which is a non-invasive and powerful
technique allowed me to take repeat measurements of cardiac function. Although the blood
pressure and histopathological phenotype was found to be less severe than previously
reported (see below), it was revealed that ventricular hypertrophy in treated TGR{Cyplal-
Ren2) animals does not develop until two weeks after blood pressure elevation showing that
this event is downstream consequence of RAS activation and/or hypertension. In addition,
adaptative mechanisms were clearly observed in heart since cardiac output was reduced in
parallel with cardiac hypertrophy development.
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Peripheral resistance was increased as measured in mesenteric vessels in vitro. The lumen
diameter of mesenteric arteries of TGR(Cyplal-Ren2) animals were affected by inward
remodeling as compared to controls. Response to intraluminal pressure was significantly
reduced in the vessels isolated from the treated animals even at low pressure (20mmHg).
Histopathology results showed that this inward remodeling is dependent on an increase in the
cross-sectional area of the tunica media. Since blood pressure is a function of cardiac output
and peripheral resistance, it appears that this increase is an important factor. In addition, a
decrease in cardiac output would represent an adaptative response from the heart. Aorta wall
track echography demonstrated a stiffening (calculated as compliance and distensibility) of
the abdominal aorta. This effect is likely to be a result of blood pressure increase and
remodeling. However, a decrease in the compliant, blood pressure-dampening properties of
the aorta could contribute towards the gradual blood pressure elevation after the initial period
of hypertension due to the transgene activation. Because aorta wall track echography is a
semi-invasive procedure requiring cannulation and subsequent ligation of the femoral artery,
only two measurements can be done. In the present work, aorta wall track echography was
only employed in the final week of treatment due to equipment use restriction but it would
be informative to collect measurements at the start of the experimental period.
Increased collagen deposition was present over the whole kidney. In the aorta, the number
and size of elastic fibres was increased and changes in smooth muscle cell morphology were
associated with hypertrophic events. Surprisingly, no cardiac fibrosis was observed. The
remodelling events which lead to increased ventricular mass have been shown to be linked to
increased cell size and/or number but also inappropriately excessive production of
extracellular matrix (ECM). This is confirmed in studies of myocardial infarction in which
the inhibition ofDNA synthesis and collagen deposition in myocardial interstitium by ACE
inhibitor suggests a role for Angll in interstitial and perivascular fibrosis (Dostal et al. 1996).
Clearly, ECM deposition in the heart is not the causative mechanism for ventricular
hypertrophy in the present study. Histopathological stains in the mesenteric bed for elastin,
collagen and reticulin were performed and only collagen staining was higher in treated
animals than in controls. Accumulation of ECM proteins within the renal interstitium and
atrophy of the tubules have been identified in chronic renal disease (Klahr and Morrissey
2003). In vitro studies have shown that both Angll and endothelin 1 (ET-1) promotes the
synthesis of fibronectin and collagen in a dose-dependent manner in vascular smooth muscle
cells (Grainger et al. 1994). It is therefore possible that these mechanisms are independent of
blood pressure increase and are a result of RAS activation either through local Angll
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production or through prorenin actions which remain to be determined. The (pro)renin
receptor does not, however, appear to be involved. The regulation of this putative (pro)renin
was further investigated in TGR(Cyplal -Ren2) animals. Inhibition of the (pro)renin receptor
was also performed using a decoy peptide spanning the handle region of the prorenin protein.
8.5 Phenotypic differences in colonies ofTGR(Cyplal-Ren2) rats
Experiments using these animals from a separate re-derived colony at the University of
Maastricht, however, revealed a different phenotype from the original work (Kantachuvesiri
et al. 2001), notably an inflammatory tissue response which was reduced, an increased
resistance to malignant hypertension injuries and a dissimilar pattern of the vascular and
tissue injuries. Indole-3-carbinol is a natural substances occurring in cruciferous vegetables.
Most rodent chows are made from vegetal matter and therefore may contain varying amounts
of this chemicals as well as other xenobiotics able to activate the transgene and this may
explain differences in phenotype reported in Chapter 4. This was not tested.
Investigations designed to identify the factors responsible for the phenotypic differences
showed that two main influences may be involved: lower dietary sodium levels and lower
pathogen load. Comparison of the phenotype of TGR(Cyplal-Ren2) between collaborative
laboratories is not sufficient to correlate results and clearly several environmental factors
need to be considered when linking results obtained with this model. It has been previously
reported that the induced TGR(Cyplal-Ren2) animals fed a high salt diet (4%) or offered
saline solution did not display exacerbated end-organ pathology to the kidney, heart or
mesentery (although cerebrovascular injuries were detected) (Collidge et al. 2004). In
addition, the animals were found to develop salt sensitive hypertension after treatment (for
14 days) with inducer was ceased (Howard et al. 2005). Hence, dietary salt levels may
exacerbate the phenotype observed in this rats. It could be that the levels of dietary sodium in
the laboratory in Maastricht are below a threshold which is suggested by the increased
mortality rate at 12 days in the "New Orleans" population (greater than that of the
"Edinburgh"), which are fed a diet with higher sodium contents (K. Mitchell, Personal
communication). This phenomenon is also reflected in the shape of the blood pressure curve
which rose slowly in the "Maastricht" animals.
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Microsatellite marker genotyping confirmed that the animals used in the original publication
and those used for this thesis at the University ofMaastricht were of the same strain and that
the phenotype was not modified due to different genetic background. Unfortunately, this
procedure also provided evidence for a genetic contamination in the new re-derived colony
of TGR(Cyplal-Ren2) animals held at the University of Edinburgh and prevented further
experiments to perform salt diet modulation or to study the importance of a pathogen-
induced phenotype. Another important aspect is the inducer dose which is associated with a
severity of the hypertensive response both in terms of blood pressure and end-organ damage
[J. Peters, Personal communication and (Kantachuvesiri et al. 2001)].
8.6 Putative (pro)renin receptor inhibition using a decoypeptide
In the TGR(Cyplal-Ren2) rat model, inhibition of the putative (pro)renin receptor was
performed using a decoy peptide spanning the handle region of the prorenin protein (Chapter
6). This peptide had been previously associated with alleviation of inflammatory vascular
injuries in a model of diabetic nephropathy (Ichihara et al. 2004) through competitive
binding to the (pro)renin receptor. In my studies using TGR(Cyplal-Ren2) animals,
however, the decoy peptide caused no improvement in malignant hypertensive injuries
observed in the heart. Indeed, left ventricular hypertrophy and fibrinoid necrosis of
intramural right coronary arteries was observed in all animals. Prorenin decoy peptide
administration did not alleviate glomerular enlargement or fibrinoid necrosis of intrarenal
vessels. A small effect was, however, seen in the mesenteric vessels which showed
hypertrophic remodelling but did not develop segmental fibrinoid after administration of the
decoy peptide. The animals used for this pilot study originated from the TGR(Cyplal-Ren2)
colony held in Edinburgh and were of mixed genetic background. Right ventricular infarcts
which have not been previously observed in this model may be a consequence of the mixed
strain origin and one may wonder what would be the factors involved. Very few studies have
been focussing on this isolated cardiac complication and no studies have been done to
correlate right ventricular infarction to genetic components.
Ichihara et al, (2004) applied the inhibitor to a model of diabetic rats prior to the appearance
of vascular lesions. In my study, the decoy peptide was administered concurrently to
transgene inducer treatment for a period of only 14 days rather than over a period starting
prior to the development of vascular lesions or hypertension which may explain the lack of
improvement in the phenotype. This work therefore indicates that non-proteolytic activation
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of prorenin through the recently published (pro)renin receptor does not play a crucial role in
malignant hypertension in the inducible transgenic rat model of high prorenin. However, it
would be interesting to study the effects of the same inhibitor peptide on diabetic
nephropathy animal models which already display renal vascular lesions. The role of non-
proteolytic activation of prorenin by the putative (pro)renin receptor in the development of
the lesions could therefore be separated from a role in the maintenance of the injuries. A
larger scale study with TGR(Cyplal-Ren2) would be useful to find out whether uptake of
prorenin in the heart was decreased or inhibited. If this was the case, it would provide proof
of prorenin uptake through the (pro)renin receptor. This is unlikely unless prorenin and
prorenin uptake has no role in the phenotype of these rats. If prorenin is still detected in the
heart, it would indicate that a separate, yet unidentified, uptake pathway for unglycosylated
prorenin is involved.
8.7 Foetal renin granulation - a system regulated by maternal or
foetal RAS?
As part of my studies on prorenin, I investigated prorenin synthesis and maturation, and in
particular renin granulogenesis during embryogenesis when prorenin may play a role in
development, foetal RAS regulation and salt homeostasis. Chapter 7 described studies of the
presence of renin granules in the kidney during embryogenesis and if, so at what stages these
granules are first detectable. The data indeed showed that dense core and immature renin
granules are completely absent for juxtaglomerular (JG) cells and smooth muscle cells
before birth. The data raises the question of whether embryonic kidneys possess active renin
at all. Are embryonic kidneys able to produce active renin? It may be that the foetal RAS and
prorenin carry out other functions than blood pressure regulation such as organogenesis. The
data indicate that mouse foetal smooth muscle cells are not able to package and process
prorenin into renin through the regulated pathway. Hence, the possibility of a lack of
prorenin maturation highlights the fact that prorenin may be released solely through the
constitutive during embryonic development.
Additional experiments may be useful to confirm three important aspects of this work. 1)
Measurements of prorenin and renin (which were not performed due to technical restrictions
in both foetal plasma and kidney samples may provide unequivocal evidence of a pivotal
role of prorenin during development, either indirectly though the RAS or directly via
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putative binding proteins or receptors. 2) Immunogold techniques to confirm morphological
identification of renin granules may be useful to remove any bias or false positive in the
analysis, This should be considered in all cases when an expert pathologist is not available
for the analysis. 3) Quantitative evaluation of renin granules in samples from different
treatments may be useful to compare the effects of different regimen, notably when
comparing a downstream effect on foetal kidneys from treated dams. The experiments
described in this thesis were, however, not set up to provide statistical meaningfulness.
If renin granules are absent in the mouse foetus, does renal prorenin which is released
constitutively possess a direct role in early renal development? Prorenin is now known to be
activated without changes in molecular weight through an alternative activation mechanism.
In contrast, foetal kidneys from rats and sheep have been shown to possess renin dense core
granules. Although my results are in contradiction with results obtained with NMRI mice
(Minuth et al. 1981), this report did not include electron microscopy data and it is possible
that other structures such as lysosomes were mistaken for renin granules. In conclusion, the
mouse appears to be unique for this foetal granulation phenotype. Information about the
presence of granulation in humans seems to be dogmatic and it is believed that human foetal
kidneys do possess dense core renin granules. The literature, however, does not support this
theory. Only one publication relating to perinatal human renin granulation reveals that the
juxtaglomerular index was zero (or one) which suggests that the human JG cell is agranular.
The methodology used (secretory granule staining) at times when renin JG granulation
research was most active, may not provide an accurate technique and again other secretory
vesicles may have been mistaken for renin granules. It may be informative to investigate
human renin granules in archived foetal kidney electron microscopy samples. The mouse
may provide an appropriate model to study this aspect of kidney and RAS physiology.
Renin granule production could be stimulated by maternal sodium depletion and maternal
treatment with two ACE inhibitors shown to differ in their ability to cross the placental
barrier. Hence, it appears that the prorenin maturation is under the control of maternal and
the foetal RAS. They may act as redundant systems when homeostasis is threatened in the
foetus or/and could play separate roles in blood pressure regulation and establishment of
embryonic structures during normal physiological processes. In addition, the present study
revealed that foetuses from mothers fed a high sodium diet had no renal renin granules pre-
natally. It is possible that a high salt diet during pregnancy may suppress the foetal RAS
further and compromise neplirogerresis. The effects of high salt during pregnancy on blood
pressure in adulthood has been a matter of debate but it is possible that foetal programming
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by high (or low) salt resets the renin-angiotensin system or the tubulo-glomerular feedback
loop to a lower level and triggers an inadequate sodium handling in the adult. It is known
that perinatal Angll decrease interferes with renal development and has long-term
consequences in the adult in terms of blood pressure (Woods et al. 2001). To reinforce this
concept, Ross et al. showed that Angll infusions in the peri-natal period triggers an increase
in blood pressure in the foetus (Ross et al. 2005) demonstrating a crucial influence of Angll
in foetal RAS regulation. The ACE inhibitor, captopril, has been shown to cross placenta in
the sheep (Stevenson et al. 1995) and rabbit (Broughton Pipkin et al. 1982) while enalapril
does not (Stevenson et al. 1995). It may not reflect what happens in the mouse but if
captopril does indeed gain access to foetal circulation while enalapril does not, the results
can be interpreted to show that foetal granulation is under both the maternal and foetal
control since granules were detected prenatally with both drug treatment and with salt
depletion.
This redundant system may represent a protective mechanisms during the perinatal period
while the foetal system is preparing for life ex-utero but only when maternal homeostasis is
threatened to preserve adequate blood pressure levels. Foetal renin may therefore not be
essential for haemodynamics purposes at this developmental stage and may solely be
involved in embryonic growth. Although at El8.5 the main architecture (tubular and
vascular) of the kidney is complete, kidney maturation is still on-going. Since the placenta
contains proteases, Angll might not cross placenta from the maternal circulation and locally
produced Angll is likely to be involved in nephrogenesis.
8.8 Future work
As highlighted in the "Discussion and conclusions" sections at the end of Chapters 3, 4, 5, 6
and 7, the work presented in this thesis may benefit from the following additional
experiments. These experiments were not undertaken for the present work due to time or
technical restrictions.
Localisation of the (pro)renin receptor protein in embryonic and adult tissue sections
would confirm the mRNA data. In addition, an anti-mouse putative (pro)renin
receptor antibody would allow the repetition of binding and immuno-precipitation
studies done with human material by Nguyen et al. using mouse cell/tissues. It
would also make possible the comparison of the putative (pro)renin receptor protein
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levels by Western blotting in TGR(CyplaJ-Ren2) which would have complemented
the real-time PCR data. It cannot be excluded, although the (pro)renin receptor
mRNA levels were not different between control and transgenic animals, that post-
transcriptional up-regulation is occurring. An up- or down-regulation of the putative
(pro)renin receptor would have demonstrated an involvement of this molecule in the
malignant hypertension injuries observed in this model.
It appears also essential when the Edinburgh colony is re-established to repeat, on a
larger scale, the "prorenin handle region" experiment to confirm that the putative
(pro)renin receptor is not involved in the malignant hypertension of TGR(Cyplal-
Renl) rats.
A full study using the TGR(Cyplal-Ren2) animals from the colony housed in
Maastricht and varying the dietary sodium levels would provide useful information
in the sensitivity of this model to this physiological stimulus. Similarly, when the
colony is re-established in Edinburgh (due to genotypic contamination), a
comparison between re-derived animals and non-re-derived animals (for example,
those housed in Greiswald) would give insight in the influence of the pathogen load
in the pathophysiology of malignant hypertension. In addition, measurements of
plasma and tissue prorenin levels as a routine screen when using these animals may
be a powerful tool to explain phenotypic differences.
To complete studies described in Chapter 7 on renin granulation during embryonic
development, measurement of foetal plasma and foetal kidney renin/prorenin
contents could be undertaken. This would confirm the electron microscopy results
and ascertain prorenin as a pivotal protein in nephrogenesic independently or as part
of a local RAS system. Immunogold techniques would remove bias and ascertain the
identity of renin granules. The differences in transplacental crossing of the two ACE
inhibitors used would also strengthen the result presented and foetal plasma and
kidney analysis could be analysed by HPLC for this purpose.
The results described throughout this thesis and the publications discussed have
provided a range of evidence for the existence of additional receptors and/or
molecules which may interact with prorenin. This interactions may be involved in
the uptake and activation of prorenin in tissues such as the heart, notably in the rat
model, TGR(Cyplal-Ren2), studied in the present body of work. One technique,
termed "yeast two-hybrid" may reveal new biological "partners" or chaperones for
prorenin. In this assay, two fusion proteins are created: the protein of interest, which
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is constructed to have a DNA binding domain attached to its N-terminus, and its
potential binding partner, which is fused to an activation domain. If both proteins
have an interaction, the binding of these two will form an intact and functional
transcriptional activator. This newly formed transcriptional activator will then
trigger a reporter gene transcription, which is simply can be easily detected and
measured. In this way, the amount of the reporter produced can be used as a measure
of interaction between the protein of interest and its potential partner. Hence The
yeast two-hybrid assay would be an elegant means of investigating prorenin
interactions with other proteins. It is expected that the putative (pro)renin receptor
and other "described prorenin binding proteins" would be identified by such
procedure. It would be interesting to investigate whether M8-9 would have
interactions with prorenin and whether additional targets would be obtained.
Prorenin sequence from several species could be used. In addition, the advantages of
the system is that, following identification of new proteins interacting with prorenin,
mutations can be introduced in the sequence to highlight regions important in the
interaction.
8.9 Final remark
The widespread expression of the putative (pro)renin receptor, its phylogenic conservation in
lower species, its homology with M8-9 and the lack of evidence for regulation of the
(pro)renin receptor in TGR(Cyplal -Ren2) animals suggests that the function of this protein
may need to be re-assessed. The work reported in the present thesis indicates that non-
proteolytic activation of prorenin through the recently published (pro)renin receptor does not
play a crucial role in malignant hypertension in the inducible transgenic rat model of high
prorenin. Further studies are needed to understand alternative physiological roles including
during embryogenesis for this newly identified gene. While the role of prorenin in the
pathogenesis of malignant hypertension of TGR(Cyplal-Ren2) is unquestionable, it is still
unclear how prorenin gains access to the heart and whether uptake through an alternative
receptor occurs. The data presented in this thesis suggest that prorenin may be the only
"renin species" present in the developing mouse kidney and indicate that renin was not
stored or processed through the regulated pathway as observed in the adult. Hence, prorenin
may play a crucial role during foetal development which may involve the synthesis ofAngll
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10.1 ANNEX 1: PCR Primers


























primer 1) JJM 518




primer 1) JJM 519




primer 2) JJM 520




primer 2) JJM 521




primer 3) JJM 522




primer 3) JJM 523




primer 4) JJM 524













GGGCTTCTCTGTGAAGGAAGAC Rat renin receptor
cDNA
Rat renin receptor
(Real time - reverse)
JJM 955
GGGCCGGTGGAATAGGTT Rat renin receptor
cDNA
190
Real-time Quantitative PCR primers
Name Sequence Target
Rat renin receptor (Real





Rat renin receptor (Real
time - reverse) JJM 955








































































10.2 ANNEX 2 : CLUSTAL Classification ofamino-acid substitutions
The conservation line output in the CLUSTAL format alignment file is made up of three
commonly used characters.
indicates positions which have a single, fully conserved residue






















These are all the positively scoring groups that occur in the Gonnet Pam250 matrix. The
strong and weak groups are defined as strong score >0.5 and weak score =<0.5 respectively.
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Amount Shipped: 32.3 Mgs
Final Purity (%): 96
Peptide Content %:
Appearance: Lyophilized Powder
Solubility: lmg/ml in acidic solution pH<7.5 (basic peptide)
Conjugation:
Peptide Name: RILL
Terminal Modifications N-Term:[H] C-Tcim:[OH]
Chemist's Notes:
Column: Discovery Bio Wide Pore C-18, 250mmX4.6mm, 5pm
Mobile Phase: A=0.1% TFA/Water
B=0.1% TFA/Acetronitrile
Gradient: 0 to 2 min.: 100% A
2 to 20 min.: 0 to 67.5% B
Detection: 214nm
Storage Conditions: -20 C for Long Term
4 C for Short Term
Released By: Date Released: /Ol/QfaS'
Sigma-Genosys makes no claims to the peptide's ability to function in the specific
application of the customer. AH peptides are shipped lyophilized and as gross
weight. Peptide for research use only.
Sigma-Genosys
1442 Lake Front Circle
The Woodlands, Texas 77380-3600
800 234 5362
Sigma-Genosys Ltd.
Homefield Road Business Park
Homefield Road, Haverhill CB9 8QP, UK
44 0 1440 767000
Sigma-Genosys Japan K.K. Cashmere Scientific Company
777-13 Nishi-L Shin-Ko, Ishikari No. 2-1,2F, Lane 40
Hokkaido, Japan Chang-An W. Road
81 133 73 5005 Taipei, Taiwan 104
886-2-25416188
Sigma-Aldrich Pty Ltd.
Unit 2,14 Anella Avenue Sigma-Aldrkh Korea
Castle Hill NSW 2154 Samhan Camus Annex, 10th Floor
Australia 17-26 Yoido-dong, Yungdeungpo-ku
800 800 097 Seoul, Korea
82 2 783 5211
Sigma-Aldrich Canada Ltd.
2149 Winston Park Drive
Oakville, Ontario L6H 6J8
CANADA 905 829 9500
Sigma-Aldrich Pte- Ltd.
102E Pasir Panjong Road
#08-01 CitilinkWarehouse















C : \CHEM3 2 \ 1 \METHODS\ANALYTICAL_LC.M
10/4/2005 2:42:49 PM by ad
LC runs for peptide analysis
Seq. Line : 6
Location : Vial 6
Inj : 1
Inj Volume : 10 jzl
Actual Inj Volume : 5 jil
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier 6 Dilution Factor with ISTDs
Signal 1: VWD1 A, Wavelength=214 nm, TT
Peak RetTime Type Width Area









0.1831 1.78489e4 1525.02637 96.5721
0.1390 310.64813 34.81441 1.6808
0.1572 322.90814 31.56318 1.7471
Totals 1.84825e4 1591.40396
*** End of Report ***
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